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Chapter 1 
General Introduction
Background
Asthma and COPD (chronic obstructive pulmonary disease) are both entities of obstructive
airways diseases. In Dutch general practice the prevalence of asthma and COPD is 
estimated to be approximately 1-5%.1 Recent data from the Dutch Continuous Morbidity
Registration in four general practices located near Nijmegen demonstrate a prevalence
of asthma as well as COPD of approximately 2%, which doubled over the past 15 years
(see Table 1.1).2 Tirimanna et al also revealed an increase in the prevalence of asthma
and COPD in the Netherlands between 1977 and 1992, especially in milder cases of the
disease3, which are commonly treated in general practice. United States consensus 
9
Table 1.1: The prevalence and incidence of asthma and COPD in general practice
according to the Continuous Morbidity Registration in the Netherlands (see text).2
Asthma COPD
prevalence % incidence % prevalence % incidence %
1971-1975 0.78 0.23 1.88 0.45
1976-1980 0.83 0.18 2.14 0.28
1981-1985 0.86 0.18 1.95 0.15
1986-1990 1.37 0.27 2.11 0.22
1991-1995 1.91 0.30 2.60 0.30
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reports on asthma and COPD state a rising prevalence and rising mortality of asthma,
both of 30%4, and of COPD of 30 and 40% respectively5 in the past two decades.
Theoretically these alarming data point to the importance of diagnosing and treating
subjects with asthma and COPD as early as possible. These observations should be 
considered within the context of the (Dutch) general practice research of the past decades. 
The benefits and potentials of early detection, monitoring and treatment of patients
with other chronic illnesses in general practice (in particular cervical cancer and 
hypertension) have been studied extensively.6-8 It would be interesting to know if early
detection and treatment of patients with asthma and COPD will be clinically effective.
In fact ‘treatment’ in medical care is multifactorial, while evidence-based medicine 
evaluations often centre on one particular kind of intervention.9 In asthma, for example,
preventing exposure to allergens, and, in COPD, giving up smoking have proved to be
valuable ‘treatment’ options. This thesis focuses specifically on drug treatment of 
asthma and COPD. Bronchial inflammation is considered to be the underlying cause of
clinical asthma and probably also of COPD (see below). Recent (Dutch) consensus
reports on asthma and COPD in general practice advise the prescription of anti-
inflammatory drugs, i.e. inhaled corticosteroids, as the cornerstone of treatment, 
especially in asthma.10,11 In this thesis research data about several aspects of treatment
with inhaled corticosteroids are presented.
The eventual purpose of clinical research is improvement of patient care. As the 
majority of patients with (mild) asthma and COPD are treated in general practice12, this
is by far the best domain for investigating aspects of treatment. Part One of this thesis
presents data from a general-practice-based intervention with inhaled corticosteroids,
the so-called DIMCA project (DIMCA is an acronym for early Detection, Intervention
and Monitoring of Asthma and COPD). The design and part of the results of DIMCA
have already been published.3,13-19 In this thesis I will investigate several aspects of early
intervention with inhaled corticosteroids in patients with mild signs of asthma or COPD
without a clear diagnosis, participating in the DIMCA programme.
The prescription of inhaled corticosteroids as treatment of choice has obviously 
proved to be beneficial in asthma, but, until now, not so in COPD. Questions about the 
optimal start, duration and dosage of treatment with inhaled corticosteroids remain
unanswered where asthma and COPD patients are concerned. These questions 
constitute the basis of Part Two of this thesis.
In Part Three of the thesis the summary and the general discussion is presented.
Clinical presentation and pathophysiology of asthma
Asthma is clinically characterized by bronchial symptoms and bronchial hyper-
responsiveness partly provoked by exposure to allergic or nonspecific stimuli.20
In Figure 1.1, the dark grey zone represents the clinical manifestation of asthma as a
combination of bronchial hyperresponsiveness, symptoms such as wheezing and 
dyspnea and atopy. 
The mucosa contributes to a large extent to maintaining bronchial hyper-
responsiveness by release of inflammatory mediators as histamine and 
cytokines21 and by infiltration of eosinophils.22 Chronic bronchial inflammation may 
result in damage and structural changes of the bronchial wall, also known as ‘airway 
10
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re-modelling’.23 This process may have been responsible for the increased lung function
decline that was demonstrated during 15 years in 1,095 adult patients with chronic asthma.24
Early treatment of asthma with inhaled corticosteroids
Inhaled corticosteroids form the cornerstone of treatment of bronchial inflammation,
especially in asthma.25 They were introduced in the 1970s as a new anti-inflammatory
treatment for moderate to severe asthma, and were promoted for their safety compared
to oral glucocorticoids.26 Inhaled corticosteroids reduce the infiltration of inflammatory
cells (such as mast cells, macrophages, T-lymphocytes and eosinophils) in the 
bronchial mucosa27 and inhibit the release of inflammatory mediators from these
cells.25 Clinically, in the case of asthma, inhaled corticosteroids reduce bronchial 
hyperresponsiveness and symptoms.28
The past ten years showed a gradual shift from treatment with inhaled corticosteroids
in moderate to severe asthma to treatment of milder cases.28,29 Several reports on
patients with asthma show that bronchial inflammation is already present in very mild
stages of the disease.21,30 Theoretically, remodelling of the airways as a result of chronic
bronchial inflammation may be prevented by treatment with inhaled corticosteroids 
as early as possible. It was shown that treatment with inhaled corticosteroids 
in patients with newly diagnosed asthma resulted in improvement of markers of 
airway inflammation31, preservation of lung function32, and a reduction in hospital
admissions.33
11
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Figure 1.1:  Theoretical model of the relationship between the main features 
contributing to or being at risk of the clinical manifestation of asthma.
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Clinical presentation and pathophysiology of COPD
COPD is defined by irreversible bronchial obstruction and includes chronic bronchitis,
small airways disease and emphysema.34 The disease is clinically characterized by the
presence of continuous chronic bronchial symptoms (dyspnea, productive cough). The
bronchiolar changes and alveolar destruction are mostly initiated by cigarette 
smoking.35 In Figure 1.2 a simplified model is presented, showing the contribution of
an increased permanent airway obstruction, symptoms and smoking to the clinical
manifestation of COPD (dark grey zone).
The inflammation in bronchi and small airways is characterized by an increase in
neutrophils and the production of mediators and proteolytic enzymes. These enzymes,
generated by inflammatory cells, and oxidants, inhaled with cigarette smoke, are 
regarded to be responsible for the destruction of the alveolar structures, resulting in
emphysema.36 Both inflammation (leading to bronchial obstruction) and destruction
are responsible for a progressive decline in lung function (represented by the FEV1,
the forced expiratory volume in one second), while the physiological FEV1 decline is
0.02-0.03 L/year.37
Early treatment of COPD with inhaled corticosteroids
Prescription of inhaled corticosteroids in COPD is common in general practice38, 
although the role of these anti-inflammatory drugs in COPD is not clarified. Inhaled
corticosteroids have recently been shown to reduce the number of neutrophils in the
bronchial mucosa of patients with COPD.39 On the other hand, Keatings et al showed
that a 2-week treatment with 800 µg inhaled budesonide did not result in a reduction
of eosinophil and neutrophil activation markers in induced sputum in 13 patients with
COPD.40 The evidence of their clinical benefit remains a matter of debate.41 Three 
long-term studies to be published, did not demonstrate a convincing influence of 
inhaled corticosteroids on the long-term course of lung function.42-44 Three other large
long-term studies not yet published (EUROSCOP, ISOLDE and COPENHAGEN CITY
LUNG), in which patients with different stages of COPD were treated with different
dosages of inhaled corticosteroids, also do not seem to demonstrate a clinical relevant
influence of inhaled corticosteroids on lung function decline.45 On the other hand, a
recent six-monthly study of patients with moderate COPD who were treated with 
high doses of inhaled corticosteroids found small improvements in lung function, 
exacerbations and symptoms.46
In patients with COPD there is not yet clear evidence of a preservation of lung 
function by early treatment with inhaled corticosteroids (in contrast to asthma).
However, in persons at risk of developing COPD, i.e. cigarette smokers, a form of 
inflammation has shown to be present.35 Theoretically, early treatment with inhaled 
corticosteroids could avoid increasing inflammation and hence prevent the occurrence
of irreversible changes in the bronchial wall.
Detection of early stages of asthma and COPD
If early intervention (with inhaled corticosteroids) were to prove efficacious, subjects
would ideally have to be detected before the disease has manifested itself clinically. In
12
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such a very early stage, the ‘disease’ will be largely asymptomatic. To detect it at this
stage, objective measures of the lung function will be required.
In asthma, asymptomatic bronchial hyperresponsiveness has shown to be a possible
precursor of the disease (light grey zone in Figure 1.1).47 Theoretically, in COPD, the
observation of a small increase of the FEV1 decline with near normal lung function and
without symptoms may indicate the start of irreversible bronchial obstruction (light grey
zone in Figure 1.2). 
Part one of the thesis
In the DIMCA programme bronchial hyperresponsiveness and an increased FEV1
decline were chosen as objective early indicators of asthma and COPD respectively. 
It was hypothesized that these possible precursors, if not treated with inhaled 
corticosteroids, would lead to clinical cases. This was the main hypothesis of the
DIMCA programme. Therefore, in these patients with mild signs of asthma and 
COPD the clinical effects of inhaled fluticasone propionate, a relatively new inhaled 
corticosteroid, were assessed. The results of this study - the intervention part of the
DIMCA programme - presented in Chapter 3 form the main body of Part One of this
thesis. 
Inhaled corticosteroids, once started with, have to be taken daily over a long period of
time and may cause local adverse effects and, in higher doses, also systemic side-effects.
The absence of severe symptoms in very mild cases in a screening programme such as
the DIMCA programme, and the fear of adverse effects, may influence the willingness
to undergo early treatment.48 Also, the occurrence of side-effects of inhaled cortico-
steroids49 once treatment has started may decrease compliance rates. These issues are
also investigated in the intervention part of the DIMCA programme. Chapter 2 describes
13
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Figure 1.2: Theoretical model of the relationship between the main features 
contributing to or being at risk of the clinical manifestation of COPD.
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the willingness to use inhaled corticosteroids in early stages of asthma or COPD.
Chapter 4 decribes the compliance to inhaled fluticasone propionate in subjects with
early signs of asthma and COPD. 
Part two of the thesis
This thesis does not only report on the experimental data from the DIMCA project, but
also tries to put these data into a wider perspective. Questions about the optimal start,
duration and dosage of treatment with inhaled corticosteroids have to be resolved,
where asthma and COPD patients are concerned. Meta-analysis was one of the methods
used for this purpose (Chapter 5 and 7).
A top-down strategy (start high, go low once control is achieved) is advised in 
recent consensus reports on asthma, also in patients who had never used inhaled 
corticosteroids ('corticosteroid-naive’ patients).50 However, this advice is not supported
by clinical evidence. Chapter 5 describes a meta-analysis of the effect of inhaled 
corticosteroids on bronchial responsiveness (the hallmark of asthma) in patients with
‘corticosteroid-naive’ asthma.
In the light of the possible adverse effects of inhaled corticosteroids, it is important
to assess if patients on inhaled corticosteroids can stop this treatment in a stable phase
of the disease. Chapter 6 deals with this problem, using data from a previous study of
our research group concerning patients with mild asthma.
As I have already stated, the clinical effects, optimal dose and duration of treatment
with inhaled corticosteroids in COPD remains a matter of debate. In Chapter 7, a meta-
analysis is performed of studies assessing the long-term effect of inhaled corticosteroids
in patients with COPD. Only patients with a strict diagnosis of COPD, i.e. without 
asthma features, were analysed. In order to minimize the influence of publication bias,
published as well as unpublished studies were checked. We found an unpublished
French study, of which we were able to use the original data for the meta-analysis.51 As
a result of our contacts with the French authors, we were also given the opportunity to
analyse and publish the whole original data set in cooperation with Prof. J.Ph. Derenne
and Prof. T. Similowski, the investigators in question. Chapter 8 presents the two-year
clinical effects of inhaled corticosteroids in a French group of patients with moderate
COPD.
Research questions
The research questions and corresponding chapters of Part One and Part Two of this
thesis are:
Part one (data from the DIMCA study)
Chapter 2 Is the willingness of patients with mild signs of 
asthma or COPD to use inhaled corticosteroids*
dependent on the fear of adverse effects?
Chapter 3 What are the clinical effects of inhaled corticosteroids
in patients with  ‘mild signs of COPD’ or ‘mild signs
of asthma’?
14
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Chapter 4 Are patients with early signs of asthma and 
COPD compliant during treatment with inhaled 
corticosteroids?
Part two
Chapter 5 What is the effect of inhaled corticosteroids on 
bronchial responsiveness in ‘corticosteroid-naive’ 
asthma?
Chapter 6 Is it possible to stop inhaled corticosteroids in a 
stable phase of mild asthma?
Chapter 7 and Chapter 8 What are the clinical effects of inhaled corticosteroids
in patients with moderate to severe COPD?
*In this thesis the words ‘corticosteroids’ and ‘steroids’ are identical. The manuscripts
in which these words are used have been submitted to several journals, which use
either of these words.
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Abstract
Treatment of chronic airflow obstruction with inhaled corticosteroids at an early stage
has been shown to preserve the lung function. We tested the hypothesis that ‘fear of 
corticosteroids’ may be an important reason for nonparticipation in the Detection, early
Intervention and Monitoring programme on Chronic obstruction pulmonary disease
(COPD) and Asthma (‘DIMCA’) project. 
One thousand seven hundred and forty nine adult subjects from 10 general practices
were invited to participate in the several parts of the ‘DIMCA’ programme. Refusers
were questioned about the reason(s) for nonparticipation. 
Together the screening, monitoring and three drug interventions of the study showed
on average 25-35% refusers. The most frequent reasons for nonparticipation were
absence of pulmonary symptoms and lack of time. For those invited to take part in one
of the three drug interventions, ‘dislike of medication’ was the most important reason
for nonparticipation (33, 45 and 67% of the refusers). ‘Fear of corticosteroids’ specifically
was the reason for nonparticipation in 8% of the refusers on the basis of ‘dislike of
medication’. 
We concluded a specific fear of corticosteroids was not a major obstacle for early
intervention with inhaled corticosteroids. 
Introduction
Inhaled corticosteroids are considered as first-line treatment in asthma.1 Treatment with
inhaled corticosteroids in adult patients with newly detected asthma has been shown to
preserve the lung function.2 In chronic obstructive pulmonary disease (COPD), inhaled
corticosteroids may prove to be beneficial to subgroups of COPD patients in the 
short-term,3 but the long-term effects are still under investigation.4 To be able to treat
asthma and COPD at an ‘early’ stage, detection of subjects with few symptoms might be
necessary. 
Inhaled corticosteroids are promoted for their relative safety, though local side-effects
such as hoarseness and oral candidiasis, and when used in high doses, also systemic
side-effects such as suppression of serum cortisol levels, have been described.5 In 
their study, Bosley et al6 discussed psychological factors associated with poor compliance
in asthma. They reported that in some asthmatic patients an unjustified fear of 
corticosteroids or an overemphasis of the side-effects of corticosteroids have been 
recognized as a possible reason for underusage of these drugs. We hypothesized that
‘fear of corticosteroids’ was the main reason for nonparticipation in our large Detection,
Monitoring and early Intervention programme with inhaled corticosteroids in COPD
and Asthma. (‘DIMCA’) study.
Methods
‘DIMCA’ design and refusers
In 1991, a random sample of 1,749 apparently healthy adult subjects from 10 general
practices in the area of Nijmegen, the Netherlands were invited by letter to participate
in a screening programme on signs and symptoms of asthma and COPD. Six hundred
and four subjects with mild signs/symptoms were subsequently invited to participate in
22
ASTHMA AND COPD – TREATMENT WITH INHALED CORTICOSTEROIDS 
Van GrunsvenDEF  13-09-1999 22:33  Pagina 22
a 2 yr monitoring programme with quarterly lung function measurements. Two 
hundred and fifty two patients showed an increased lung function decline or bronchial
hyperresponsiveness during the study period and they were invited by letter to 
participate in one of three randomized, double-blind, placebo-controlled intervention
trials with an inhaled corticosteroid (fluticasone, 500 µg daily). Subjects could only 
participate in one trial. 
‘Drug intervention 1’ (duration 1 yr) included patients selected within 6 months of
monitoring with undetected COPD. ‘Drug intervention 2’ (duration 2 yrs) started 
after 1 yr of monitoring and included patients with a rapid decline in lung function and
signs of bronchial hyperresponsiveness. After the 2 yr monitoring period, patients with
a moderately increased decline in lung function or with signs of bronchial 
hyperresponsiveness were included in ‘Drug intervention 3’ (duration 1 yr for patients
with bronchial hyperresponsiveness and 2 yrs for patients with an increased decline in
lung function). In the letters of invitation for the screening, monitoring and trials, the
reason for selection was explained. Subjects invited for the trials were also informed in
writing about the effects and possible side-effects of fluticasone. Written informed 
consent was obtained from all participants of the trials. Refusers were defined as 
subjects who were considered eligible for the screening, monitoring or one of the 
drug interventions, but who actively refused to participate after a mailing and one phone
call, urging participation.
Measurements
In 1996, all refusers received by mail a multiple choice questionnaire concerning the
reasons of nonparticipation by mail (Table 2.1). The questionnaire had been developed
especially for this study. Subjects were allowed to give more than one reason for non-
participation. The final question in the questionnaire asked whether the decision to not
participate would change if this programme was not an experiment but part of routine
medical care. The refusers who did not respond to the questionnaire were sent one
reminder. In order to gain more specific details about the reasons for refusal, refusers
who had given permission in the questionnaire were phoned again and reasons for
refusal explored in a structured standardized interview. 
Results
The refusal rates were: 34% (95% confidence interval (CI) 32-36%) for the screening;
25% (95% CI 21-29%) for the monitoring; 35% (95% CI 23-49%) for Drug intervention
1; 33% (95% CI 23-44%) for Drug intervention 2; and 28% (95% CI 20-37%) for Drug
intervention 3. Refusers did not differ from participants with respect to age or sex. The
refusers of the monitoring part had a higher level of education than the participants.
Two hundred and sixteen (52%) of the 411 subjects who were sent a questionnaire
completed and returned the questionnaire immediately. Another 28 (7%) subjects
responded after a reminder (Table 2.1). The overall response rates in the different stages
were 48-94%. The main reason for refusing to participate in one of the stages of
‘DIMCA’ was the absence of respiratory symptoms (33-67% of the refusers). Time 
constraints were mentioned by 5-49% of the refusers. Additional in-depth interviews in
46 subjects identified that work and children were critical reasons for nonparticipation.
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Dislike of testing or research was stated by 8-49% of all refusers.
For those invited to one of the three drug interventions, dislike of using medication
emerged as the most import reason for non-participation (33-67% of the subjects).
Twenty three subjects of the intervention group were interviewed in more 
depth. General dislike of medication and general worries concerning side-effects were
mentioned most often (15 (65%) of the refusers to intervention). Only 2 (8%) subjects
mentioned fear of (side-effects by) using corticosteroids specifically. Finally, 54% of 
all refusers stated that they would participate in a project like ‘DIMCA’ if it was part of 
routine medical care.
Discussion
The absence of pulmonary symptoms, lack of time and dislike of medication were 
the main reasons for refusal to participate in an early detection and intervention 
programme with inhaled corticosteroids in asthma and COPD (‘DIMCA’ project). A 
specific ‘fear of corticosteroids’ was found to be a relatively minor reason for refusal. 
In every step of the ‘DIMCA’ project, one out of every three subjects eligible did not
participate. This rate is comparable with nonparticipation rates in several screening 
programmes in older patients concerning breast or uterine cervical cancer, colonic 
cancer and coronary heart disease, ranging 20-69%7.
Only those subjects who gave permission to be phoned for additional information
about their refusal were phoned. Therefore, the in-depth-interview results about the
determinants of refusal, including the fear of corticosteroids, may have been distorted
in some way. 
The absence of pulmonary complaints was a main reason for refusal to enter one of
the three parts of the project. Absence of complaints is likely to be an understandable
reason for absence of motivation. In a colorectal cancer screening programme 83% of
the refusers found the procedure unnecessary, because there were no symptoms.8 Lack
of time is mentioned as an important reason for refusal to screening studies.9-14 In the
present study, one out of three refusers cited lack of time, especially due to work and
family commitments. A possible solution to this problem may be flexibility in time of
appointment (evening, weekend). Dislike of the test is one of the main reasons for non-
participation in preventive screening programmes. 9,10,14,15 In two gynaecological mass
screening programmes, refusers thought the examinations were more unpleasant 
compared to the participants.10,15 In the present study, only a few refusers had a specific
aversion to the lung function tests. 
The present study showed a high rate of general dislike of medication. This is not an
unexpected finding, because most of the subjects of the ‘DIMCA’ study showed only
mild bronchial symptoms. Several studies have shown that the fear of side-effects of
drugs is a common reason for refusal to be treated with hormonal replacement 
therapy16-18, diazepam19 and aspirin20, or to be vaccinated.21,22 The general aversion 
to drugs in our study was accompanied by only a small rate of specific fear of 
inhaled corticosteroids. It is our experience that in the clinical practice patients often do
not consider inhaled drugs as ‘real medicines’ like tablets. Furthermore, inhaled 
corticosteroids may not have the same impact as oral prednisone, which is popularly
known as a ‘kill or cure remedy’. 
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Results of the first drug intervention study of our ‘DIMCA’ project show there are
indications that treatment with inhaled corticosteroids may preserve the lung function
in undetected COPD.23 However, the costs and effectiveness of early detection and 
preventive treatment with inhaled corticosteroids in (largely asymptomatic) asthma 
and COPD have to be weighed carefully before a large scale prescription of inhaled 
corticosteroids may be advisable. 
This is the first (experimental) study describing obstacles in implementing a 
screening and early intervention strategy with inhaled corticosteroids in chronic
obstructive pulmonary disease and asthma in general practice. The absence of 
pulmonary complaints and lack of time as well as a general resistance to medication
were the main determinants of nonparticipation in a relatively healthy and active 
population. However, in contrast to our hypothesis, doctors do not have to fear 
that inhaled corticosteroids in particular are an obstacle to participation in early 
pharmacological intervention in asthma or chronic obstructive pulmonary disease.
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Abstract
Early treatment with inhaled steroids may prevent (irreversible) bronchial obstruction in
patients with asthma and chronic obstructive pulmonary disease (COPD). From a 
theoretical perspective, one could argue that treatment with inhaled steroids should 
be started as soon as the first clinical indications of asthma or COPD appear. We 
investigated the clinical effects of fluticasone propionate in subjects showing ‘mild signs
of COPD’ or ‘mild signs of asthma’ without a clinical diagnosis. 
All subjects were detected in a two-phase detection program in the general adult 
population and had been monitored for two years. Subjects with a moderate increase in
decline in FEV1 of more than 40 ml/year (i.e. mild signs of COPD) were invited for a
two-year randomized placebo-controlled trial with fluticasone 250 µg b.i.d. via Rotadisk®
versus placebo. Subjects who showed signs of bronchial hyperresponsiveness (PC20-
histamine of ≤ 8 mg/ml and/or reversibility of bronchial obstruction ≥ 10% of FEV1
predicted, i.e. mild signs of asthma) were invited for a one-year randomized placebo-
controlled trial. The FEV1 was assessed every three months, PC20 histamine every six
months at a lung function laboratory. Symptoms were recorded weekly by the patients.
In the ‘COPD’ trial the main outcome parameter was the course of postbronchodilator
FEV1, in the ‘asthma’ trial the PC20 histamine. A multivariate repeated measurement
analysis was performed. 
In the ‘COPD’ trial, 48 subjects (24 fluticasone, 24 placebo) participated. The overall
course of FEV1 during the study was not beneficially changed by fluticasone in 
comparison with the placebo group. However, after 3 months of study the 
postbronchodilator FEV1 had increased significantly with +182 ml(SE=64 ml, p=0.004)
in the fluticasone group in comparison with the placebo group. In the ‘asthma’ trial, 
29 subjects (14 fluticasone, 15 placebo) participated. Bronchial hyperresponsiveness 
was not influenced by fluticasone in comparison with placebo. In both trials, there 
were no significant differences in symptoms between the fluticasone and placebo 
treated patients. 
In conclusion, fluticasone propionate (250 µg b.i.d.) did neither reverse the 
deterioration in FEV1 in subjects with mild signs of COPD during two years of 
treatment, nor improve the level of PC20 histamine in patients with mild signs of 
asthma during one year of treatment.
Introduction
Bronchial inflammation is the main cause of bronchial hyperreactivity and symptoms
in asthma and also plays an important role in the genesis of irreversible bronchial
obstruction in patients suffering from chronic obstructive pulmonary disease (COPD).1
Inhaled steroids are considered to be the cornerstone of the treatment of asthma,2
and perhaps also of the treatment of (subgroups of patients with) COPD.3 If the 
inflammatory process of the bronchial wall continues, irreversible changes will occur -
and thus increasing obstruction- like inflammatory cell infiltration, goblet cell 
hyperplasia, basement membrane thickening and airway smooth muscle hyperplasia
and hypertrophia, a process called ‘airway remodelling’.4
Even newly detected asthma patients have already shown symptoms of airway 
mucosal inflammation.5 In these patients, early anti-inflammatory therapy with inhaled
steroids has shown to preserve lung function,6 and thus theoretically to prevent airway
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remodelling. Therefore, recent guidelines on asthma advise treatment with inhaled 
steroids in mild (persistent) stages.2,7 There are also indications that inhaled steroids
decrease the progressive lung function decline (>80 ml/year) in subjects with mild to
moderate COPD.8 Theoretically, treatment with inhaled steroids should be started as
soon as the first clinical features of asthma or COPD appear. 
Mild abnormalities in lung function are not always accompanied by bronchial 
symptoms.9 In such cases, subjects with early indications of COPD (like increased lung
function decline) or asthma (like signs of bronchial hyperresponsiveness) should be
detected early by monitoring lung function, in order to make succesfull treatment 
possible. On the other hand, the (small) clinical effects may be overshadowed by a 
number of adverse effects of the early introduction of inhaled steroids, such as local
side-effects,10 medicalization and the increased cost of healthcare costs for subjects with
a low level of symptoms. 
The efficacy of early treatment with inhaled steroids was investigated in an 
‘experimental design’ in two groups of subjects with mild signs of COPD or asthma.
Patients were selected from an undiagnosed population sample, who had finished the
detection and two-year monitoring part of DIMCA. DIMCA is an acronym for
Detection, Intervention and Monitoring of COPD and asthma. 
Methods
Patients
The two-stage detection program of DIMCA was presented elsewhere.11 Figure 3.1
roughly shows the patient flows in DIMCA. There was no evidence of recruitment or
selection bias during the two parts of the detection program.11 For the first stage of the
DIMCA detection program, a random sample of undiagnosed adult subjects from 10
general practices in the area of Nijmegen were invited to participate in a screening 
program. Screening consisted of a symptoms questionnaire and a lung function 
assessment. Subjects with a positive screening result started a 2-yr monitoring 
period, which was the second stage of the detection. Every 3 months, lung function
(including reversibility), bronchial responsiveness, exacerbations and symptoms were
assessed. Subjects with a moderate or severe bronchial obstruction or bronchial 
hyperresponsiveness during the first year of monitoring were invited to participate in
one of two trials with inhaled fluticasone propionate (DIMCA 1 and 2).   
Results of DIMCA 1 have been reported elsewhere.12,13 When after the 2-yr 
monitoring period subjects did not show any signs or symptoms they were considered
healthy ('false-positives’). Subjects with persisting mild signs of COPD or asthma 
after two years of monitoring were recruited for an intervention with inhaled 
fluticasone propionate 250 µg b.i.d. Subjects with a moderate increase in decline in 
(prebronchodilator) FEV1 of more than 40 ml/yr after the monitoring were invited to
participate in a 2-yr trial, DIMCA 3a ('mild signs of COPD’). A criterion of ‘chronic
cough and/or sputum production at least three months a year during the two-year 
monitoring’ in subjects with a measured (prebronchodilator) FEV1 decline of 40-80
ml/yr was added to minimize the possibility of false-positives.14 A second, mutually
exclusive, group of subjects was invited (DIMCA 3b, ‘mild signs of asthma’) for a 1-yr
trial if they fulfilled at least two of the following three inclusion criteria assessed during the
2-yr monitoring period: 1)PC20 histamine ≤ 8 mg/ml (≥ 2x of 3 yearly measurements),
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Figure 3.1: Patient flow in DIMCA and trial profile of DIMCA 3a and 3b.
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2)reversibility in FEV1 ≥ 10% of FEV1 predicted (≥ 1x of 9 quarterly measurements), 3)≥
1 exacerbation per year or ≥ 1 attack of dyspnea/wheezing during the two-year monitoring
period. Exclusion criteria of both trials were diagnosed asthma or COPD, other 
pulmonary diseases, a history of serious clinical systemic disease likely to interfere with
the objectives of the study (congestive heart failure), pregnant or lactating women,
women of childbearing age who are not taking adequate contraceptive precautions, use
of ß blocking agents, patients unable to use the diskhaler or the peakflowmeter, known
or suspected hyperreactivity to inhaled ß agonists. From all patients who fulfilled the
selection criteria and participated, a written informed consent was obtained. The study
was approved by the local ethical committee.
Trial designs and treatment
Besides the different duration of DIMCA 3a (2 years) and 3b (1 year) the study protocols
were highly similar. Two separate double-blind, randomized, placebo-controlled studies
were performed. In DIMCA 3a, subjects were stratified for FEV1 decline (40-80 ml/yr
versus >80 ml/yr). Patients in each study were randomized to either treatment with 
fluticasone propionate (Flixotide®) 250 µg b.i.d via Rotadisk® or placebo. Participating
family physicians were aware of the official Dutch guidelines on treatment of asthma
and COPD in general practice, including a quit-smoking recommendation at the start
of the study. Also at the start of the study, all participants were informed of a drug 
compliance study: this was done by counting the (full and empty) disks returned. Each
3-monthly lung function visit a package of 50 Rotadisks® (each containing four 
dosages of the study drug, enough for 100 days) was supplied. Patients were instructed
to rinse their mouth after the use of the dry powder inhalations. In addition, the 
inhaler technique was checked at each visit and subjects were asked about their 
compliance. If the inhaler technique was insufficient or subjects stated non-compliance,
they received new inhaler instructions or were encouraged to take the drug twice daily. 
Patients were not allowed to use pulmonary medication other than an inhaled 
short-acting bronchodilator if needed (salbutamol (Ventolin®), terbutaline (Bricanyl®)
or ipratropium bromide (Atrovent®) in case of acute bronchial symptoms. In case of an
exacerbation, the family physician in attendance was instructed to treat in a standardized
way with a 10-day course of prednisone and a broad spectrum antibiotic. Subjects 
with aggravating (pulmonary) disease or suffering from serious adverse effects which
interfered severely with the trial protocol were withdrawn from the study. Information
about serious and minor adverse events was collected and reported.
Measurements
At the start of the studies and half-yearly thereafter, all patients visited a lung function
centre for assessment of lung function, bronchial responsiveness and symptoms. After
3, 6, 9, 15, 18 and 21 months, lung function and symptoms were measured at the 
family practice. During the study, subjects kept a weekly report in which they recorded
the morning and evening peak flow (PEF) and bronchial symptoms. 
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Spirometry 
At the start of the studies and after 6, 12, 18 and 24 months, spirometry (FEV1, FIV1,
FVC, MEF25, MEF50, MEF75) was performed by a trained lung function assistant at
the lung function center using a Microspiro HI-298 (Chest Corp., Japan).15 During 
the same performance, static lung function parameters (IVC, RV and TLC) were 
measured with a wet Gould spirometer.16 At intermediate quarterly visits, spirometry
was performed in the family practice using a hand-held turbine spirometer (Microplus,
SensorMedics; USA). The practice nurses were thoroughly trained. According to the
ATS criteria, the FEV1 corresponding with the highest sum of FEV1 and FVC out of
three satisfactory forced expiratory maneuvres was chosen for analysis.17 At the family
practice, FEV1’s that deviated more than 10% from the mean of three FEV1 maneuvres
were excluded from analysis. The postbronchodilator FEV1 was assessed 15 minutes
after administration of four puffs of 200 µg Ventolin® with a spacer (Volumatic®) 
at the lung function center and at the family practice. Airway reversibility was 
expressed as the increase in FEV1 as a percentage of FEV1 predicted.16 Measurements
were only performed in exacerbation-free periods and not within 8 hours of use of a
bronchodilator.
PC20 histamine
The PC20 histamine was assessed half-yearly in the lung function center according to
the method of Cockcroft.18.. The concentration of histamine provoking a 20% fall in
FEV1 (PC20) was calculated by linear interpolation of adjacent data point which were
log2 transformed.
PEF level and diurnal variation
The PEF was assessed weekly by the subjects with the Miniwright® peakflowmeter.
Three maneuvres were recorded in the morning and in the evening. The highest 
morning and evening PEF were used for analysis. The diurnal variation was assessed
weekly by the following formula: {evening PEF minus morning PEF} divided by the
mean PEF of these two measurements.
Exacerbations
Exacerbations were recorded by the family physician. An exacerbation was defined as at
least two positive answers to the following three items: 1)increased complaints of cough
and/or wheezing and/or dyspnea, 2)change in color of phlegm, 3)increased use of 
bronchodilators, modified from Brand et al.19 When the period between two successive
visits for an exacerbation was less than four weeks, it was considered to be the same 
exacerbation.
Symptoms, ‘episode of increased symptoms'
Four symptoms (cough, dyspnea, wheezing and phlegm) were recorded weekly by the
patients in their reports. Each symptom was recorded on a scale ranging from 0 to 3
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(from 0: no complaints, to 3: all days and/or nights past week). The total weekly score
was assesssed (0-12). When at least one of the following items within the weekly report
was indicated, an episode of increased symptoms was considered to be present: 1) 
increased cough, wheezing or dyspnea, 2)change in color of phlegm, 3)increased use of
bronchodilators, 4)having a cold. When in the following week no item was indicated, the
episode was considered to be finished.
Rescue medication
Each quarterly visit, the number, dose and days of use of bronchodilating rescue 
inhalations were recorded.
Compliance and inhaler technique
All full and empty disks were returned and counted. Individual compliance rates 
were determined by expressing the dosage taken (number of dosages provided minus 
number of dosages left) as a percentage of the amount prescribed during the study
period.
The inhaler technique was checked half-yearly at the lung function laboratory. Four
essential items (breathe out before inhalation, head upright, deep and strong inhalation
and holding breath for 5 seconds) were added to a total score ranging from 0 (very bad)
to 4 (very good). A score of at least 3 was considered sufficient.
Functional status
Functional status was assessed by means of ‘COOP/WONCA-charts’20 at the quarterly
visits in the family practice (0, 3, 6, 9, 15, 18 and 21 mo). Within each of the six charts
of 1) ‘fysical fitness’, 2) ‘feelings’, 3) ‘daily activities’, 4) ‘social activities’ and 5) ‘changes
in health status’ and 6) ‘general health’ the Figure (1 out of 5 Figures) that best fitted
their current status had to be chosen. Each of the Figures had a score ranging from 1
(very good) to 5 (very bad).
Eosinophils
In DIMCA 3b, blood eosinophils were counted at the start and after 12 months of the
trial in the lung function laboratory. Values were expressed in number x109 per liter.
Smoking behaviour
Smoking history was assessed at the start of the trial and expressed as the number of
pack years; number of cigarettes/day multiplied by years smoked and divided by 20.
Changes in smoking behaviour during the study (number of cigarettes/day) were recor-
ded every three months.
Allergy
At the start, all subjects underwent a skin allergy test with 16 allergens (pollen, house
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dust mite, fungi, pets). Subjects were considered allergic when the wheal of at least one
allergen exceeded 2/3 of the histamin control.
Analysis
The statistical package of SAS was used in all analyses21 PC20 values were log2
transformed, eosinophil values were transformed by the natural logarithm (ln) in the
analyses.
In DIMCA 3a, the main outcome parameter was the course of postbronchodilator
FEV1. With 3-monthly measurements of the FEV1, the study duration had to be at least
2 years to assess a reliable course in the FEV1.14 Secondary outcome parameters were
prebronchodilator FEV1 and PC20 histamine. 
In DIMCA 3b, the level of PC20 histamine was the main outcome parameter. A 1-yr
study was estimated to be long enough to assess possible changes in the level of the
PC20 histamine accurately. Secondary effect measures were pre- and postbronchodilator
FEV1 and the PEF.
Intention-to-treat analysis was performed in both DIMCA 3a and DIMCA 3b. In all
the analyses, the effect of fluticasone compared to placebo was considered statistically
significant with p<0.05. 
The effect of fluticasone versus placebo on all primary and secondary outcome 
parameters was measured with a multivariate repeated measurement technique, in
which patient, treatment and time effects were analyzed separately. In individual
patients, one follow-up assessment of the independent variable had to be performed for
inclusion in the analysis. 
The effect of fluticasone in comparison to placebo on the MEF values and symptoms
were also analyzed separately by a repeated measurement analysis. Changes in 
eosinophil counts were tested with the independent Student’s t-test. Differences in
functional status scores per item between the fluticasone and placebo group were 
assessed with the Wilcoxon Ranktest (Z-score). Differences in the number of exacerbations
and episodes of increased symptoms between the actively treated and placebo group
were compared by means of the Poisson test. 
The following independent covariates were used in the models with the primary and
secondary outcome parameters FEV1 and the PC20: age, height, sex, baseline FEV1,
baseline PC20 and baseline airway reversibility, number of pack years, presence of 
allergy. Also the following effect modifiers, which could possibly have influenced the
course of FEV1 or PC20 during the study, were added to the model: the number of
exacerbations, the number of cigarettes smoked daily, the use of bronchodilators and
compliance to the trial drug during the study. In a backward selection procedure only
independent variables with p ≤ 0.05 were maintained in all models. 
Power calculation
We assumed that the within-patient variation of the FEV1 measurement was 100 ml. 
DIMCA 3a: In a group of 28 subjects with mild to moderate COPD, a decrease in the
FEV1 decline from 160 ml/year to 100 ml/year during treatment with inhaled steroids
was shown.8 Therefore, the minimal detectable difference was set on 60 ml. In a 
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subgroup of 16 patients who had finished the two-year monitoring period early, the
mean SD of the FEV1 decline was 66 ml.22 Thus with an alpha=0.05 and a power=0.8,
the number of evaluable patients needed was 16 (one-tailed test). Taking into account a
withdrawal of 10%, 18 patients per treatment arm had to be recruited.
DIMCA 3b: An increase in FEV1 level of approximately 450 ml after 6 months of 
treatment with inhaled steroids (beclomethasone 800 µg daily) was demonstrated in a
group of patients with mild to moderate asthma.8 We estimated our minimal detectable
increase in FEV1 level after one year of study to be at least 100 ml. With an alpha=0.05
and a power=0.8, the number of evaluable patients needed was 28 (one-tailed 
test). Taking into account a withdrawal of 10%, 16 patients per treatment arm had to be
recruited. 
Results
Participants versus non-participants
Seventy four subjects of DIMCA 3a and 45 subjects of DIMCA 3b (which, if extrapolated,
is 19,4% of the general population11) met the inclusion criteria. Twenty-one of these 74
and 12 of these 45 subjects refused participation in the trial concerned. The major 
reason for refusal in both trials was a ‘general dislike of medication’. Other main 
reasons for refusal were ‘lack of time’ and ‘dislike of testing’. An extensive description
of reasons for non-participation to all different parts of the DIMCA program was 
published elsewhere.23 In DIMCA 3a, five subjects were excluded by the investigator
before randomization (2 used 8 blockers, 2 moved away and 1 wanted to have a child).
Four subjects were excluded before randomization to DIMCA 3b on the basis of using ß
blocking agents (2 subjects) or inhaled steroids (2 subjects). The clinical characteristics of
the participants in both trials were comparable with the non-participants in all clinical
relevant parameters.
Patient characteristics
Table 3.1 shows the baseline characteristics of DIMCA 3a. Beside a significantly higher
number of pack years in the fluticasone group, the trial groups were fully comparable at
baseline. Despite randomization, in DIMCA 3b the baseline FEV1 as a percentage of
FEV1 predicted was significantly higher in the fluticasone group than in the placebo
group (Table 3.2).
Fulfilment of intervention
In DIMCA 3a, 12 (of the 48) subjects stopped prematurely with the treatment (6 
fluticasone, 6 placebo), and in DIMCA 3b, four (of the 29) subjects (2 fluticasone, 2
placebo) (Figure 3.1). The most important reasons of drop-out were throat irritation (see
section Adverse Events) and dislike of medication in absence of symptoms. These 
reasons did not differ between the fluticasone and placebo group within either trials.
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Table 3.1: DIMCA 3a. Baseline characteristics (SD are given in parentheses). 
Fluticasone Propionate, n=24 Placebo, n=24
Age (yr) 46(10) 47(11)
Height (cm) 170(7) 172(10)
Male/Female 12/12 13/11
FEV1 pre (L) 3.05(0.70) 3.17(0.76)
FEV1 pre (%pred.) 95(18) 98(17)
FEV1 pre/VC (%) 75(10) 77(6)
FEV1 post (L) 3.16(0.68) 3.19(0.79)
FEV1 post (%pred.) 98(15) 99(18)
FEV1 decline during monitor stage (ml/yr) -109(46) -124(66)
PC20 histamine (mg/ml), geometric mean 14.2 9.2
Airway reversibility (% of FEV1 pred.) 4.0(5.1) 3.0(4.0)
MEF25 (%pred.) 76.7(30.6) 83(21.2)
MEF50 (%pred.) 65.6(27.4) 68.5(24.1)
MEF75 (%pred.) 62.5(60.6) 57.5(20.6)
Symptoms 1.7(1.5) 1.3(1.3)
Allergy (Y/N/no test) 8/15/1 10/13/1
Pack years 11.9(9.5)*p=0.02 5.8(8.4)
Smoker (yes/no) 12/12 8/16
Cigarettes/day 16(8)n=12 15(11)n=7
Table 3.2: DIMCA 3b. Baseline characteristics (SD are given in parentheses).
Fluticasone Propionate, n=14 Placebo, n=15
Age (yr) 46(12) 48(10)
Height (cm) 173(12) 170(8)
Male/Female 6/8 4/11
FEV1 pre (L) 3.20(0.91) 2.67(0.65)
FEV1 pre (%pred.) 97(10)*p=0.012  87(10)*
FEV1 pre/VC (%) 76(10) 69(8)
FEV1 post (L) 3.32(0.88) 2.81(0.65)
FEV1 post (%pred.) 101(10)**p=0.014 91(9)**
FEV1 decline during monitor stage (ml/yr) +18(48) +2(43)
PC20 histamine (mg/ml), geometric mean 8.2 7.0
Airway reversibility (% of FEV1 pred.) 3.7(3.1) 5.2(4.7)
PEF mo (l/min) 479(97) 441(68)
PEF ev (l/min) 479(96) 459(69)
Diurnal PEF variation (l/min) 3.4(3.2) 4.6(2.4)
MEF50 (%pred.) 62.9(20.0)***p=0.047 49.2(14.2)***
Symptoms 0.8(1.3) 1.3(1.6)
Allergy (Y/N/no test) 6/5/3 4/11
Pack years 7.6(10.9) 8.1(8.0)
Smoker (yes/no) 4/10 6/9
Cigarettes/day 19(5)n=4 11(9)n=6
Blood eosinophil count (x109/L) 0.13 0.17
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Figure 3.3: DIMCA 3b: Course of pre- and
postbronchodilator FEV1 (%pred.) and PC20
histamine of the fluticasone group versus the
placebo group. Difference scores, SE and number of
measurements at each point in time in the study were
presented. For reasons of clearness the measurements at
the family practice at 6 months were omitted from the
Figure. One-year estimates (with 95% c.i. and p-value) of
the effect of Fluticasone Propionate versus Placebo on 
the variable presented were calculated with repeated
measurement analysis. FP = fluticasone, PL = placebo, 
LC = assessment in lung center, otherwise in the family
practice.
Figure 3.2: DIMCA 3a: Course of pre- and
postbronchodilator FEV1 (%pred.) and PC20
histamine of the fluticasone group versus the
placebo group. Difference scores, SE and number of
measurements at each point in time in the study were
presented. For reasons of clearness the measurements at
the family practice at 6 and 18 months were omitted from
the Figure. Two-year estimates (with 95% c.i. and p-value)
of the effect of Fluticasone Propionate versus Placebo on
the variable presented were calculated with repeated
measurement analysis. FP = fluticasone, PL = placebo, LC
= assessment in lung center, otherwise in the family 
practice.
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Effects on lung function and PC20
In DIMCA 3a, repeated measurement analysis showed no overall statistically significant
difference in the course of postbronchodilator FEV1 between the fluticasone and 
placebo group (Figure 3.2). However, after 3 months of study the postbronchodilator
FEV1 had increased significantly with +182 ml in the fluticasone group in comparison
to the placebo group (SE=64 ml, p=0.004). The prebronchodilator FEV1 showed a 
comparable course (Figure 3.2). The PC20 did not show significant overall effects of 
fluticasone versus placebo (Figure 3.2).
In DIMCA 3b, no significant effects of fluticasone compared to placebo were shown
on the PC20 and the FEV1 (Figure 3.3). In DIMCA 3b, neither a significant effect of 
fluticasone compared to placebo was shown on the morning PEF (Figure 3.4), nor on
the evening PEF or diurnal variation.
In both trials, baseline MEF values were slightly impaired (Table 3.1 and 3.2).
However, fluticasone did not modify the course of MEF25, MEF50 and MEF75 versus
placebo.
Effects on exacerbations, episodes of increased symptoms, symptoms, use of 
escape bronchodilator drugs, and blood eosinophil count
In DIMCA 3a, 6 exacerbations occurred in five patients of the fluticasone group, and in
the placebo group 4 (in three patients). In the fluticasone group, 127 episodes of 
increased symptoms occurred in 18 patients, in the placebo group 57 such episodes were
counted in 17 patients (p=0.0001, Poisson-test). The mean duration of the episodes was
2 weeks in the fluticasone group and 4 weeks in the placebo group.
In DIMCA 3b, no exacerbations occurred. In the fluticasone group, 19 episodes of
increased symptoms occurred in eight patients (with a mean duration of 3 weeks) 
versus 26 episodes in the placebo group in seven patients (with a mean duration of 4
weeks), p=0.45, Poisson-test. 
Symptoms did not differ significantly between fluticasone and placebo in both trials.
In addition, in both trials no differences were observed between the fluticasone and
placebo group according to the use of escape bronchodilator drugs during the trial (in
DIMCA 3a, six placebo and five fluticasone patients used such a drug, in DIMCA 3b two
placebo and two fluticasone patients).
Blood eosinophil count was not influenced by fluticasone compared to placebo in
DIMCA 3b.
Effects on functional status
In DIMCA 3a, the baseline COOP/WONCA chart scores varied from ‘not impaired’
(1.2(SD 0.6) according to ‘social activities’) to ‘slighly impaired’ (2.4(SD 1.2) 
‘general health’). The majority of patients of both the fluticasone and placebo groups
perceived no overall change of the different items of the COOP/WONCA charts score.
No statistical significant differences between fluticasone and placebo were shown with
regard to each item of the general health status. In DIMCA 3b, the same pattern of
COOP/WONCA scores was observed.
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Adverse events during intervention
In DIMCA 3a, four serious adverse events occurred, of which none was considered to
be related to the trial drug. One patient of the fluticasone group developed polymyalgia
rheumatica requiring prednisone. This patient was withdrawn from the study. Another
patient of the fluticasone group had a period of severe headache and was hospitalized.
In the placebo group, one patient suffered from polyposis nasi and one from a uterus
leiomyoma, both requiring hospitalization. Fourteen (29%) subjects reported (minor)
adverse events that could be related to the trial drug (6 in the fluticasone group: dry 
throat, itching cough after inhalation of trial drug, throat pain {stopped use of trial 
drug for that reason}, scraping throat, retching, hoarseness; 8 in the placebo group:
hoarseness {stopped}, dry cough, itching throat, itching cough {stopped}, irritation of
pharynx (4x), {2 stopped}). 
In DIMCA 3b, one patient in the placebo group suffered from a serious adverse effect
which required hospitalization: angina pectoris-like complaints. In 8 of the 29 subjects
(28%), (oral) side-effects of the trial drug were reported, 5 of the fluticasone group (1
with hoarseness, 2 with throat irritation {one patient stopped use of trial drug for that
reason}, 1 with a dry mouth, 1 with loss of taste) and 3 of the placebo group (1 with
itching cough, 2 with painful throat {1 stopped}). 
In both trials, no cases of oral candidiasis were identified.
Compliance and inhaler technique
In DIMCA 3a, compliance was 72% of the prescribed dose (range 7 to 102%), showing
no difference between the fluticasone and placebo group. In DIMCA 3b, compliance
was 71% (range 8-99%). The subjects in the fluticasone group showed statistically lower
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Figure 3.4: DIMCA 3b: Course of morning peakflow of the fluticasone group in
comparison to the placebo group. Difference scores, SE and number of measurements at each
point in time in the study were presented. The one-year estimate (with 95% c.i. and p-value) of the effect of
Fluticasone Propionate (FP) versus Placebo (P) on the PEF was calculated with repeated measurement analysis.
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compliance rates (58{SE=8}%) than those in the placebo group (83{SE=4}%, p=0.011).
In DIMCA 3a, the inhaler technique was insufficient on one assessment (of five) in 4 
of the 24 participants of the fluticasone group, and in 3 of the 24 participants of 
the placebo group. Two of the 29 participants of DIMCA 3b (both belonging to the 
fluticasone group) showed an insufficient inhaler technique on one assessment (of
three) in the study.
Discussion
This study showed that a long-term inhaled steroids treatment of subjects with mild
signs of COPD (moderately increased lung function decline) or mild signs of asthma
(indications of bronchial hyperresponsiveness) did not influence the course of lung
function or bronchial hyperresponsiveness, respectively.
The FEV1 was the main outcome parameter of DIMCA 3a. The slowly progressive
FEV1 decline (>40 ml/yr) was not reversed by treatment with fluticasone in comparison
to placebo, although a slight significant increase of FEV1 after 3 months of study was
shown. A short-term increase of the FEV1 during treatment with inhaled steroids, 
followed by a progressive decline parallel to placebo was also reported in two large 
multicenter studies in patients with diagnosed (moderate to severe) COPD, the 
EUROSCOP and ISOLDE trial (oral presentations ERS 1998).
In mild asthma, bronchial hyperresponsiveness is supposed to be a more accurate
indicator of inflammation than the FEV1, because bronchial obstruction may be the 
consequence of bronchial hyperresponsiveness,24 especially in early asthma. In DIMCA
3b, the PC20 histamine increased with approximately half a dose step during treatment
with fluticasone in comparison to placebo. However, this increase was not statistically
or clinically significant. The diurnal or morning PEF did not improve either by 
treatment with fluticasone versus placebo. Also, the high baseline level of FEV1 (95-98%
pred.) did not change during treatment with fluticasone versus placebo. Unfortunately,
the randomization had not succeeded according to the FEV1, which was significantly
lower in the placebo group than in the fluticasone group. It may be argued that the room
for improvement was so small in the fluticasone group that it was hard to show any 
positive effect on FEV1. Also, a type 2 error might have occurred, because the trial did
not include the 32 subjects needed as prescribed by the power calculation.
In both trials, additional analyses with interaction terms of the treatment with 
allergy, reversibility of obstruction, PC20 histamine and smoking behaviour did not
reveal subgroups with significant clinical effects of fluticasone compared to placebo on
the main outcome parameters.
As far as the performance of FEV1 measurements with a portable spirometer25 can
be validated in the family practice, this performance was reliable. A sample of 10% 
of assesments of the FEV1 in the family practice showed a reproducibility of 4% on 
average. Also, reanalyzing the data with only the assessments on the lung function
center did not change the main conclusions. 
Although the FEV1 has been widely accepted as the golden standard of bronchial
obstruction and thus of the state of bronchial obstruction in COPD or asthma, the value
of the measurement of FEV1 in very early stages of asthma and COPD is doubtful, 
especially in the presence of only small deviations of FEV1. It was hypothesized that
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patients with mild obstructive airways disease, whose pathophysiologic abnormalities
are linked to the small airways, may be underdiagnosed if spirometry which measures
flow rates at low lung volumes (FEF25-75/50) is not performed.26 Indeed, at the start of
both the trials the MEF values were slightly impaired (approximately 65% of predicted
values), indicating (mild) obstruction of the peripheral airways. However, both in
DIMCA 3a and 3b no effect of fluticasone in comparison to placebo was shown on
MEF25, MEF50 and MEF75.
In COPD, other clinical characteristics of progression or monitoring of treatment 
like ‘quality of life’ attract more and more attention.27 In DIMCA 1 (investigating 
undetected subjects with a persistently reduced lung function) it was shown that 
seeking help from the family physician was associated with impairments in the quality
of life and not with respiratory symptoms or a reduced lung function.28 Significant 
disturbances in the quality of life may also occur with near normal spirometry in
patients with COPD.27 Nevertheless, in DIMCA 3a the generic health status as 
measured with the COOP/WONCA-charts did not show any clear impairment at the
start of the study. This result reflects that a (subjectively) healthy group was selected.
Consequently, it is no surprise that no improvement during treatment with fluticasone
in comparison with placebo was found. 
Recent placebo-controlled trials in COPD showed that treatment with 1000 µg 
fluticasone propionate daily increased the lung function level in six months29 and 1500
µg beclomethasone or 1600 µg budesonide daily decreased the decline in FEV1 during
two years.30 Perhaps the daily dose of 500 µg fluticasone in our study was too low to
achieve a reversal in the progressive lung function decline in DIMCA 3a. 
As already stated, although subjects of DIMCA 3a ('mild signs of COPD’) were 
selected on the basis of an increased decline of (prebronchodilator) FEV1 (on average 
-120 ml/year), they only suffered from mild disturbance of FEV1 (95-98%pred.). During
the subsequent two-year treatment period, the prebronchodilator (as well as the 
postbronchodilator) FEV1 declined less progressively: in the fluticasone group the
(uncorrected) decline was -63 ml/yr versus -78 ml/yr in the placebo group (difference
not significant), which may have been caused by ‘regression to the mean’. In the 
placebo group a statistical significant difference between the 4-year course of pre- and
postbronchodilator FEV1 (-63 ml/yr versus -44 ml/yr, p=0.011) was observed, which may
point to an increase of some (reversible) bronchial inflammation. In the fluticasone group
such difference was not shown, which may indicate some anti-inflammatory effect of
fluticasone on the reversible inflammatory components of bronchial obstruction in
these patients with mild signs of COPD.31 This hypothesis was supported by additional
analysis of reversibility in FEV1. At the end of the trial the airway reversibility tended to
be higher in the placebo group than in the fluticasone group (difference
+2.3%(SE1.2%)). 
In DIMCA 3b, patients were selected on the basis of signs of bronchial hyper-
responsiveness during the monitoring period. Asymptomatic bronchial hyper-
responsiveness is a wellknown phenomenon.32 This may partly explain our 
negative results. On the contrary, Zhong et al showed that 10 out of 50 students with
asymptomatic bronchial hyperresponsiveness developed asthma in the following two
years.33
Only few exacerbations occurred during the trials. Therefore, we chose to introduce
a new variable ‘episode of increased symptoms’. The mean duration of the episodes
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were slightly shortened in DIMCA 3b by treatment with fluticasone in comparison to
placebo, but no beneficial effect of fluticasone in comparison to placebo was shown on
the frequency of obstruction-related symptom episodes. Symptoms and the use of 
bronchodilators during the study were not affected either by treatment with inhaled
fluticasone versus placebo, probably also because of the mild disturbances at baseline. 
Fluticasone propionate is a new inhaled steroid, promoted for its higher local 
potency and thus less systemic side-effects than earlier inhaled steroids.34 Thirty 
percent of the subjects perceived some side-effect of fluticasone in a moderate daily dose
of 500 µg, especially oral complaints. However, this percentage was not different from
the subjects of the placebo groups. The occurrence of side-effects was not related to the
level of compliance during the trials (on average 70% of the prescribed dose). The lower
level of compliance in the fluticasone group of DIMCA 3b could not be fully explained.
However, reanalyzing the data with only the compliant subjects did not change the
results. 
When we translate the results of this study into the family practice, we conclude that
there is no reason for establishing inhaled steroids in subjects with ‘mild signs of
COPD’ or ‘mild signs of asthma’ without a clear diagnosis. Family physicians should
therefore be encouraged to focus on adequate treatment and follow-up of patients when
a diagnosis of (mild) COPD or asthma has been established. A general screening of the
population in order to detect undiagnosed (mild) asthma or COPD is not supported by
this observation. 
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Abstract
In a prospective study, we investigated the long-term compliance to fluticasone 
propionate (FP) by dry powder inhalation (Rotadisk®) in subjects with early signs of
asthma and COPD without an established diagnosis. 
Subjects were selected from a large screening program on early stages of asthma and
COPD (‘DIMCA’ program) in the general practice. Forty eight adult subjects with ‘early
signs of COPD’ (slightly increased FEV1 decline of >0.04L/yr) and 29 adult subjects
with ‘early signs of asthma’ (signs of bronchial hyperresponsiveness or reversibility) 
participated to a randomised placebo-controlled trial with fluticasone propionate
(Flixotide® 500µg daily) versus placebo with a duration of two years or one year 
respectively. Compliance was measured by counting Rotadisks® returned. By means of
a questionnaire participants were asked about perceived effects and/or side-effects of
the trial drug. 
The mean overall individual compliance rates of 72% (range 7 to 102%) in the ‘early
COPD’ trial and 71% (range 8 to 99%) in the ‘early asthma’ trial were maintained
throughout the study. Perceived effectiveness (12% of the participants) or side-effects
(30% of the participants) of the trial drug were not related to compliance. The willingness
of patients to use the trial drug in daily practice if efficacy would be proved was 
statistically significantly related to compliance during the trial (p=0.017). 
It was concluded that the compliance rates found were relatively high in patients with
symptoms of mild asthma or COPD without an established diagnosis. Conviction of the
importance of treatment influenced compliance more positively than perceived (side-)
effects. These results again emphasize the importance of patient education in 
establishing early treatment with inhaled corticosteroids.
List of abbreviations
BHR = bronchial hyperresponsiveness
COPD = chronic obstructive pulmonary disease
DIMCA = Detection, Intervention and Monitoring program of COPD and Asthma
FEV1 = forced expiratory volume in one second
FP = fluticasone propionate
PC20 histamine = provocative concentration of histamine inducing a 20% drop in FEV1
Introduction
The clinical effect of a drug is not only dependent on the specific action of the drug, but
also on the patient’s way of using it. Hence, compliance is an important factor.1 In case
of chronic disorders, extensive literature reviews show compliance levels of up to 50%
of the prescribed drugs.2,3 ‘Clinical characteristics’ (age, sex, severity of the disease) have
not shown a strong relationship, but factors such as the ‘doctor-patient relationship’,
‘simplicity of the regimen’ and ‘patient health beliefs that the disease is serious’ seem
to be important determinants of compliance.4,5
Recent guidelines on asthma encourage the prescription of inhaled corticosteroids
for asthma, and perhaps for COPD as well, in family practice as soon as possible in
order to prevent irreversible loss of lung function.6,7 In the light of the determinants of
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compliance stated above, such preventive therapy with inhaled corticosteroids may only
succeed if patients trust their doctor in prescribing the right drugs when necessary, the
regimen is simple and patients believe that the prognosis of their asthma or COPD is
serious enough to justify the long-term daily use of inhaled corticosteroids. Generally,
inhaled corticosteroids have to be taken twice daily with the use of a dry powder inha-
ler device or a metered dose inhaler. Inhaled corticosteroids do not give immediate
relief of symptoms, and may cause local side-effects like throat irritation.8 In patients
with low or even absent symptoms, these factors may compromise compliance when
the ‘treament is perceived to be worse than the disease’. Therefore, patient education
seems of utmost importance to achieve maximal compliance rates.9
We investigated the long-term compliance to the inhaled corticosteroid fluticasone
propionate (FP) by dry powder inhalation (Rotadisk®) in an experimental study in 
subjects with early signs of asthma and COPD without an established diagnosis.
Reasons for non-compliance stated by the patients were assessed. Finally, the ‘perceived
effectiveness and side-effects’ of the trial drug, ‘ease of use’ of the inhaler and 
‘willingness of patients to use the trial drug in daily practice after proved efficacy’ were
investigated and related to compliance during the study. 
Method
Patients 
The trials in which compliance was measured were part of the ‘DIMCA’ project, a large
Detection, Intervention and Monitoring study in COPD and Asthma in family practice.
An extensive design and purpose of the study was presented elsewhere 10. Figure 4.1
shows the trial profile. In short: a random sample of 1,749 apparently healthy adult 
subjects from 10 family practices in the area of Nijmegen were invited to participate in
a screening program on signs and symptoms of asthma and COPD, followed by a 
two-year surveillance of those with possible signs and/or symptoms. Subjects with a
moderately severe bronchial obstruction or bronchial hyperresponsiveness during the
first year of monitoring were invited to participate in one of two trials with FP versus
placebo (DIMCA 1 or DIMCA 2). Subjects who, during the surveillance period, showed
‘early symptoms of COPD’ (increased FEV1 decline of >0.04 L/yr) or ‘early symptoms 
of asthma’ (bronchial hyperresponsiveness (PC20 histamine ≤ 8 mg/ml) and/or 
reversibility of obstruction (increase in FEV1 ≥ 10% as a percentage of the FEV1 predicted
after application of 800 µg inhaled salbutamol) were recruited for a trial with FP versus
placebo with a duration of two years (DIMCA 3a) or one year (DIMCA 3b) respectively.
From all the patients who met the selection criteria and participated, a written informed
consent was obtained. The study was approved by the local ethical committee.
Study design
Both trials were randomised, double-blind and placebo-controlled studies. All subjects
were treated with the inhaled corticosteroid FP (Flixotide®) Rotadisk® 2dd250 µg or a
placebo by the Diskhaler®. At the start of the trials, the patients were given detailed
information about the anti-inflammatory action of the trial drug, the chance of getting
a placebo, possible local adverse effects (throat complaints) and the importance of using 
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Figure 4.1: Trial profile of the 'early COPD' (DIMCA 3A) and 'early asthma'
(DIMCA 3B) trials in the DIMCA project.
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the drug daily. The clinical effects of FP versus placebo in both the trials will be 
reported later.
Measurements 
At the start of the study, patients were told by the investigator that compliance 
measurements would take place during the whole study. At each three-monthly visit
lung function and symptoms were assessed. In addition, at each visit a fixed amount of
study medication (200 dosages of FP or placebo {50 Rotadisks®} for 100 days) was 
provided. The next visit, all full and empty disks had to be returned. In absence of the
patients, all boxes were counted manually. On each occasion subjects were encouraged
to continue the daily inhalation scheme (1 inhalation 2 times a day) and the inhalation
technique was checked and problems with the study drugs were discussed. At each 
six-monthly visit, subjects were asked by means of a structured questionnaire whether
they had succeeded in taking the inhalations as prescribed, and if not the reason for this
('forgotten’ {especially in absence of symptoms}, ‘absence of symptoms’, ‘no time’,
‘side-effects’ or ‘miscellaneous’ {holidays, illness, irregulair services}). At the end of the
study or after dropping out subjects were questioned by telephone, by means of a 
structured questionnaire, whether they had perceived the trial drug as ‘effective’, and
whether they had perceived ‘side-effects’ of the trial drug. They were also asked about
the ‘ease of use’ of the inhaler and whether they were willing to use the trial drug in daily
practice if it would show to be effective in preventing lung damage in the long-term. 
Analysis 
An intention-to-treat-analysis was performed, meaning that all avaliable full and empty
packages returned were analyzed until subjects finished the study or dropped out. When
a complete box was not returned it was considered missing and not analyzed.
Individual compliance rates (%) were determined by expressing the dosages taken
(number of dosages provided minus the number of dosages left) as a percentage of the
amount prescribed during the study period. Patients were considered to be compliant if
the arbitrary overall compliance rate during the study period was at least 70%. 
In order to investigate a time trend in compliance during the study, individual 
three-monthly compliance rates were assessed. 
With the use of the univariate ANOVA-test, compliance rates to the trial drug were
related to ‘perceived effectiveness and side-effects’, the ‘ease of use of the inhaler’ and
the ‘willingness to use the trial drug in daily practice’ if the trial drug would show 
effectiveness. 
One subject of the ‘early COPD’ trial stopped the drug use as early as within three
months of study, and did not return the box. The compliance rate of this patient was not
analyzed therefore.
Results
Forty-eight subjects participated in the ‘early COPD’ trial (DIMCA 3a), 29 subjects in the
‘early asthma’ trial (DIMCA 3b). In Table 4.1, the main baseline characteristics are
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shown, indicating only small deterioration in FEV1, reversibility of obstruction and PC20
histamine, the latter especially in the ‘early asthma’ group. Thirty-six subjects finished
the two-year ‘early COPD’ trial and 25 subjects finished the one-year ‘early asthma’ trial
(Figure 4.1). Throat complaints and unwillingness to take medication daily were the
main drop-out reasons. No difference in number and reason of dropping out was shown
between the FP and placebo groups of both trials.
Within each of the trials 95%, of all boxes supplied to the patients were returned. The
packages returned contained 88 percent, full or empty of the full disks supplied in the
‘early COPD’ trial (FP 90%, placebo 86%), and 86% in the ‘early asthma’ trial (FP 87%,
placebo 85%). 
Counting disks showed overall individual compliance rates ranging from 7% to 102%
in the two-year ‘early COPD’ trial (mean compliance rate 72%) and 8 to 99% in the 
one-year ‘early asthma trial (mean rate 71%). Figure 4.2 shows a comparable pattern of
division of overall individual compliance rates in the ‘early COPD’ trial compared to the
‘early asthma’ trial. Sixty-two percent (29 of 47) of the participants of the two-year ‘early
COPD’ trial and 69% (20 of 29) of the participants of the one-year ‘early asthma’ 
trial had individual compliance rates of at least 70%. Within the ‘early COPD’ trial, 
compliance rates between the FP and placebo group were comparable (71 an 73%
respectively). In the ‘early asthma’ trial, the subjects in the FP group showed statistically
significantly lower overall compliance rates (58(SE=8)% than in the placebo group
(83(SE=4)%, p=0.011).
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Table 4.1: Baseline characteristics of the 'early COPD' (DIMCA 3a) and ‘early 
asthma’ (DIMCA 3b) trials. Standard deviations or ranges are given in parentheses. Explanation
of characteristics: FEV1%pred. = forced expiratory volume in one second (L) as a percentage of the 
predicted value (which depends on age, sex and height), allergy: present when ≥ 1 of 16 common 
allergens appear to be positive (skin test), pack years = (number of cigarettes smoked daily divided by
20) x (number of years smoked), PC20 histamine: concentration of histamine necessary to induce a
20% drop in FEV1), reversibility %FEV1pred.: increase in FEV1 after administering 800 µg salbutamol
(expressed as a percentage of FEV1pred.), symptoms: wheezing, dyspnea, cough, productive cough in
the past three months, each item adding 1 point in a score of 0-4.
DIMCA 3a DIMCA 3b
(n=48) (n=29)
Age (yr) 47(29-71) 46(30-70)
Male/female (n) 25/23 10/19
FEV1%pred. 96(17) 93(11)
Allergy +/- (n) 18/28/2 10/16/3
Smokers (%) 42 37
Pack years (mean number) 9(0-29) 7(0-31)
PC20 histamine (mg/ml) 11.3(5.7) 5.3(3.5)
Reversibility % FEV1pred. 3(5) 5(3)
Symptoms 1.5(1.4) 0.6(0.9)
Bronchodilators y/n (n) 6/42 2/27
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During the two-year ‘early COPD’ trial, the three-monthly compliance rate of all 
participants decreased slightly from 80(SE=4)% to 71(SE=8)% (Figure 4.3). Only during
months 12 and 15, decreases were statistically significant compared to the start of the
trial. In the one-year ‘early asthma’ trial compliance decreased slightly, not statistically
significant, from 75(SE=5)% to 73(SE=6)%. When only the compliance rates were 
analyzed in subjects who completed the trial drug protocol ('explanatory analysis’),
approximately the same pattern of decrease was shown (from 84%(SE=4%) to
71%(SE=8%) and from 79%(SE=4%) to 73%(SE=6%) respectively). 
In 128 (66%) of all 195 six-monthly registrations on compliance, available subjects
participating in each of both trials stated that they had been fully compliant during the
preceding six months. The mean compliance rate to the trial drug in these patients was
86% of the prescribed dose during this period, compared to 62% in patients admitting
they had not been fully compliant during the past six months. The stated reasons for
non-complying were ‘forgotten’, especially in absence of symptoms (42%), ‘absence of
symptoms’ (3%), ‘no time’ (14%), and ‘miscellaneous’, holidays, illness, irregulair 
services (26%). Fifteen percent of the reports about non-compliance concerned 
‘side-effects’. The reasons of non-compliance were comparable between both trials or
the use of FP versus placebo.
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Figure 4.2: Overall individual compliance rates to inhaled FP (% of prescribed FP)
with respect to the trials (DIMCA 3a and 3b). 
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For practical reasons, only 74 of the 77 participants of both trials were questioned by
telephone after finishing the study or dropping out. Nine of the 74 patients (12%)
questioned (four from the ‘early COPD’ and five from the ‘early asthma’ trial) had 
perceived some effectiveness of the trial drug (less pulmonary symptoms like dyspnea
or cough), six of which also reported some side-effects especially throat complaints. A
total of 22 (30%) percent of the 74 participants in the trials who were questioned reported
side-effects of the trial drug, which they related to the trial drug (painful or irritated
throat, loss of taste, headache). This percentage was approximately the same within both
trials and trial drug arms. The perceived effectiveness and/or side-effect of the trial drug
was not related to individual overall compliance rates (Table 4.2). No significant 
differences appeared between both of the trials or the FP or placebo group.
Handling the Diskhaler® caused seven of the 74 participants some problems (three
of the ‘early COPD’ trial and five of the ‘early asthma’ trial). For example, two subjects
found it difficult to perform the different actions, one patient had a visual disability and
consequently problems with the numbers on the Rotadisk® indicating the number of
unused dosages (4 to 1), one subject simply preferred a tablet. Patients who found the
inhaler easy to use tended to be more compliant than subjects who had some problem
with using the inhaler (Table 4.2).
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Figure 4.3: Change of compliance with inhaled FP (% of percentage FP) during
DIMCA 3a and DIMCA 3b. Standard errors are presented. The number of packages returned at
each particular point in time in the study are depicted (the number of patients participating in the trial
drug protocol at each particular point in time are given in parenthesis). Within both trials, compliance
rates at each assessment were tested with baseline compliance (paired t-test), in case of significance
(p<0.05), this is indicated in the Figure below.
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Fifty-five of the 74 patients questioned (74%) stated they would be willing to inhale
the trial drug daily if it would be strongly advised by the family physician as a means to
prevent lung damage in the long-term. Thirteen subjects hesitated about being treated
with the trial drug if judged necessary by the family physician and six subjects would
only start treatment when the severity of symptoms would justify daily inhalation.
Subjects who stated they were not willing to use the trial drug in daily practice if it was
proved effective were significantly less compliant than subjects who hesitated or were
willing to use the drug in case of proved effectiveness (Table 4.2). Four of the five 
‘definite’ refusers came from the ‘early asthma’ trial (2 FP, 2 placebo).
Discussion
Two out of three patients with early signs of COPD or asthma without an established
diagnosis appeared to be compliant during long-term treatment with FP, although 30%
of the patients perceived side-effects and only 12% perceived effectiveness of FP. One of
ten subjects had some problems with the use of the dry powder inhaler. Only one 
of twelve subjects would refuse the treatment with FP in the daily practice, even if 
prevention of irreversible loss of their lung function would be proved. In these patients,
compliance rates were significantly lower than in patients who realized, if efficacy would
be proved, the disease could be serious enough to justify preventive treatment with 
inhaled corticosteroids.
The mean overall compliance rate to FP was 72%. One may suppose that patients
with a very mild degree of the disease, as in our study are less compliant than patients
with more severe forms of the disease. However, there are insufficient consistent 
clinical data to support this view.11,12 Earlier clinical trials with inhaled corticosteroids
reported compliance rates of 60-80% in moderate asthma patients13,14 and 80-85% in
moderate COPD patients.15,16 However, the assessment periods in these studies with
inhaled corticosteroids were relatively short (12 weeks to six months)13-16 or assessments
were done at the start of the study.15,16 Only one clinical study was published measuring
the compliance to a bronchodilator during a two-year study period.17 In this two-year
study in 3,923 patients with mild to moderate COPD, the overall compliance to 
ipratropium bromide or placebo by metered dose inhaler was comparable to our study,
being approximately 70%.17 These data support the finding in two asthma trials with
both preventive and symptom-relieving inhaled drugs that compliance may not be 
drug-dependent but rather patient-dependent.13,14
Compliance decreased only slightly, and not statistically significantly, during the 
two-year study period. Forgetting to take the study drug, mainly because of a lack of
symptoms, was the main reason for non-compliance as stated by the patient. In the
Lung Health study, the phenomenon of a slowly decreasing compliance rate has also
been shown, also with forgetting as the main reason of non-compliance stated.17 Local
adverse effects (oral complaints like irritation, cough, candidiasis and hoarseness of 
the voice) are well-known side-effects of the use of inhaled corticosteroids, and may 
influence long-term compliance. Indeed, in 30% of the subjects studied local effects
were reported by the patients. However, in accordance to the literature,11,12 in our study
adverse effects turned out to be not an important reason for non-compliance (stated in
only 15% of the reports on non-compliance). Moreover, both the perceived inability of
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the study drug to reduce bronchial symptoms if present (in almost 90% of the 
participants of our study), as well as the perception of side-effects were not related to the
level of compliance. Additional analyses showed that no relationships were found
between most of the patient characteristics and compliance (sex, smoking behaviour,
lung function and symptoms). Only a higher age was related to a higher level of 
compliance, which has been suggested by some authors.4 These results support the
growing opinion that not only patient characteristics but also perceived effectiveness of
the drug or adverse effects do not determine compliance gross.11,12
Well-known determinants of compliance are a simple treatment regimen, a good
patient-doctor relationship and patient understanding of the rationale for treatment.5
Patients in our trial had to inhale twice daily. Compliance has shown to increase when
the daily number of intakes decreases from 4 to 2.18 Only 10% of the subjects studied
reported problems with the inhaler, although a study of Petrie et al showed that patients
preferred the Turbohaler® to the Diskhaler® because it was more convenient to carry
and easier to use.19 Subjects in our study who found the Diskhaler® easy to use tended
to be more compliant than subjects who did not. The investigators also informed all 
participants orally and in writing about the purpose of the trial and the action, and 
possible adverse effects, of the trial drug, and repeated their message regularly during
the study. They also tried to build up a good relationship with individual patients 
during the study by informing regularly about their health status. Although not the 
purpose of the study, perhaps all these efforts to help patients to fulfill the study 
protocol enhanced their compliance. Contrary to this, the investigators of the Lung
Health Study hypothesized that stronger prompting might discourage subjects who 
wished to discontinue using the drug.17 In our study, a statistical significant relationship
was found between the willingness to be treated with the trial drug when efficacy would
be proved on one hand and compliance as has been assessed during the study on the
other hand. This result supports the opinion that when patients believe their disease is
serious enough to justify daily treatment, their compliance will be higher than when
they are sceptical about the severity of their disease and hence about the profit of 
treatment. Thus, in accordance to recent opinions, education seems to be the keyword
in enhancing compliance, especially in mild asthma.20
One has to be cautious with the translation of the results of this study into general
practice. In clinical studies, compliance rates are higher than in general practice, 
mainly because of a selection of subjects which have shown to be compliant.1 First, 
In our ‘DIMCA’ study all subjects had been monitored for as long as for two years and
had all shown compliance to the assessment protocol so far. Secondly, one out of three
subjects had refused to participate in each of the parts of ‘DIMCA’.21 The main reasons
for refusal were ‘lack of symptoms’ and ‘lack of time’ in this relatively healthy and 
active group of patients.21 This may have caused an overestimation of the rate of 
compliance measured when translated into general practice. However, 54% of the 
refusers is willing to use FP if its effect is proved and treatment with FP is part of 
routine clinical care.21 Moreover, 74% of the subjects who participated in the trials of
this study are willing to be treated with FP in daily practice unconditionally if such is
advised by their family physician. 
Compliance rates pertain only to subjects during the time they were actually 
participating in the trial drug protocol. However, 16 of the 77 participants (21%) dropped
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out during the study. In general practice these subjects would be indicated as ‘non-
compliers’. This may have caused a slight overestimation the overall compliance in ‘real
life’.
Half of the patients received placebo inhalations throughout the study. Placebo 
treatment may have caused an underestimation of the perceived effects or side-effects
of FP. However, no differences were found in the perception of clinical effects or side-
effects between placebo and FP. Therefore, the lower compliance rate in the FP group in
comparison to the placebo group in the ‘early asthma’ trial could not be fully explained.  
Counting disks as an objective measure of compliance may cause an overestimation
of actual compliance depending on whether patients will return all issued medication
packages.22 Therefore, in this study the patients were asked to return empty disks as
well. This way, the acceptable percentage of almost 90% of the prescribed disks were
returned, full or empty. Of course, it remained unclear whether the missing disks were
dumped empty or full. And, counting disks periodically does not give insight into the
daily pattern of use of the trial drug like as much as electronic monitoring of compliance.23
At the start of the study, the investigators also told patients frankly that compliance
would be measured throughout the study in order to assess ‘feasibility’ aspects. Telling
patients that compliance will be measured is known to increase compliance significantly
in comparison to measuring the compliance blindly.24 This may have caused an 
overestimation of compliance in ‘real life’ to some extent, because patients did not want
to disappoint the investigator. 
Finally, the questionnaire about the willingness to use the drug in daily practice and
perceived (side-) effects of the study drug was supplied at the end of the trial. Recall bias
can therefore not be fully excluded.
The first analyses of DIMCA 1 (which measures the effect of FP in subjects with
undiagnosed COPD) show that there are indications that FP may preserve the lung
function.25 Since our study of patients with early signs of asthma or COPD without a
diagnosis has shown satisfactory compliance, non-compliance in subjects with a clear
diagnosis of asthma and COPD will only be a relative barrier in establishing treatment.
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Abstract
Background: Inhaled corticosteroids are the most efficacious anti-inflammatory drugs in
asthma. International guidelines also advocate the early introduction of inhaled 
corticosteroids in corticosteroid naive patients. A study was undertaken to assess the
effects of inhaled corticosteroids on bronchial hyperresponsiveness in patients with 
corticosteroid naive asthma by conventional meta-analysis. 
Methods: A Medline search of papers published between January 1966 and June 
1998 was performed and 11 papers were selected in which the patients had no history
of treatment with inhaled or oral corticosteroids. Bronchial responsiveness to 
bronchoconstricting agents was considered as the main outcome parameter. Doubling
doses (DD) of histamine or methacholine were calculated.
Results: The total effect size of inhaled corticosteroids (average daily dose 1000 µg)
versus placebo in the 11 studies was +1.16 DD (95% confidence interval (CI) +0.76 
to +1.57). When only the eight short term studies (2 to 8 weeks) were analysed the effect
size of the bronchoconstricting agent was +0.91 DD (95% CI +0.65 to +1.16). No 
relationship was found between the dose of inhaled corticosteroid used and the effect
on bronchial responsiveness.
Conclusion: This meta-analysis in patients with corticosteroid naive asthma
indicates that, on average, high doses of inhaled corticosteroids decrease bronchial
hyperresponsiveness in 2-8 weeks. It remains unclear whether there is a dose-response
relationship between inhaled corticosteroids and effect on bronchial hyperresponsiveness.
Introduction
Asthma is a chronic inflammatory disease of the airways.1 Inflammatory cells (mast
cells, eosinophils, lymphocytes and macrophages) are present even in patients with mild
asthma.2 Levels of bronchoconstrictor mediators such as histamine and prostaglandins,
which are known to be associated with inflammation, are also increased in mild 
asthma.3 Inhaled corticosteroids are the most effective anti-inflammatory drugs.1
There are indications that early introduction of inhaled corticosteroids may prevent
remodelling of the airway epithelium in patients with asthma and thus irreversible loss
of lung function.1 Recently revised international consensus reports on asthma therefore
advocate the administration of inhaled corticosteroids not only in moderate and severe
asthma, but also in mild asthma.1,4 One of the new recommendations of rapid control
of mild asthma is to start treatment with higher daily doses of inhaled corticosteroids
(up to 1000 µg) than in earlier reports (200-400 µg).5,6 Surprisingly, no systematic
reviews on the effects of inhaled corticosteroids in patients with mild corticosteroid
naive asthma are available to support this recommendation. Hatoum et al performed a
meta-analysis of the effects of treatment with inhaled corticosteroids in patients with
mild chronic asthma based on five published articles,7 and found a significant increase
in the peak expiratory flow (PEF) after treatment. However, PEF was the only main 
outcome parameter used. No measure indicative of bronchial inflammation was 
included. Furthermore, the previous use of inhaled corticosteroids was not an exclusion
criterion of the meta-analysis. It is therefore possible that in all cases the asthma was
‘mild’ because of a (previous) successful treatment with inhaled corticosteroids.
We have therefore performed a meta-analysis of all randomised controlled studies of
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inhaled corticosteroids in patients with corticosteroid naive mild asthma. Patients 
with mild asthma have nearly normal spirometric values and few symptoms, while 
significant bronchial inflammation is present. Bronchial hyperresponsiveness (BHR),
which is considered by many as an indirect measure of inflammation, was therefore
used as the main clinical outcome parameter of the meta-analysis. We also assessed 
the minimum dose of inhaled corticosteroid and the minimal duration of treatment
required to obtain a significant improvement in BHR.
Methods
Inclusion and exclusion criteria
Studies were only included if they reported trials on the clinical effects of inhaled 
corticosteroids in corticosteroid naive mild asthma as indicated in the title or abstract, if
they followed a randomised controlled design, and if they had a duration of at least two
weeks. Exclusion criteria included a history of treatment with inhaled corticosteroids,
absence of the assessment of BHR or the absence of adequate data about the BHR 
(either original data or effect size with standard errors in both the inhaled corticosteroid
and placebo groups).
Selection procedure
A Medline search was performed for papers published between January 1966 and June
1998 with the following ‘free-text’ words: ‘beclomethasone’, ‘budesonide’, ‘fluticasone’,
‘triamcinolone’, ‘flunisolide’, ‘inhaled (cortico)steroid(s)’, ‘asthma(tic)(s)’, ‘mild’, ‘moderate’,
‘(cortico)steroid naive’, ‘newly detected’, ‘newly diagnosed’, ‘non(cortico)steroid dependent’.
The search yielded 258 English references. All abstracts of the retrieved references were
checked manually. Thirty nine papers concerned the pathophysiology of inhaled 
corticosteroids, 24 were general reviews or consensus reports about on corticosteroids,
and 20 discussed the adverse effects of inhaled corticosteroids. One hundred and 
three papers presented the effects of inhaled corticosteroids in various conditions such
as rhinitis and pregnancy and tolerance to ß agonists. Seventy two papers included 
controlled as well as uncontrolled clinical trials of the clinical effects of inhaled 
corticosteroids in mild asthma. The reference lists of these studies were also checked for
additional references. 
By this method, 58 randomised controlled clinical trials assessing the effects of 
inhaled corticosteroids in patients with ‘mild to moderate asthma’ could be selected,8-65
all but one of which8 had a duration of two or more weeks. The method section of 39 
of the remaining 57 papers stated that some of the patients included had a history of 
treatment with inhaled or oral corticosteroids.9-47 These studies were excluded from the
systematic analysis. In three studies48-50 BHR had not been measured and these were
excluded Four of the 15 selected studies51-54 contained data on the bronchoconstricting
agent which were incomplete to estimate the true effect size (and SE) of inhaled 
corticosteroids versus placebo and therefore were not included in the analysis. Eleven
studies were therefore left for inclusion in the meta-analysis. None of these studies
assessed dose-response relationships.
65
CHAPTER 5: ‘CORTICOSTEROID NAIVE’ ASTHMA
Van GrunsvenDEF  13-09-1999 22:33  Pagina 65
Quality assessment of the controlled studies selected
All 11 clinical trials selected for the review were checked by means of a criteria list for
quality assessment of randomised clinical trials based on a recent Delphi consensus.66
When the method section contained information about a specific item on the Delphi list
a score of one point was given. In the absence of information or if there was a negative
answer to a specific question zero points were given. The total score ranged from 0 to
9, a higher score representing a higher quality. Arbitrarily, studies with a score below 6
were jugded to be of insufficient quality and were not reviewed.66
Evaluation of bronchial responsiveness (BHR)
Bronchial hyperresponsiveness to bronchoconstricting agents was considered as the
main outcome measure. The assessment of BHR differed widely between the studies,
depending on the method (methods according to Hargreave,52,55 Eiser,56,57 Chai,65
Sterk58, Yan,64 or the test method not mentioned51,59-62), the bronchoconstricting agent
(histamine, methacholine, propanolol), and the expression method used (PD20, PC15, or
PD35 in mg/ml, µg or µmol). Each of the agents was administered from the lowest 
concentration up to the minimal concentration inducing a specific fall in forced 
expiratory volume in one second (FEV1). To compare the effects of inhaled corticosteroids
on BHR between the studies, doubling doses (DD) of the triggers (log2 transformed)
were calculated (if not already done in the study). An increase of 1 DD of the trigger after
treatment with inhaled corticosteroids meant that double the amount of the trigger 
was needed to achieve the same fall in FEV1. In studies in which more than one irritant
was used for the assessment of BHR only the most common irritant (histamine, 
methacholine) was evaluated.56,59,62,65
Procedure of the meta-analysis 
In each study within the trial groups the difference in dose steps was determined by
final minus baseline assessment. When values were expressed as log10 we used the 
formula log10(final assessment) minus log10(baseline assessment) divided by log102. To
determine the SD of the differences, variances of the independent observations were
used. When the variables x and y were considered, the variance was: var(x-y) = var(x) +
var(y) − 2 x covariance (xy), or, in another formula: var(x-y) = var(x) + var(y) − 2 x
correlation coefficient x SD(x) x SD(y). This correlation coefficient could only be 
assessed within the studies in which all individual data were presented. The mean 
of these coefficients was used as an ‘estimated’ correlation coefficient within the 
remaining studies. The SD was assessed as the root of var(x-y). 
Assessment of the overall effect size was based on the method of DerSimonian and
Laird.67 The effect size of inhaled corticosteroids versus control was assessed by 
subtracting the independent effects (effect of inhaled corticosteroid compared to 
placebo, unpaired t test). In Figure 5.1 the effect size within each study is presented in
DD with 95% confidence intervals (CI) and p values. The estimate was assessed under
the condition of homogeneity. In case of significance (X2 test, p<0.05) the estimate 
was assessed under the condition of heterogeneity. Reasons for heterogeneity were
investigated, if appropriate.
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The doses of inhaled corticosteroids used were related to the effect sizes in two 
different ways. Firstly, an univariate regression analysis was used to relate increasing
doses of inhaled corticosteroid to the effect size of BHR and, secondly, a Wilcoxon rank
test was used to compare the effect size of high doses (≥ 1000 µg daily) and low doses
(<1000 µg daily) of inhaled corticosteroids. It is doubtful whether a dose of 600 µg daily
is ‘low’ for children, so we also assessed the dose-response relationship omitting the two
studies in children. 
To determine whether inhaled corticosteroids would be able to decrease bronchial
responsiveness in short-term studies we repeated the above analysis using only studies
with a maximum duration of 2-8 weeks. 
Results
Quality of studies
All 11 studies selected were of sufficient quality to be reviewed. Four studies were rated
as being of high quality (score of 8)57,58,61,64 and the remaining seven were of sufficient
quality. Most of the 11 studies failed to give an explicit description of the method of 
concealed treatment allocation or intention to treat analysis.
Method of studies
Table 5.1 shows study populations, eligibility criteria, design and intervention of the 11
studies. Two studies were performed in children with atopic asthma.56,57 One study
recruited 103 patients and was a long term study.61 Patient numbers in the other studies
varied from 10 to 40 subjects. Eligilibity criteria differed widely between the studies, 
although all studies excluded subjects who had previously received regular treatment
with inhaled corticosteroids. The duration of most of the studies varied from two weeks
to three months. One study lasted six months,57 and another for two years.61
Nine studies compared the effects of inhaled corticosteroids with placebo and six 
with ß2 agonists. The average daily dosage of inhaled corticosteroids (budesonide or 
beclomethasone) used was 1000 µg (range 400-2000 µg). 
Effects on BHR
Baseline BHR levels were in the mild asthmatic range in five of the studies58,60-63 and
in the moderate asthmatic range in the remaining studies (Table 5.2).
The overall effect BHR of inhaled corticosteroids compared with control was measured
by accumulating the separate effect sizes of the 11 selected studies. For that purpose the
original individual data55,59,65 or mean log10 values, doubling doses, or geometric mean
with SE or 95% CI of histamine or methacholine were substracted56-58,62-64 or assessed
on the basis of the graphics60,61 for all studies separately. 
Effect sizes were all in favour of the inhaled corticosteroid treatment, ranging from
+0.44 to +2.40 DD of the bronchoconstricting agent (Table 5.2). However, Figure 5.1
shows that in five of the 11 studies the inhaled corticosteroid did not have a significant
effect on BHR compared to placebo.55,58-60,65
The total effect size of inhaled corticosteroids versus placebo of the 11 studies was 
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Table 5.1: Randomised controlled clinical trials on the effects of inhaled 
corticosteroids in patients with corticosteroid naive asthma.
DB = double-blind, P = parallel, CO = cross-over, BDP = beclomethasone dipropionaat, BUD = budesonide, MDI = metered
dose inhaler, BHR = bronchial hyperresponsiveness, FEV1 = forced expiratory volume in one second; PC20 or PD20 = 
concentration or dose of provocative agent required to reduce FEV1 by 20% ore more; DD = doubling dose.
No. of patients, 
age, diagnosis
10, 22-38 y, controlled,   
non-steroid 
dependent asthma
31, 7-14 y, mild 
atopic asthma
19, 7-16 y, allergic 
asthma
16, 19-38 y, mild atopic
asthma 
10, 18-45 y, atopic,
mild asthma
14, 21-59 y, newly 
diagnosed asthma
103, 15-64 y, newly
detected asthma
12, 20-27 y, mild 
asthma
10, 20-46 y, mild 
stable ashma
40, 18-45 y, mild to
moderate asthma
25, adults, 
asymptomatic or mild
asthma
Study
Ryan55
Baets56
Kerrebijn57
Bel58
Fuller59
Laitinen60
Haahtela61
O'Connor62
Evans63
Vathenen64
Wiebicke65
Duration 
of asthma
Not specified
Not specified
Not specified
Not specified
Not specified
7,4 months
(range 2-12)
symptoms       
< 12 months
Not specified
Not specified
≥ 2 years
Not specified
Main eligibility
criteria 
Variability in FEV1 >20%,
BHR, only bronchodilators
FEV1 ≥ 75%pred, 
cromoglycate and/or 
bronchodilators, no 
dependence on (oral) 
corticosteroids
PD20 methacholine < 150
µg, FEV1 ≥ 80%pred, no
continuous medication
Non-smoking, FEV1 >
80%pred, PC20
methacholine 1-7mg/ml.
No inhaled or oral 
corticosteroids in the past
Requiring only irregular
therapy with inhaled ß2
agonists
No previous regular 
treatment 
Symptoms < 1 year, never
used  regular medication,
FEV1 reversibility > 15%,
PC15 histamine <32 mg/ml,
no history of regular 
treatment or treatment
with corticosteroids or
cromoglycate
BHR, atopy, only occasional
symptoms controlled by ß2
agonist, FEV1 > 80%pred
FEV1 > 80%pred, atopic
non-smoking, occasional
symptoms controlled only
by ß2 agonist
FEV1 > 50%pred, PD20
histamine ≤ 4 µmol, current
non-smokers, no treatment
other than an inhaled ß2
agonist
FEV1 > 75%pred, no regular
medication required, 
non-smokers, BHR present.
Design and
duration 
DB, CO,         
4 weeks
DB, P,            
2 months
DB, P,            
6 months
DB, P, 
4 weeks
DB, CO,         
3 weeks
DB, P,            
3 months
DB, P,            
2 years
DB, CO,         
2 weeks
DB, CO,         
2 weeks
DB, P,            
6 weeks 
DB, P,            
3 weeks
Intervention, 
daily dose 
400 µg BDP vs. 
placebo, MDI 
600 µg BUD vs. 
placebo, 
MDI + spacer
600 µg BUD vs. 1500
µg terbutaline, MDI
800 µg BUD vs. 
placebo, Turbohaler
1200 µg BUD vs. 
placebo, 
MDI + spacer
1200 µg bud vs. 750 µg
terbutaline, 
MDI + spacer
1200 µg BUD vs. 750 µg
terbutaline, 
MDI + spacer
1600 µg BUD vs.
placebo, Turbohaler
1600 µg BUD vs.
placebo, Turbohaler
1600 µg BUD vs.
placebo, 
MDI + spacer
2000 µg BDP + 800 µg
salbutamol vs. placebo
+ 800 µg salbutamol, 
MDI + spacer
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Table 5.2: Randomised controlled clinical trials on the effects of inhaled 
corticosteroids in patients with corticosteroid-naive asthma. 
BHR = bronchial responsiveness; DD = doubling dose; FEV1 = forced expiratory volume in one second; PEF = peak 
expiratory flow; Raw = specific airways resistance; SO2 = oxygen saturation; PC20 , PD20; = concentration or dose of 
provocative agent required to preduce a fall in FEV1 of 20% or more; HDM = house dust mite. According to effects of 
inhaled corticosteroids versus control group on lung function and symptoms: '+' or '-' means statistically significant 
increase or decrease (p<0.05), '=' means no statistically significant difference * See Figure 5.1.
Major outcome
measures
PC20 histamine
PD20 histamine/
HDM
PD20 metha-
choline
PC20 metha-
choline, max 
airway narrowing
methacholine 
PD35 histamine/
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+1.16 DD (95% CI +0.76 to +1.57, test of heterogeneity) which was statistically significant.
The confidence intervals of the effect size in the study of Baets et al in children did not
fall within the confidence interval of the total effect size when assessed under conditions
of homogeneity (p = 0.014). To determine whether heterogeneity could be explained 
by the variation in age we also assessed the total effect size without the two studies in
children56,57 but the total effect size remained statistically significant (+0.88 DD of the
bronchoconstricting agent (95% CI +0.64 to +1.14)). 
A univariate regression analysis was used to measure any dose-response relationship
between the dose of inhaled corticosteroid on the level of BHR. This analysis showed no
statistically significant relationship (regression coefficient −0.007 DD/100 µg, p = 0.87).
Correcting for study duration did not improve the relationship between the dose of 
inhaled corticosteroids and a decrease in BHR, nor was there a statistically significant
effect found when the patients were divided into two groups according to the dose of
inhaled corticosteroids (<1000 µg daily, 4 studies, total effect +1.25DD; ≥ 1000 µg, seven
studies, total effect +1.13 DD; p = 0.92, Wilcoxon rank test). This difference in effect was
somewhat higher than in the previous analyses (p-values ‘fell’ to p = 0.29 and p = 0.11, 
respectively) when the two studies in children (600 µg daily) were excluded. 
70
ASTHMA AND COPD – TREATMENT WITH INHALED CORTICOSTEROIDS 
Figure 5.1: Effect size of inhaled corticosteroids on bronchial responsiveness in
doubling doses of bronchoconstricting agent with 95% confidence intervals and 
p values. The effect size within each selected study and the overall estimate are presented. Daily doses
of inhaled corticosteroids are given. BUD = budesonide; BDP = beclomethasone; *studies in children;
#only studies in adults; ## only studies of ≤ 2 months.
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We were also interested to determine whether inhaled corticosteroids were able to
decrease BHR during short term treatment. A positive result was seen in four of the
eight studies with a relatively short duration of 2-8 weeks.56,62-64 and a negative result
was seen in the other four.55,58,59,65 We combined the separate study effects in these
short term studies to assess the overall effect size of inhaled corticosteroids compared
with control on BHR. The effect size under the condition of homogeneity was +0.91 DD
(95% CI +0.65 to +1.16) of the bronchoconstrictor in favour of the inhaled corticosteroid
(p = 0.14). We also related the effect sizes of individual studies to the dose of inhaled 
corticosteroids used in the short-term studies by univariate regression analysis wich
gave a regression coefficient of +0.02 DD/100 µg (p = 0.38). Correcting for study 
duration did not improve the relationship between the dose of inhaled corticosteroids
and decrease in BHR. A comparison of low dose (<1000 µg, 3 of 8 studies) versus high
dose inhaled corticosteroids also showed a lack of correlation between the dose used and
the level of BHR (+0.88 DD versus +1.21 DD, respectively; (p = 0.55, Wilcoxon rank test).
Discussion
Inhaled corticosteroids are increasingly considered as first line treatment for asthma,
even in milder stages of the disease.1,4 The degree of BHR is considered to be indirectly
related to degree of bronchial inflammation. This meta-analysis in patients with 
corticosteroid naive asthma indicated that, on average, high doses of inhaled corticosteroids
(mean dose 1000 µg, range 400-2000 µg daily) decreased BHR significantly within 
2-8 weeks. This finding supports recent consensus reports asthma recommending 
the use of relatively high initial doses of inhaled corticosteroids in mild bronchial 
inflammation.1,4 There were insufficient studies to determine whether doses below
1000 µg daily would have been able to produce the same result.
Inhaled corticosteroids have been shown to be the most effective inhaled anti-
inflammatory agents available in asthma and there are indications that the early 
introduction of inhaled corticosteroids may prevent loss of lung function.68 In mild
(corticosteroid naive) asthma the advantages of inhaled corticosteroids have to be 
weighed against the disadvantages. Local side effects such as oral candidiasis and 
systemic side effects such as adrenal suppression have been reported, especially with
higher doses of inhaled corticosteroids.69 It is also important to recognise that control
of BHR is an outcome wich patients with few bronchial symptoms may not consider
important and this may hamper patient-compliance.
A few comments on the method of the meta-analyse have to be made. The purpose
of the study was to assess the first-time treatment effect of inhaled corticosteroids on
bronchial inflammation so we searched the literature for studies of ‘corticosteroid naive’
asthma. This may have led to confusion about the severity and duration of asthma of the
studies included. Firstly, corticosteroid naive asthma is not necessarily mild, and
patients with moderate to severe asthma could have been corticosteroid naive. Baseline
BHR and FEV1 in most of the studies suggested mild to moderate asthma.
Unfortunately, the duration of asthma was not stated in many of the studies so asthma
of recent onset as well as longer standing ashtma (mild or moderate) might have been
present.
The method of assessment of BHR varied widely between the studies. In order to
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compare different measurements of BHR the effects were presented in doubling doses
of the trigger. Although the DD is often used as a clinical and epidemiological effect
parameter, the comparison between the different studies may have resulted in some
bias. However, both histamine and methacholine are the best validated substances for
provocation testing.70
Type 2 errors could have occurred as a number of studies analysed might not have
had enough power. A conventional meta-analysis was therefore performed to obtain a
tighter estimate of the effect size than that obtained by several smaller (and possibly
underpowered) studies. However, we are aware of the fact that such an analysis may not
totally overcome these shortcomings of individual studies. 
We performed a meta-analysis despite the diversity of the studies included. The 
studies contained populations of different ages (children and adults), asthma of 
different duration (less than one year to unspecified), and of slightly different severity,
the use of different inhaled corticosteroids, different dosages of inhaled corticosteroids,
and different study durations (two weeks to two years). These differences might have
influenced the reliability of the results to some extent. However, the direction of effect
sizes was always the same, and the different dosages and duration of the studies made
it possible to estimate dosage and time effects of drug activity. 
In this study the measurement of BHR as a hallmark of inflammation in asthma was
the primary outcome parameter of the effects of inhaled corticosteroids in patients with
corticosteroid naive mild asthma. The clinical relevance of an overall effect size of
approximately 1 DD of the trigger after treatment with inhaled corticosteroids of patients
with corticosteroid naive asthma is not yet clear. This difference is thought to be 
clinically relevant in patients with moderate and severe asthma.71 In those with 
corticosteroid naive asthma the improvement in BHR may be of greater importance
because, in most cases, there is less room for improvement than in moderate and 
severe asthma. There are indications that bronchial inflammation precedes bronchial
obstruction and thus probably symptoms in asthma.72 Patients with corticosteroid 
naive (mostly mild) asthma may have nearly normal spirometric parameters and few
symptoms on testing. Improvements with treatment are therefore difficult to obtain.
Measurement of BHR was therefore chosen as an indicator of bronchial lability.
Nevertheless, in half of the 11 studies analysed there was a significant improvement in
lung function (PEF and/or FEV1) after treatment with inhaled corticosteroids.56,59-61,64
Three of the six studies in which symptoms or the use of bronchodilators were 
evaluated reported a statistically significant decrease in one of these parameters after 
treatment with inhaled corticosteroids.56,61,64
Most studies showed a clinically significant decrease in BHR after treatment with
high doses of inhaled corticosteroids compared with the control drug. However, only in
the two-year study by Haahtela et al in patients with corticosteroid naive mild asthma
did long term treatment with a high dose of inhaled corticosteroids eventually cause
BHR to return to ‘non-asthmatic’ levels.61 Although the first six weeks of treatment 
with inhaled corticosteroids contributed most to the effect on BHR, the PC15 histamine
increased gradually during the two year study. A gradual decrease in the level of BHR
during 12-24 months of treatment with inhaled corticosteroids was also reported in two
studies in patients with moderate asthma.73,74 The six-month study by Kerrebijn et al
and the three month study by Laitinen et al also found that the first 6-8 weeks of 
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treatment with inhaled corticosteroids contributed most to the decrease in BHR.57,60
In the light of these results we suggest that the dose could probably be tapered after 
six weeks to a lower dose (200-400 µg), both to avoid adverse effects and gradually to 
diminish the inflammation in the long term. 
No relationship between the dose of inhaled corticosteroids and the level of BHR was
found. It is possible that the only low dose study included in the analysis55 (400 µg
daily) was too short to show an optimum improvement within the study period of four
weeks, so we cannot fully exclude the possibility of a dose-response effect.
Unfortunately, no studies were analysed in which dose-response relationships were 
tested. Larger and more long term studies are urgently needed in patients with 
corticosteroid naive asthma to assess the effects of first time with inhaled corticosteroids
at different dosages and periods of treatment on both BHR and lung function and
symptoms.
In conclusion, this meta-analysis has indicated that, on average, high doses of 
inhaled corticosteroids (mean dose 1000 µg, range 400 to 2000 µg daily) decreased
BHR within 2-8 weeks in patients with corticosteroid naive asthma. It remains unclear
whether lower doses of inhaled corticosteroids can achieve the same results. In the
meantime it may be wise to follow the recent treatment protocols of consensus reports
on asthma advocating a top-down strategy with inhaled corticosteroids once control of
symptoms has been achieved.
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Abstract
Background: This study investigated if long-term therapy with inhaled corticosteroids
could be discontinued in mild asthma when patients are in a clinically stable phase of
the disease. Data were derived from a 2-year randomized controlled, bronchodilator
intervention study in family practice. 
Methods: The experimental (stop-steroid) group consisted of 19 asthmatic patients
who had used inhaled corticosteroids daily during at least the year preceding this study
and who stopped using these drugs because of participation in the bronchodilator 
intervention study. The control (no-steroid) group consisted of 70 patients with asthma
who had not used corticosteroids in the year preceding the study. At the start of the study
(8 weeks after stopping steroids), the two groups were completely comparable in all 
relevant characteristics. During the 2-year study, patients were treated only with a 
bronchodilator (salbutamol or ipratropium bromide). Outcome measures were: 
exacerbations, symptoms, annual decline in forced expiratory volume in 1 second
(FEV1), annual change in nonspecific bronchial responsiveness (PC20-histamine) and the
need for additional corticosteroid therapy because of symptoms of increased airway
obstruction. 
Results: In the stop-steroid group, 12 of 19 patients (63%) dropped out during 
the study period because of a deterioration of their clinical condition and need for 
additional (inhaled) corticosteroid treatment. In the no-steroid group, only eight
patients dropped out for this reason (11%). In the stop-steroid group, who did not 
use steroids for at least 1 year, the annual FEV1 decline was much larger than in the 
cimparison subjects (165 versus 40 ml/yr).
Conclusion: Stopping maintenance treatment with inhaled corticosteroids may not be
advisable in all patients with mild asthma. Instead of stopping or interrupting 
treatment, family physicians are advised to determine the minimal effective daily dose
of inhaled corticosteroids for each individual patient that provides adequate control of
the disease. 
Introduction
The current understanding that inflammation is a major pathophysiologic mechanism
of asthma1 has resulted in a shift in treatment policy towards the early introduction of
inhaled corticosteroids.2,3 In addition, some recent studies4-6 have suggested that inhaled
corticosteroids can improve the long-term outcome of asthma. The tendency toward
early use of inhaled steroids is strengthened by the finding in two independent studies
that continuous therapy with bronchodilators, the usual alternative to steroid treatment,
may have adverse effects on the control of asthma7 and on the progression of asthma.8
Since continuous therapy with bronchodilators may be detrimental, treatment with
inhaled corticosteroids is probably the only currently available therapy that has been
shown to improve the long-term course of asthma. 
Since the majority of patients with asthma are treated in family practices,9,10
family physicians will be prescribing this therapy for a growing number of patients. 
An important question for family physicians and patients is whether treatment with
inhaled corticosteroids can be interrupted or stopped when patients are in a stable phase
of the disease. Since inhaled steroids do not have a direct symptom-relieving effect,
patient compliance with this medication is a major problem,11 and patients may even
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ask their family physician to stop maintenance treatment with inhaled steroids when
their asthma is stable. Although inhaled steroids have relatively mild side-effects, oral
candidiasis, hoarseness, and irritation of the oropharynx may occur, and systemic effects
may develop when doses of 800 µg or more are used.12 All these aspects make the above
question very relevant. 
If corticosteroids ‘cure’ the underlying mechanisms of asthma and chronic bronchitis
to some extent, steroid treatment can probably be interrupted. If they only suppress 
inflammation temporarily, discontinuing of steroids might be difficult. Some information
is available about the effects of stopping treatment with inhaled corticosteroids in
patients referred for specialist treatment. In one study with moderate-to-severe asthmatic
children, stopping inhaled steroids appeared to cause trouble.13 Haahtela et al showed
that discontinuation of treatment with inhaled steroids in mild asthma often was
accompanied by exacerbation of the disease and may have resulted in irreversible loss
of lung function.14 In another study with mild asthmatic adults, it was shown that
improvements in asthma caused by 1 year’s use of inhaled steroids could be maintained
for at least 3 months after stopping steroid treatment.15 No studies have been performed
in patients from family practice who had not been referred for specialist treatment.
Since most of these patients probably have mild asthma, it seems relevant to investigate
the possibilities of stopping inhaled steroids in these patients.
This study assessed the effects of stopping treatment with inhaled corticosteroids on
long-term control and progression of asthma in a family practice. Data of 89 patients
with asthma from a previous published large intervention study were evaluated.8
Methods
Patients
The study population consisted of 89 asthma patients who entered a 2-year randomised
controlled study of bronchodilator therapy in family practice.8 Figure 6.1 shows 
enrollment of the subjects. Patient selection, and the inclusion and exclusion criteria of
the intervention study have been described in detail elsewhere.8 Twenty-nine family
physicians were asked to select all their patients aged 30 or older with symptoms of 
asthma or chronic bronchitis. Inclusion criteria included only patients with a mild-
to-moderate airway obstruction (forced expiratory volume in 1 second [FEV1] or
FEV1/EVC at least two standard deviations below their predicted value16 but more 
than 50% of the predicted value) and/or bronchial hyperresponsiveness to histamine
(provocative concentration of histamine that produces a 20% fall in FEV1 [PC20], and
PC20 ≤ 8 mg/ml). Exclusion criteria were: dependency on corticosteroids, chronic heart
failure, malignant disorders, or other life-threatening diseases. Only patients with 
airway reactivity due to asthma were included. The criteria for the diagnosis of asthma
were based on the standards of the American Thoracic Society.17 Asthma was defined as
the combination of: 1) reversible obstruction (FEV1 increased by more than 15% of the
baseline value 60 minutes after the administration of 80 µg ipratropium bromide and
400 µg salbutamol), 2) bronchial hyperresponsiveness to histamine (PC20 ≤ 8 mg/ml),
3) dyspnea, and 4) allergy and/or wheezing. 
The experimental (stop-steroid) group had 19 asthmatic patients who had 
continuously used (inhaled) corticosteroids daily during at least 1 year preceding the
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study and stopped because of participation in the bronchodilator intervention study.
These patients had been given permission by their physician to stop corticosteroids, and
they entered an 8-week washout period before the start of the bronchodilator study,
during which inhaled corticosteroid treatment (and other pulmonary medication) 
was stopped. During this period, only as-needed inhaled salbutamol or ipratropium
bromide were prescribed. No patients had an exacerbation during this washout period
and were therefore not excluded from the study. 
The control (no-steroid) group consisted of the remaining 70 asthmatic patients who
had not used inhaled corticosteroids in the year preceding the study. The clinical 
characteristics of the stop-steroid and no-steroid groups are shown in Table 6.1. At the
start of the study, the two groups had no significant differences.
The study was approved by the Medical Ethics Committee of the University of
Nijmegen. All patients gave informed consent. 
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Figure 6.1: Enrollment of study subjects. A total of 524 patients were selected at the start of
the 2-year bronchodilator trial; 300 patients did not participate in the study for several reasons (see
arrows). Of the 224 patients who eventually took part in the bronchodilator trial, only patients with 
asthma (n=89) were used in this study. No dropouts occurred in the 8-week washout period. At the 
start of the study, the stop-steroid group had 19 asthmatic patients. Due to dropout after 1 and 2 years 
of study, only 10 and 5 patients remained, respectively. The no-steroid group had 70 asthmatic patients.
After 1 and 2 years of study, only 62 and 54 patients remained, respectively.
n = number of patients
FEV1 = forced expiratory volume in 1 second
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Outcome measures
The stop-steroid and no-steroid groups were followed for 2 years while receiving 
standard bronchodilator treatment. The main outcome measure during this period 
was the annual decline, if any, in FEV1. On the basis of earlier research,6,8 it was 
determined that the minimum detecTable difference in FEV1 decline was 120 ml/yr,
with an individual standard deviation of the FEV1 decline of 100 ml. With an alpha of
.05 and a power of .8 the number of patients who could be evaluated had to be at least
10 in each study group. 
Secondary outcome measures during this period were: the number of exacerbations,
severity of symptoms and annual change in nonspecific bronchial responsiveness
(PC20-histamine). An important outcome measurement and endpoint in this study was
the need for corticosteroid therapy due to too severe or too many exacerbations. The
category ‘too severe exacerbations’ was defined as exacerbations not sufficiently treated
by a 10-day course of oral prednisone, adding broad spectrum antibiotics if necessary.
The category ‘too many exacerbations’ was more than two exacerbations annually.
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Table 6.1: Patiënt characteristics.*
Variable Experimental Control 
‘Stop Steroid’ Group ‘No-steroid’ group
Number 19 70
Age, years 56 (12) 51 (12)
Gender, male/female 6/13 35/35
Symptom score 4.6 (1.5) 4.9 (1.7)
# of packs/year of smoking 12(10) 12 (16)
Smokers, yes/no/no data 2/8/9 27/38/5
Allergy,** yes/no/no data 5/6/8 24/40/5
FEV1 %predicted 71 (19) 72 (20)
FEV1/IVC, % 62 (15) 61 (11)
Reversibility FEV1, % predicted 17 (10) 14 (11)
PC20-histamine, mg/ml .6 1.3
* Characteristics are of the 19 patients of the stop-steroid group (continuous use of inhaled corticosteroids
during the year preceding the study), and the 70 patients of the no-steroid group (no use of corticosteroids
during the pre-study period). Standard deviations or ranges are in parentheses. Differences in dichotomic
variables were statistically compared using the chi-square test and were compared in normally distributed
variables using the the unpaired Student's t test. No statistically significant differences were present.
** Allergy was defined as at least one positive test out of seven RAST (Radio Allergo Sorbent Tests).
FEV1 - Forced expiratory volume in 1 second as a percentage of the predicted value
IVC - Inspiratory vital capacity
PC20- histamine - Provocative concentration of histamine (the dose of histamine producing a 20% fall in
FEV1 ). Geometric mean PC20 is given.
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Measurements
Respiratory symptoms
The severity of respiratory symptoms (cough, phlegm, dyspnea) was assessed weekly by
each subject on a scale of 0-4 and recorded in a diary. A score of ‘4’ indicated worst
symptoms and ‘0’ indicated no symptoms. The total score was computed by adding the
cough, phlegm, and dyspnea scores (maximum 4 points each) to yield a total score. The
highest (most symptomatic) possible score was 12.
Exacerbations
Exacerbations were defined according to Fletcher et al,18 with modifications of Boman
et al19 as the occurence of mucopurulent sputum, cough and at least one of the 
following symptoms: general malaise, symptoms of common cold, fever, dyspnea, 
increased sputum production, increased sputum thickness, foul-tasting sputum, or
increased difficulty of expectoration. In case of an exacerbation, a 10-day tapering-down
course of oral prednisone was given (25, 25, 20, 20, 15, 15, 10, 10, 5, 5 mg).
FEV1, PC20-histamine and reversibility of airway obstruction
No bronchodilating medication was taken for at least 8 hours before the assessments of
airway obstruction. Measurements of FEV1 were performed with the Microspiro HI-298
spirometer® (Chest Corporation, Japan) by two qualified laboratory technicians.20
Patients had to perform three satisfactory forced vital capacity (FVC) maneuvres on all
occasions. Data were taken from the curve with the highest sum of FVC and FEV1. The
bronchial responsiveness to histamine was measured using the method described 
by Cockcroft et al21 and expressed as the PC20-histamine value. After the FEV1 had 
returned to baseline value, the increase in FEV1 60 minutes after the inhalation of both
400 µg salbutamol and 80 µg ipratropium bromide was assessed. 
Smoking behaviour
The number of cigarettes per day was recorded by the patients in a weekly report. The
smoking history was retrospectively assessed and quantified in pack years. 
Treatment during two-year follow-up 
All patients received bronchodilator therapy alone during the 2-year study period, either
continuously (salbutamol 400 µg or ipratropium bromide 40 µg, four times daily) or on
demand (only dry powder capsules of salbutamol 400 µg or ipratropium 40 µg during
complaints or exacerbations).8 No inhaled steroids or cromoglycate were permitted.
Patients using salbutamol during the first year crossed over to ipratropium bromide
during the second and vice versa.8
Analysis
The scores of cough, phlegm, and dyspnea were combined in the total symptom score.
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The annual FEV1 decline was determined by linear regression of FEV1 over the course
of time (maximum of seven measurements). PC20 values were 2log transformed prior
to analysis. The annual changes of PC20 were estimated by linear regression of
2logPC20 in the course of time (maximum of five measurements). 
The influence of stopping treatment with inhaled corticosteroids on the outcome
variables was assessed by multiple analysis of variance (MANOVA), adjusting for age,
gender, height, smoking, pack years, allergy, initial PC20 and FEV1, reversibility of
obstruction, and bronchodilator treatment during the study.22 The relation between 
clinical characteristics and the annual FEV1 decline after stopping treatment with 
steroids in the stop-steroid group was also investigated by means of MANOVA. 
The effects of stopping steroids on decline in lung function and change in bronchial
hyperresponsiveness, exacerbations, and symptoms were only investigated in subjects
who could stop using steroids for at least 1 year (explanatory analysis, no intention-
to-treat analysis).
Results
In the stop-steroid group, 12 of the 19 patients (63%) dropped out during the 
2-year study period because of a deterioration of their clinical condition and need for
additional (inhaled) corticosteroid treatment, vs only eight of the 70 patients (11%) in
the no-steroid group (chi-square=20.1, P<.0001). Of the 12 dropouts from the stop-
steroid group, eight needed additional corticosteroids during the first 6 months of the
bronchodilator trial (Table 6.2).
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Table 6.2: Number of dropouts, period of dropout, and reasons for dropout during
the 2-year study*.
Experimental  Control ‘No-steroid’ 
‘Stop-steroid’ Group 
Group  n=19 n=70
n (%) n (%)
0-6 months • Too severe or too many exacerbations 
(needing steroids) 8 (42) 1 (5)
• Other reasons** 4 (6) 4 (6)
6-12 months • Too severe or too many exacerbations 
(needing steroids) 0 (0) 0 (0)
• Other reasons** 0 (0) 0 (0)
12-24 months • Too severe or too many exacerbations 
(needing steroids) 4 (21) 1 (5)
• Other reasons** 4 (6) 4 (6)
* - in both the stop-steroid and no-steroid groups
** - Lack of motivation, emigration, malignancy, side effects of bronchodilator study medication
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When the patients who could continue bronchodilator without inhaled steroids during
at least 1 year were analyzed, the following data were found (Table 6.3). The annual FEV1
decline was larger in the stop-steroid group (165 ml/yr) than in the no-steroid group (40
ml/yr) (P=.022). No differences between groups were found with respect to symptoms,
exacerbations, and the annual change in PC20. 
No feature could predict the effect of stopping inhaled corticosteroids at the start 
of the study. Allergy, initial FEV1 and PC20, reversibility of obstruction, and smoking
behaviour before and during the study were all unrelated to the difference in annual
decline in FEV1 in the stop-steroid and no-steroid groups.
Discussion
Long-term treatment of asthma with inhaled corticosteroids is becoming increasingly
important for family physicians. Two recent guidelines about the therapeutic 
management of asthma advocated the early introduction of inhaled corticosteroids in
subjects with asthma.2-3 Since most patients with asthma are treated in primary 
care9-10 and indications for the use of inhaled corticosteroids are increasing, family 
physicians will have to prescribe this kind of therapy for a growing number of patients.
For family physicians, an important therapeutic question about treatment with inhaled
corticosteroids is whether maintenance therapy with these drugs can be discontinued
when adequate control of the disease has been achieved. This question has not yet been
addressed in a long-term follow-up study in patients selected from family practice.
Therefore, it seemed appropriate to study the ability to stop steroid therapy under close
observation, as we did in this study. 
This study shows that it is difficult to stop treatment with inhaled corticosteroids in
patients with mild asthma. Of the 19 patients in whom steroids were stopped, 12 (63%)
needed additional corticosteroids during the 2-year study period, mostly during the 
first 6 months after stopping. This percentage was much higher than in the group of
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Table 6.3: Effects of stopping treatment with corticosteroids.
Experimental  Control
‘Stop-steroid’ Group ‘No-steroid’ Group P value
n=10 n = 62
FEV1 decline, ml/year 165 (50) 40 (20) .022
PC20 decline, doubling dose/yr .33 (.62) .33 (0.22) 1.000
Exacerbations, number/year 1.1 (.3) .8 (0.1) .216
Symptom score 2.0 (.5) 2.2 (0.3) .697
Table shows the effect of stopping treatment with corticosteroids on symptoms, exacerbations, the annual
decline in FEV1 (forced expiratory volume in 1 second), and PC20 (provocative concentration of histamine
producing a 20% fall in FEV1) in patients with mild asthma who could stop using corticosteroids at least
during 1 year. Standard errors of the mean are in parentheses. Differences were tested by means of the
unpaired Student's t test. 
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subjects not using steroids regularly (11%). In the patients who stopped steroids 
and were able to continue treatment with bronchodilators alone (without inhaled 
steroids) for at least 1 year, the annual decline in ventilatory function was much higher
than in the no-steroid group. However, no increased deterioration in bronchial 
hyperresponsiveness was found in the patients stopping inhaled corticosteroids.
Perhaps the PC20 had already declined during the washout period just before the start
of the study.23,24
The high percentage of patients who needed additional corticosteroid therapy and 
the large decline of FEV1 in the patients stopping treatment with steroids suggests that
inhaled steroids do not cure but only suppress underlying disease processes. It even 
suggests the existence of a ‘rebound’ increase in airway inflammation and a consequent
excessive increase in airway obstruction after the withdrawal of steroids. Short-term 
studies in asthma demonstrated a decline in FEV1 and an increase in nonspecific 
bronchial responsiveness after withdrawal or dose reduction15 of inhaled steroids.23-25
One long-term study in patients with asthma referred to specialist treatment also
showed a decline in FEV1 level after stopping inhaled budesonide14. After stopping 
treatment with oral steroids or replacement by inhaled corticosteroids, fatal asthma26
and severe asthma relapse27 may occur as late as 4-8 months after discontinuation.
Fortunately, none of the stop-steroid group in our study had fatal or near-fatal asthma
after cessation of steroids. The syndrome of pseudorheumatism (myalgia, arthralgia,
joint swelling, etc.) in some asthmatic patients stopping treatment with oral steroids28
might also suggest a rebound increase in systemic and local inflammatory processes. 
In origin, this study had another research question, and the information presented in
this report represents a reanalysis of study data. A disadvantage of such a re-analysis is
that the study protocol was not specifically designed for the purpose for which we used
it. Therefore, the research reported here can only serve as an observational study. As a
consequence, the study (stop-steroid) and comparison (no-steroid) groups do not really
have an experimental-control relationship. Measuring dropouts as an outcome might
have interfered with the main outcome measures of the study (FEV1decline,
PC20decline etc.), since the study was unblinded and not randomized. Patients in 
the stop-steroid group had already taken an inhaled steroid for at least 1 year and could
easily drop out during the study on the basis of this pre-study medication experience.
However, despite the many dropouts in the from the experimental (stop-steroid) group,
we were still able to show a significantly faster decline of FEV1 in this group than in the
no-steroid group (165 vs. 40 ml/yr). A better design to answer this paper’s question
would have been a randomized, controlled, double-blind study in which one group of
patients would continue and another group would discontinue the medication. Before
firm conclusions can be drawn about the possibility of stopping inhaled steroids, such
a study is absolutely necessary.
In spite of this limitation, we believe this study suggests that physicians should be
careful in their decision when to stop inhaled steroids in patients with asthma. For 
this study, we selected only those patients who had mild degrees of airway obstruction
(FEV1 was 75% of the predicted value), mild symptoms, and who, in the opinion of the
responsible family physician, could potentially stop the use of inhaled corticosteroid 
therapy. No measured differences were detected in characteristics at the start of the
study between the patients who had used inhaled corticosteroids and those who had not,
8 weeks after stopping the steroid treatment. During this 8-week washout period, we
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observed whether the symptoms were well controlled by bronchodilators alone and if no
exacerbations or signs of increasing airway obstruction developed. If patients had not
responded well to this bronchodilating therapy alone, they would have been excluded
from the study. However, this did not occur.
As mentioned earlier, at the start of the study the stop-steroid and no-steroid groups
were identical for all erlevant characteristics. As a consequence, their needs for steroid
therapy should also be identical. Therefore, the use of steroids seems to pose a risk in
patients in that future discontinuation of the drug is associated with a deterioration in
lung function. The majority of the stop-steroid group had been referred to the lung 
specialist before the start of the use of steroids. Therefore, we could overtake the mean
initial FEV1 of this group of patients. The mean FEV1 percentage predicted was 71%, the
same level as at the start of the study. However, the reason for referral in the stop-
steroid group could have been an unstable (steroid-dependent) asthma. Theoretically, it
is possible that the deterioration in lung function of the stop-steroid group was caused
by this fact. In that case, an 8-week washout period would not have been long enough
to eliminate the protective effect of steroids in  the airways. Nonetheless, this study’s
data suggest that if a physician is considering stopping inhaled steroid therapy in a
patient with apparently mild (stable) asthma, the patient must be monitored closely for
at least 6 months after stopping.
Conclusions
Stopping maintenance treatment with inhaled corticosteroids in patients with mild 
asthma might be troublesome. In this observational study, about 60% of the patients
needed additional inhaled corticosteroids after discontinuation of the drug, most of
them during the first 6 months after stopping. In the patients who could continue 
without corticosteroids during at least 1 year, the annual decline in ventilatory function
was much larger than in the comparison group. Instead of stopping inhaled steroids,
family physicians are advised to determine the minimal effective daily dose of inhaled
corticosteroids that provides adequate control of the disease in individual patients. 
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Abstract
Background: The role of inhaled corticosteroids in the long term management of 
chronic obstructive pulmonary disease (COPD) is still unclear. A meta-analysis of the
original data sets of the randomised controlled trials published thus far was therefore
performed. The main question was: ‘Are inhaled corticosteroids able to slow down the
decline in lung function (FEV1) in COPD?’
Methods: A medline search of papers published betwen 1983 and 1996 was 
performed and three studies were selected, two of which were published in full and one
in abstract form. Patients with ‘asthmatic features’ were excluded from the original data.
Ninety five of the original 140 patients treated with inhaled corticosteroids (81 with 1500
µg beclomethasone daily, six with 1600 µg budesonide daily, and eight with 800 µg
beclomethasone daily) and 88 patients treated with placebo (of the inital 144 patients)
were included in the analysis. The effect on FEV1 was assessed by a multiple repeated
measurement technique in which points of time in the study and treatment effects
(inhaled corticosteroids compared with placebo) were investigated.  
Results: No baseline differences were observed (mean age 61 years, mean FEV1 45%
predicted). The estimated two year difference in prebronchodilator FEV1 was +0.034
l/year (95% confidence interval (CI) 0.005 to 0.063) in the inhaled corticosteroid group
compared with placebo. The postbronchodilator FEV1 showed a difference of +0.039
l/year (95% CI -0.006 to 0.084). No beneficial effect was observed on the exacerbation
rate. Worsening of the disease was the reason for drop out in four patients in the 
treatment group compared with nine in the placebo group. In the treatment group 
six of the 95 subjects dropped out because of an adverse effect which may have been
related to the treatment compared with two of the 88 patients in the placebo group.
Conclusions: This meta-analysis in patients with clearly defined moderately severe
COPD showed a beneficial course of FEV1 during two years of treatment with relatively
high daily dosages of inhaled corticosteroids.
Introduction
The role of anti-inflammatory therapy (inhaled corticosteroids) is still unclear in the
management of patients with stable chronic obstructive pulmonary disease (COPD). 
In contrast to asthma, several international consensus reports on the management 
of COPD mention that the evidence for beneficial effects of inhaled corticosteroids 
on lung function and symptoms has not yet been established.1,2 In asthma, inhaled 
corticosteroids have beneficial effects by reducing inflammation in the airways. Although
inflammation seems to be present in the airway walls of patients with COPD (in terms
of macrophages, T cells, and neutrophils), the specific immunopathology is thought 
to be different from asthma.3 Short-term treatment with both inhaled and systemic 
corticosteroids may have some beneficial effects on symptoms and lung function level
in subgroups of COPD patients, in particular those with partially reversible airways
obstruction.4 Two long-term uncontrolled and retrospective studies have shown that
systemic corticosteroids slowed down the progression of deline in lung function in
patients with moderate and severe COPD.5,6 The effects of prednisone were observed
after 6-24 months, the effects being larger with doses of 10 mg and higher.5,6 Especially
in the long term, however, systemic corticosteroids may cause serious side effects. If
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long term treatment with corticosteroids is needed, it would therefore be preferable to
replace systemic by inhaled corticosteroids.1,2
Thus far, three long term prospective clinical trials on inhaled corticosteroids in
COPD have been published in full,7-9 and two in abstract form.10,11 All studies showed
more or less beneficial effects of inhaled corticosteroids on the decline in lung function.
In two of these studies it was shown that patients with ‘asthma features’ - that is, high
bronchodilator response and bronchial responsiveness - may respond better to inhaled
corticosteroids.4,12 However, the inclusion of ‘asthmatic’ COPD patients in each of 
these studies may have caused an overestimation of the beneficial effects of inhaled 
corticosteroids. It would be interesting to re-analyse the effects of inhaled corticosteroids
only in the patients with clearly defined COPD, preferably by a cumulative analysis to
avoid, as far as possible, underestimations of the effects of inhaled corticosteroids by
subgroup analysis of each separate study.
We have therefore performed a meta-analysis of the original individual patient 
data from these studies, selecting only patients with a strict diagnosis of COPD. The 
primary question was: ‘Are inhaled corticosteroids able to slow down the decline in 
lung function?’ Secondary questions were: ‘What is the point in time when inhaled 
corticosteroids start to have a significant effect on the course of lung function?’, ‘Is there
a dose-effect relationship?’, and ‘Which clinical characteristics predict the effect?’
Methods
selection of studies for the meta-analysis
A Medline search covering the period from 1983 to 1996 with the ‘free-text’ words
‘COPD’, ‘chronic airflow obstruction’, ‘obstructive airways disease’, ‘chronic airflow
limitation’, ‘chronic bronchitis’, ‘inhaled corticosteroids’, ‘beclomethasone’, ‘budesonide’,
and ‘fluticasone’ yielded 94 references. The reference list of these studies was also 
checked for usable studies. We also checked Biosis (1991-1996), On Line Contents
(1993-1996), ‘GLIN’ (Grey Literature Netherlands, 1982-1996), The Cochrane Library,
and finally Embase (1993-1996). No new references were found using the keywords
above. Only studies with a duration of at least 24 months were considered to be long
enough to assess long term effects of inhaled corticosteroids on the decline in lung 
function. Only five studies met this criterion.7-11 Three studies were published in 
full,7-9 and two as abstracts.10,11 In order to be able to compare the effect of inhaled 
corticosteroids with that of placebo, only randomised, placebo controlled clinical trials
were included.7,9,10 Therefore, the self-controlled study of Dompeling et al8 and the 
therapeutic trial of Weir et al11 were not used in the meta-analysis. 
Details of the studies
In Table 7.1 patient selection criteria, method, and analysis of the three studies are 
summarized. Renkema et al7 investigated the effects of a two years of treatment with
inhaled budesonide (1600 µg/day) versus inhaled budesonide plus prednisone 
(5 mg/day) versus placebo on decline in lung function, symptoms, exacerbations, and 
drop outs in 58 non-allergic patients with moderate to severe COPD. In the French 
multicenter study by Derenne et al10 the effects of inhaled beclomethasone (1500
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Table 7.1: The three placebo-controlled trials on the long-term effects of inhaled corticosteroids in
bud = budesonide, plac = placebo, pred = prednisone, becl = beclomethasone, terb = terbutaline, ipra = ipratropium
Inclusion criteria
Exclusion criteria
Setting
Design
Duration of study
Study drugs
Concomitant  drugs
Outcome
Criteria pulmonary dropout
Definition exacerbation
Treatment of exacerbation
Method of allergy measurement
Compliance check
Statistical analysis:
Overall method
Subgroup?
Measurement of FEV1 decline
Financial support
Renkema et al7
Clinical diagnosis of COPD based on history (persistent dyspnoea without
sudden attacks of dypnoea; FEV1 <80% pred; RV>100%pred; specific 
compliance(Csp) >100% pred after bronchodilation; no signs of allergy
(negative skin test results), total serum IgE < 200 IU/ml, eosinophils in
peripheral blood < 250x103/ml; stable phase of disease; α1-antitrypsin 
within normal range; (ex-)smoker 
Age ≥ 70; continuous corticosteroid therapy; severe concomitant disease
Clinical, one centre
Double blind,  placebo controlled, 3 parallel arms
24 months
Bud 800 µg bd MDI through Nebuhaler® + plac 1dd versus bud 800 µg
bd + pred 5 mg 1dd versus plac bd + plac 1dd
Anticholinergics, β2 agonists, theophylline or antihistaminics
FEV1decline; symptoms; duration of exacerbations
≥3 exacerbations within 3 consecutive months; severe progressive 
deterioration of lung function level
Increased complaints of dyspnea and/or cough and/or sputum with(out)
fever
7 days pred (35-30-25 mg etc), and a course of antibiotics if necessary
Skin tests, serum IgE, eosinophil count
Weighing canisters; counting tablets
Explanatory analysis of variance
No
Linear regression, ≥ 3 measurements needed
Astra Pharmaceuticals
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ticosteroids in COPD: Inclusion and exclusion criteria, method and analysis.
Derenne et al10
Age ≤ 75; ‘chronic bronchitis’; FEV1 30-60% pred;
revFEV1<10% pred; PaO2 >55 mg Hg; usual treatment
without corticosteroid; no exacerbation in the last
three months; written informed consent 
Other pulmonary diseases; corticosteroids past 15
days; unable to follow protocol; pregnant or lactating
women; stomach ulcer without treatment, pulmonary
tuberculosis; IgE > 200IU/ml and eosinophils
>500x103/ml
Clinical, multicentre
Double blind, placebo controlled, 2 parallel arms 
24 months
Becl 1500 µg MDI versus plac
Anticholinergics, β2 agonists, theophylline,  mucolytics,
almitrine
Level of FEV1; level of PEF; duration of corticosteroid
course
Insufficient effectiveness
(1) increase of dyspnea and/or (2) purulent sputum
and fever
(1) course of pred and/or (2) course of antibiotics 
≤ 15 days 
Serum IgE and eosinophil count
Verbal check
Repeated measurement analysis, explanatory analysis
No
Repeated measurement
GlaxoWellcome Inc. 
Kerstjens et al9(subgroup)
Age 18-60; ‘symptom-based diagnosis of COPD’; 
FEV1 <FEV1pred.-1.64SD and  >1.2l;  PC20histamine 
≤8 mg/ml
Maintenance treatment with corticosteroids; asthmatic
attacks
Clinical, multicentre
Double blind, placebo controlled, 3 parallel arms
30 months
Terb 2 mg + becl 800 µg MDI versus terb 2 mg + ipra
160 µg versus terb 2 mg + plac
Salbutamol 400 µg on demand
Drop-outs; level of FEV1; FEV1decline; level of PC20
Doctor's initiative: >2 corticosteroid courses/3 months
or >4/year; patient's initiative: >>symptoms
Increased symptoms and >4 additional
salbutamol/day
12 days pred (30-30-25-25 mg etc)
Skin tests, serum IgE, eosinophil count
Weighing canisters
Analysis of variance, explanatory
Yes
Linear regression from month 3 on, ≥4
measurements needed
Netherlands' Health Research Promotion Program
(SGO). Pharmaceutical companies: Astra
Pharmaceuticals, Boehringer Ingelheim, Glaxo
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µg/day) versus placebo on lung function level and the duration of exacerbations were
assessed during two years in 194 patients with moderate to severe COPD. Kerstjens et
al9 investigated the effects of 800 µg inhaled beclomethasone and placebo on lung 
function level and decline and bronchial responsiveness during 30 months in a group
of 274 patients with moderate asthma or COPD. A subgroup analysis was performed in
51 patients with a symptom based diagnosis of COPD.
selection of patients for the meta-analysis
In order to be able to exclude patients with ‘asthma features’ in the analyses and also to
maximise the contribution of individual patient data, we used the original clinical data.
Firstly, rigid diagnostic criteria were framed based on the most recent guidelines 
on COPD.1,2 The protocols and data bases of the three studies concerned were 
then collected. Thirdly, the investigators of the studies were sent an output of the 
baseline characteristics and follow up data of their own study, in order to avoid 
misinterpretations of their study data. 
Inclusion criteria for individual patients in the meta-analysis
(1) Pulmonary symptoms compatible with the diagnosis of COPD (chronic breathlessness
especially on exertion and/or (productive) cough during ≥ 3 months per year in two 
successive years).
(2) Aged 40 and over.
(3) FEV1 following treatment with ß2 agonist (≥ 400 µg salbutamol or ≥ 500 µg 
terbutaline) ≤ FEV1 predicted - 1.64SD.
(4) Bronchodilator response to ß2 agonist (≥ 400 µg salbutamol or ≥ 500 µg terbutaline)
≤ 9% of FEV1 predicted.
(5) Previous or current smoker.
Exclusion criteria of individual patients in the meta-analysis:
(1) α1-Antitrypsin deficiency.    
(2) History of asthma.
effect parameters for the meta-analysis
The primary effect parameter was prebronchodilator decline in FEV1 measured at two
monthly7 or three monthly intervals9,10 according to the recommendations of the
ERS.13 All FEV1 measurements were made in a stable state - that is, in the absence of an
exacerbation. 
The secondary effect parameters were postbronchodilator decline in FEV1, the number
of drop outs, and the number of exacerbations. FEV1 after inhalation of ipratropium
bromide was not assessed in all studies so only post-ß2 agonist FEV1 values were used.
In two studies FEV1 following treatment with ß2 agonist was only assessed annually,7,10
and in one study six monthly.9 In the study of Kerstjens et al9 a higher dose of ß2
agonist was used (1 mg terbutaline) than in the other studies (500 µg terbutaline7 and
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400 µg salbutamol10). Because of these differences within the studies in frequency,
dosage and type of bronchodilator used to measure postbronchodilator FEV1, the 
prebronchodilator but not the postbronchodilator FEV1 was used as the primary effect
parameter in the meta-analysis.
In all three studies the number of drop outs and the reasons for drop out were 
recorded. The reasons for drop out were divided into ‘worsening of disease’, ‘adverse
effects’ and ‘other’ (personal reasons, unspecified reasons).
The number of exacerbations was recorded in all three studies. An exacerbation was
defined similarly - that is, a doctor’s diagnosis of increasing repiratory symptoms 
requiring a short course of systemic corticosteroids7,9 and/or antibiotics.10
Bronchial hyperresponsiveness was not used as a dependent variable or as a 
determinant of corticosteroid response because this clinical characteristic was not 
assessed in all studies. Also symptoms were not used as dependent variables because of
too large variations in registration between the studies.
baseline characteristics for the meta-analysis
The continuous variables were age, height, FEV1 (litres), FEV1 (expressed as a percentage
of FEV1 predicted), FEV1/IVC (%), airway reversibility (bronchodilator response to ß2
agonist, expressed as a percentage of FEV1 predicted), smoking history (number of 
pack years (cigarettes/day x years smoked divided by 20)), number of cigarettes/day, 
and allergy (total IgE, expressed as IU/ml). Dichotomic variables were sex, smoker 
(current/ex), regular use of anticholinergics, ß2 agonists, theophylline, mucolytics or
almitrine (Vectarion, a respiratory stimulant). 
analysis of data
The SAS statistical package was used in all analyses.14 IgE values were log10(x+1) 
transformed in the analysis. The main independent variable was the inhaled corticosteroid
versus placebo. In the study by Kerstjens et al patients were treated with 800 µg 
beclometasone,9 in the other studies with 1500 µg beclomethasone or 1600 µg 
budesonide.7,10 Dosages of 1500 µg beclomethasone and 1600 µg budesonide were 
considered as equal dosages for analytical purposes. The prednisone + budesonide
group in the study by Renkema et al was excluded from analysis as it was presumed that
the effects of oral corticosteroids, if present, would overrule the effects of inhaled 
corticosteroids. The patients of the study by Kerstjens et al who were treated with 
ipratropium bromide were considered as a placebo group since no long term effects
other than the acute bronchodilating effect of ipratropium bromide were observed.15
Since the duration of the study by Kerstjens et al was 30 months and the two other
studies took 24 months, only patient data up to 24 months of study were used.
In the study by Renkema et al two monthly FEV1 measurements were performed
compared with three monthly measurements in the two other studies. In all the analyses
the average individual FEV1 values of the measurements of 2 and 4, 8 and 10, 14 and 16,
and 20 and 22 months were therefore used as estimates for the FEV1 at 3, 9, 15 and 21
months, respectively.
Differences in drop out percentages and reasons for drop out during the trial between
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the inhaled corticosteroid and the placebo groups were tested with the X2 test.
Differences in the number of exacerbations per year between both groups were tested
univariately with the Student’s t test. 
The effect of inhaled corticosteroids (independent of the dose) on prebronchodilator
and postbronchodilator FEV1 (litres) was measured with a multiple repeated measurement
technique in which patient and time effects on FEV1 were separately investigated in an
intention-to-treat analysis. Preliminary analysis demonstrated no measurement*treatment
interaction. For that reason a random coefficient model was chosen in which all available
individual time points of FEV1 measurements were incorporated and analysed. In a first
model the effect of inhaled corticosteroids, irrespective of the dose used, on the course
of FEV1 was compared with placebo. In a second analysis the dose effects of the inhaled
corticosteroid (800 µg beclomethasone (‘low dose’) versus 1500 µg beclomethasone or
1600 µg budesonide (‘high dose’)) on the course of FEV1 were investigated by adding
one dummy.
In order to correct for possible confounders and to be able to assess which clinical
characteristics may predict the influence of inhaled corticosteroids on the change in
FEV1, the baseline variables of age, height, sex, FEV1, airway reversibility, pack years,
smoking, IgE, anticholinergics, ß2 agonists, theophylline, mucolytics, and almitrine
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Table 7.2: Subject selection (numbers of subjects are given).
Renkema7 Derenne10 Kerstjens9
(bud 1600 µg/ (becl 1500 µg          (becl 800 µg/
bud+pred / plac) ipra/ plac)
/ plac)
Original number Total: 58 Total: 194 Total: 51
21 / 19 / 18 100 / 94 19 / 11 / 21
Meeting inclusion criteria meta-analysis:
Symptoms compatible with diagnosis of COPD 58 194 51
Age > 40 years  55 192 39
FEV1 post β2 agonist < FEV1 pred. - 1.64SD 47 185 29
Airway reversibility ( 9% pred.FEV1 43 178 29
(Ex-)smokers (>0 pack years) 53 173 51
Not meeting 1 inclusion criterion 22 36 25
Not meeting 2 inclusion criteria 6 6 8
Not meeting 3 inclusion criteria 0 0 3
Not meeting ≥4 inclusion criteria 0 0 0
Meeting exclusion criteria meta-analysis:
α1-Antitrypsin deficiency 0 0   0
Asthma history 0 0 0   
Eligible for meta-analysis: 30 (6 / 14* / 10) 152 (81 / 71) 15 (8 / 3† / 4)
bud = budesonide, plac = placebo, pred = prednisone, becl = beclomethasone, ipra = ipratropium
*Excluded from analysis because of treatment with oral corticosteroids  
† Considered as ‘placebo’ in the meta-analysis
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were introduced into the model. The number of exacerbations during the study was also
introduced into the model. In addition, data on the number of cigarettes smoked daily
during the study (assessed at each visit) were incorporated into the analysis at each time
point of measurement. Only baseline data of the number of cigarettes smoked daily
were available from the study by Renkema et al. However, smoking behaviour was
shown to be remarkably constant during the study.7 Compliance rates and a complete
registration of all adverse effects during the studies were not available for all three studies.
First, all possible interaction terms of the independent variables with treatment were
incorporated into the model. Secondly, in a backwards procedure variables with the 
highest p value were subsequently deleted until only variables with p≤ 0.05 remained. 
No analysis was performed with linear regression based measurement of FEV1
decline. Preliminary analysis demonstrated a non-linear course in the FEV1: the explained
variance of individual linear regression analysis of FEV1 was only 24% on average (SD
24%, range 0 to 99%). 
Results
subject selection
The selection procedures of subjects for the meta-analysis are presented in Table 7.2.
The most important reasons for exclusion were ‘mild obstruction’ (FEV1 ≥ FEV1 predicted
- 1.64 SD, 42 of original 303 patients) or ‘reversible obstruction’ (> 9% of the FEV1
predicted, 53 of 303 patients). Twenty eight of the 58 subjects (48%) in the study 
by Renkema et al were excluded from the meta-analysis, 15 because of reversible 
obstruction. From the study by Derenne et al 42 (17%) of the 194 patients were excluded
from the meta-analysis, 21 because they were never-smokers. Subjects in the study by
Kerstjens et al were younger and had less severe airway obstruction than in the other two
studies. Therefore, only 15 (29%) of the 51 subjects in this study were eligible for the
meta-analysis. Within each study the baseline characteristics between the patients in the
inhaled corticosteroids group and the placebo group eligible for the meta-analysis did
not differ significantly in all relevant parameters.
Baseline data 
Table 7.3 shows the combined baseline characteristics of the 183 subjects selected. 
No statistically significant differences between the inhaled corticosteroids group and
placebo group were present in the relevant parameters. 
Effects of inhaled corticosteroids on FEV1 (repeated measurement analysis) 
In Figure 7.1 the effect of two years of treatment with inhaled corticosteroids, irrespective
of their dose, on the prebronchodilator FEV1 is presented versus placebo, and in Table
7.4 the results are presented after adjustment of variables with p≤ 0.05. The estimate
was +0.034 l/year (95% confidence interval (CI) 0.005 to 0.063), which was statistically
significant (p = 0.026). If the dose of inhaled corticosteroids was included in the model,
the estimate was +0.002 l/year (95% CI -0.061 to +0.065) for the low dose of inhaled
corticosteroids and +0.039 l/year (95% CI 0.008 to 0.070) for the high dose (p=0.043). 
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The same procedure with postbronchodilator FEV1 showed a two year treatment
effect for the inhaled corticosteroid group versus the placebo group of +0.039 l/year
(95% CI -0.006 l to 0.084 l, p=0.095) (Table 7.4, Figure 7.2), which was maintained
only in the high dose group if the dose of inhaled corticosteroids was taken into account. 
Determinants of lung function slope and corticosteroid response
Table 7.4 shows an independent effect of the following two variables on a beneficial
course in FEV1: the use of short-acting ß2 agonists and a higher baseline FEV1. No 
interaction of any of the variables analysed with the inhaled corticosteroid treatment was
observed. 
Effect of inhaled corticosteroids on exacerbations and drop-outs 
During the study the mean (SD) number of exacerbations per year was 0.9 (0.9) in the
inhaled corticosteroid group, and 1.0 (1.3) in the placebo group (p>0.05; Table 7.3). The
drop out rate during the study was 36% in the inhaled corticosteroid group and 32% in
the placebo group (Table 7.3). In the placebo group twice as many patients dropped out
due to worsening of the disease compared with the actively treated group (9/88 versus
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Table 7.3:  Mean (SD) baseline characteristics and exacerbation and drop out rates of
patients using inhaled corticosteroids (irrespective of the dose) or placebo.
Inhaled Corticosteroids Placebo         
(n = 95) (n = 88)
Age (years) 61 (7) 61 (7)
Height (cm) 170 (7) 168 (7)
Male (n) 89 79
FEV1 (l) 1.42 (0.47) 1.30 (0.38)
FEV1 (% pred) 46 (11) 44 (10)
FEV1/IVC (%) 49 (13) 47 (11)
Airway reversibility (% of FEV1 pred) 3.2 (2.7) 2.9 (2.5)
Pack years 40 (25) 43 (24)
Smoker (current/ex) 32/63 34/54
Cigarettes/day (n) 17 (12) 17 (11)
Log10(IgE+1) (IU/ml) 1.71 (0.59) 1.67 (0.50)
Regular use of (% of patients):
Anticholinergics 25 32 
Shortacting ß2 agonists 60 62
Theophylline 56 53
Mucolytics 33 40
Almitrine 10 13
During the study:
Exacerbations/year 0.9 (0.9) 1.0 (1.3)
Drop outs (n) 35 29
Reason for drop out (n):
Worsening of the disease 4 9
Adverse effects 17 12
Other reasons 14 8
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Figure 7.1: Course of prebronchodilator FEV1 in the inhaled corticosteroid and
placebo groups. SE values and numbers of subjects participating in the study at each point of 
measurement are presented.
Figure 7.2: Course of postbronchodilator FEV1 of the inhaled corticosteroid and
placebo groups. SE values and numbers of subjects participating in the study at each point of 
measurement are presented.
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4/95 patients, p=0.11). No patients dropped out in the low dose inhaled corticosteroid
group. Comparison of the baseline characteristics between those who fulfilled the 
protocol and the drop outs within each trial group showed no indications of selective
drop out or ‘survivor effect’.
Adverse effects
In the inhaled corticosteroid group 17 of the 95 subjects dropped out because of adverse
effects compared with 12 of 88 in the placebo group(X2=0.62, p=0.43). All these drop
outs were in the study by Derenne et al. An additional investigation of the adverse effect
files of these patients showed that in six of the 95 subjects in the active group the adverse
event leading to drop out may have been related to the treatment (cough, dysphonia,
sore throat, anorexia, problems with taste and the nasal organ, and headache). In the
placebo group the cause of drop out in two of the 88 subjects could have been related to
treatment (cough, dysphonia, sore throat) (X2=1.78, p=0.18). No serious adverse effects
related to the treatment occurred.
Discussion
We combined the original data of three published long term intervention studies with
inhaled corticosteroids in moderately severe COPD, selecting only patients with clearly
defined disease. The meta-analysis showed a significant beneficial effect of inhaled 
corticosteroids compared with placebo on the course of the prebronchodilator FEV1
during two years of treatment (+0.068 l), whereas only a tendency towards an effect of
inhaled corticosteroids on postbronchodilator FEV1 was shown. However, the latter
results pertain to only three data points. A specific measurement*treatment effect was
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Table 7.4: Influence of inhaled corticosteroids compared with placebo on the change
in prebronchodilator and postbronchodilator FEV1 (l) by repeated measurement 
analysis. The model presents only variables with p≤0.05.
Two-year SE         p value (Pr>F)
estimate (l/year)
Prebronchodilator:
Treatment effect (inhaled corticosteroids versus   +0.034 0.015 0.026 
placebo, n=183) 
FEV1 baseline (l) +0.97 0.027 0.0001
β2 agonists (yes) +0.063 0.025 0.012
Almitrin (yes) -0.075 0.038 0.048
Postbronchodilator:
Treatment effect (inhaled corticosteroid versus   +0.039 0.023 0.095 
placebo, n=183)
Height (m) +0.64 0.222 0.004
Reversibility FEV1 (as % of predicted FEV1) +0.014 0.005 0.003
FEV1 baseline (l) +0.92 0.036 0.0001β2 agonists (yes) +0.058 0.027 0.034
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lacking. A daily dose of 1500/1600 µg of the inhaled corticosteroid was more effective
than 800 µg. No beneficial effect was observed on the exacerbation rate or drop out 
rate. Finally, no interaction effect of the variables assessed on the response to inhaled
corticosteroids was found. 
When the three original studies contributing to the meta-analysis were considered,
no heterogeneity was seen in the beneficial effect of inhaled corticosteroids on the FEV1.
Renkema et al demonstrated a median decline of FEV1 of 60 ml/year in the placebo
group and 30 ml/year in the budesonide group.7 Due to large interpatient variations this
difference was not significant. Kerstjens et al found the FEV1 to increase significantly by
+7.4% (3,1) % predicted in the beclomethasone group compared with the placebo 
group after the first six months of study.9 The study by Derenne et al demonstrated an
improvement in FEV1 of +1.44% from baseline in the experimental group compared
with -0.62% in the placebo group (p=0.05) during the two-year study.10 Subjects of
these three studies who were excluded from our meta-analysis were patients who had 
features of asthma in addition to COPD. An interesting finding was that, although we
selected only patients with clearly defined COPD for the analysis, a beneficial effect of
inhaled corticosteroids on the course of FEV1 remained present. 
Several shortcomings of the study should be mentioned. Firstly, we presented the
results of a ‘re-analysis’ using studies with a duration of only two years. Secondly, 
compliance data and the doses of concomitant drugs were not incorporated and corrected
for in the analysis. Thirdly, cost effectiveness was only assessed in the study by
Kerstjens. Rutten-van Mölken et al16 found that ‘addition of an inhaled corticosteroid to
a ß agonist leads to significant benefits in respiratory function and restricted activity
days with relatively low additional health care costs’. However, an interaction analysis in
this study showed that inhaled corticosteroids were most beneficial in patients with the
‘classic’ asthma profile (allergy, reversibility, non-smoking and mostly young). Longer
term and larger studies with more detailed registration of compliance, drug use during
the trial, and cost effectiveness are therefore required to confirm the conclusions of our
study.    
In two retrospective studies with oral prednisone in a group of patients with 
moderate and severe COPD it has been suggested that the time to reach a response to
oral corticosteroids in COPD is 6-24 months.5,6 In our meta-analysis with inhaled 
corticosteroids no specific time point of response was observed, but a sustained effect 
of inhaled corticosteroids on the course of FEV1 took place during the two years. In a
self-controlled study in 26 patients with moderate COPD Dompeling et al investigated
the effects of 800 µg beclomethasone on the course of FEV1.8 The prebronchodilator
FEV1 increased during the first six months of the trial with no further effect on the
decline in FEV1 after that. The study by Kerstjens et al showed that a response had 
already been achieved after three months.9 In both studies inclusion of COPD patients
with some ‘asthmatic features’ such as airway reversibility and allergy in both studies
might have contributed to this early response. Preliminary results of the EUROSCOP
study, a large three-year study in mild COPD with 800 µg budesonide, have also shown
an effect of inhaled corticosteroids, especially during the first three months of the study
(oral presentation, Congress of the European Respiratory Society, 1997). Further 
analysis is needed to show whether this early effect of inhaled corticosteroids may 
indicate ‘asthmatic features’ in the group of patients with COPD selected. Moreover, in
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the light of the previous studies by Postma et al5,6 with systemic corticosteroids, the
delay in reaching ‘the response’ in our study may suggest a relationship to a true effect
of inhaled corticosteroids on COPD.  
The course of postbronchodilator FEV1 tended to differ from prebronchodilator FEV1,
especially after one year and to the advantage of the placebo group. In Figure 7.2 it 
appears that the FEV1 in the placebo group increased considerably after one year of the
study. This may be explained partly by the fact that ‘all’ participants (including drop
outs) were plotted. The drop outs in the placebo group, most of which dropped out
during the first year of the study, had a lower baseline FEV1 % predicted than those who
fulfilled the protocol of the placebo group (41% versus 47% of FEV1 predicted,
p<0.0174). It was shown that the course of postbronchodilator FEV1 in patients in the
placebo group who finished the study was reasonably stable during the first year of the
study.
A daily dose of 1500 µg beclomethasone or 1600 µg budesonide was more effective
than 800 µg beclomethasone, with effects on the prebronchodilator FEV1 of 0.039
l/year and 0.002 l/year, respectively. However, in the analysis the group of patients 
treated with 800 µg beclomethasone was relatively small (n = 8) and therefore this
result has to be interpreted with great caution. On the other hand, in short term studies
with inhaled corticosteroids in patients with moderately severe COPD daily dosages of
at least 1500 µg seemed to be necessary to achieve significant improvements in FEV1.4
Watson et al found no beneficial effects on the level of lung function in a nine month
single blind follow up study with 1200 µg budesonide daily.17 In a long term therapeutic
trial (mean duration 26 months) of oral and inhaled corticosteroids in 121 patients with
non-asthmatic chronic airway obstruction, beclomethasone 750 µg twice daily seemed
to slow down the decline in FEV1.11 Unfortunately this study was not placebo controlled
and is only published in abstract form. In patients with moderate asthma, daily doses of
800 µg inhaled corticosteroids are often sufficient to achieve disease control. In the light
of our study we hypothesise that, in patients with moderate to severe COPD, differences
in the type and site of inflammation in asthma and COPD might lead to the need of 
higher dosages of inhaled corticosteroids in COPD. In COPD the largely neutrophilic
and lymphocytic inflammation seems to take place in the peripheral airways while in
asthma the predominantly eosinophilic inflammation is located mainly in the central
airways.3 These two considerations might explain the need for a higher dosage of inhaled
corticosteroids in moderate to severe COPD compared with moderate asthma. If we 
consider the preliminary results of the EUROSCOP, the dosage of inhaled corticosteroids
(800 µg budesonide daily) may have been too low to be sufficient. Two other large long
term multicenter European studies of COPD will soon present the long term effects 
of a low to medium dosage of inhaled corticosteroids in mild COPD (800-1200 µg
budesonide daily; Copenhagen City Lung Study) and a relatively high daily dose in 
severe COPD (1000 µg fluticasone; ISOLDE). This may help us to understand better the
minimal daily dose of inhaled corticosteroids required to prevent progression of the
decline in lung function in COPD.
The beneficial course of FEV1 in patients treated with inhaled corticosteroids compared
with placebo was not accompanied by a lower number of exacerbations. Bacterial 
superinfection is a common cause of acutely aggravating COPD.1 It might not be expected
that inhaled corticosteroids protect the bronchial wall of the host against bacterial 
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colonisation in patients with COPD. However, this result has to be treated with caution
because the definition of exacerbation varied between the three studies of the meta-
analysis (see Table 7.1).  
Several variables influenced the course of prebronchodilator FEV1 independently. The
regular use of both oral and inhaled ß2 agonists was related independently to an overall
change in both prebronchodilator and postbronchodilator FEV1 of +0.063 l/year after
two years. This result strongly contrasts with the general opinion that regular use of ß2
agonists cannot delay the progression of COPD.1,2 However, the route of administration,
dosages and drug names of the ß2 agonists were not specified in the largest study.10 Our
result therefore has to be interpreted with caution.
Contrary to others,4 the meta-analysis did not show a relationship between higher
levels of IgE or airway reversibility and a better response to inhaled corticosteroids in
COPD. As already mentioned, allergy was an exclusion criterion in two of three studies.
Also, subjects with reversible airway obstruction were excluded from the analysis. Both
factors may explain the absence of an interaction effect of relatively low levels of IgE 
and airway reversibility on the response to inhaled corticosteroids. No other variables 
interacted with the effect of inhaled corticosteroids.
Up to now, smoking cessation has been shown to be the only intervention able to
improve the long term morbidity and mortality due to COPD, next to supplemental 
oxygen in hypoxaemic patients.1,2,15 The results of this study indicate that, in patients
with moderate COPD (FEV1 45-55% of predicted), relatively high doses of inhaled 
corticosteroids (≥ 1500 µg) may also improve the long term prognosis. Dosages above 1
mg may cause systemic side effects, as assessed by cortisol levels.18 However, an 
additional investigation of the side effect reports from the studies by Derenne 
and Renkema with high doses of inhaled corticosteroids demonstrated symptoms 
which could have been related to the treatment (especially cough and dysphonia) in
approximately 20% of the subjects, with no difference between the active and the 
placebo groups. There were no indications of high intolerability of the study drug in any
of the three studies, not even in high doses. 
In conclusion, this is the first study of a group of patients with strictly defined 
moderate to severe COPD showing a preservation of the FEV1 during two years of 
treatment with relatively high dosages of inhaled corticosteroids (1500 µg beclomethasone
or 1600 µg budesonide daily). 
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Dr van Grunsven et al1 refer to our study comparing inhaled beclomethasone 750 µg
twice daily with placebo in the long term management of COPD (their reference 11)
and were unable to find the full report. Its reference is Bronchitis V edited by D S
Postma and J Gerritsen, published by Van Gorkum, Assen in 1994 (pages 240-4).
Our study followed up 74 patients at approximately two and five years after a double
blind steroid trial. The mean (SE) decline in FEV1 in those taking beclomethasone was
35 (21.5) ml/year at the two year follow up and 65 (10.3) ml/year at the five year follow
up (not significant). In those not receiving inhaled steroids the mean (SE) decline in
FEV1 was 112 (23.3) ml/year at the two year follow up, decreasing significantly to 25.3
(19.5) ml/year at the time of the second follow up when they were given inhaled 
beclomethasone dipropionate. There was no relationship between the response to 
the initial steroid trial and the subsequent decline in FEV1.
P Sherwood Burge
Occupational Lung Disease Unit,
Birmingham Heartlands Hospital,
Bordesley Green East,
Birmingham B9 5ST, UK
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Author’s reply
We thank Dr Sherwood Burge for his comments on our study. Indeed, the results of
their study have been presented not only in abstract form but also more in detail.1 We
apologise for this omission. As we stated in the discussion section of our study,2 Weir
et al investigated the long term effect of inhaled beclomethasone 1500 µg daily on the
decline in FEV1 in a therapeutic trial. This (uncontrolled) treatment followed an 
original randomised controlled trial of 107 patients including a group of patients with
moderately severe COPD (FEV1 <70% predicted), comparable to our study. In their
original study patients were treated with prednisone 40 mg daily, inhaled 
beclomethasone 1500 µg daily and placebo in a crossover design to assess the short
term steroid response (defined as an increase in FEV1, FVC or PEF of ≥ 20% from
baseline). Seventy four patients were reassessed approximately two and five years after
this original trial. Thirty two patients received beclomethasone only during the second
follow up period, the remaining patients were treated with beclomethasone during the
whole follow up period. In the former group of 32 patients the authors showed that
the decline in FEV1 decreased significantly when the first follow up period (without
the use of inhaled beclomethasone) was compared with the second follow up period
(during treatment with inhaled beclomethasone). This result, although not achieved 
in a randomised controlled design and therefore excluded from our meta-analysis, 
supports our finding of a significant two year treatment effect of inhaled 
beclomethasone or budesonide in a daily dose of 1500/1600 µg compared with 
placebo of +0.034 l/year.2
Dr Sherwood Burge also pointed to the absence of a relationship between the
response to the initial steroid trial and the subsequent decline in FEV1 in their study.
Indeed, an interesting finding of their study was that, although the majority (75%) of
the original 23 steroid responders had been treated with beclomethasone during the
whole follow up period, the mean (SE) decline in FEV1 of 51.5 ( 10.3) ml/year did 
not differ from the 51 non-responders of which only 50% were treated with 
beclomethasone during the whole follow up period (53.1 (8.7) ml/year). The authors
therefore concluded that the acute steroid response did not seem to be an adequate
predictor of the long term response to inhaled steroids in patients with moderate to
severe COPD. In our meta-analysis2 only patients in the study by Renkema et al had
been treated with a course of 40 mg daily during the eight days preceding the trial in
order to assess steroid responsiveness (response as defined by an increase in FEV1 of
≥ 20% from baseline). In their study only three steroid responders (of 58 patients with
severe COPD) were identified.3 In two studies in patients with mild to moderate
COPD the presence of ‘asthmatic features’ such as allergy and reversibility of 
obstruction resulted in a better long term treatment effect with inhaled 
corticosteroids.4,5 In our meta-analysis we did not find this relationship.2 This result
could be explained by our selection of subjects with strictly diagnosed 
non-asthmatic and irreversible COPD, comparable to the subjects in the study of 
Weir et al. Forthcoming data of the ISOLDE trial which was initiated by Dr Sherwood
Burge (ISOLDE is a three year randomised placebo controlled trial in 990 patients
with severe COPD treated with 1000 µg fluticasone daily), may give an more definite
answer to the question of the predictive value of a short course of oral prednisone 
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(or other asthmatic features such as reversibility and allergy) on the clinical effects 
of long term treatment of patients with moderately severe COPD with inhaled 
corticosteroids.
PM van Grunsven
CP van Schayck
Department of General Practice and Social Medicine,
University of Nijmegen,
6500 HB Nijmegen,
The Netherlands
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Abstract
Context In spite of many trials, the role of inhaled steroids in the management of COPD
has not yet been defined precisely, and evidence of their benefit remains a matter of
debate.
Objective To determine the clinical effects and safety of a two-year treatment with 1500
µg inhaled beclomethasone daily in stable moderate COPD.
Design A two-year randomized placebo controlled multicenter study was performed. 
Setting Twenty-eight outpatient lung clinics in France.
Patients Eligibility criteria were: age below 75; chronic bronchitis with the baseline
prebronchodilator FEV1 30 to 60% predicted. The increase in FEV1 10 minutes after
administration of 400 µg aerosolized salbutamol had to be less than 15% of predicted
FEV1.
Intervention Beclomethasone dipropionate (BecotideTM) metered dose inhaler 1500
µg daily (three puffs of 250 µg, twice daily) versus placebo.
Main Outcome Measures The change in the prebronchodilator FEV1 was the primary
outcome measure. The main secondary outcome parameters were the postbronchodilator
FEV1, arterial blood gases, courses of antibiotics and/or oral steroids, dyspnea and
adverse effects of beclomethasone.
Results Multi variate repeated measurement analysis showed a significant increase in
prebronchodilator FEV1 by +38 mL/yr(SE 18, p=0.031) in the beclomethasone group 
in comparison with placebo during two years. The postbronchodilator FEV1 in the 
beclomethasone group increased by +149 mL/yr(SE 70, p=0.035) in comparison with
the placebo group. The number and duration of steroid and antibiotic courses were
comparable in the two study groups. Blood oxygen saturation improved by +0.5(SE
0.2)%/yr (p=0.02) under beclomethasone as compared with placebo. Seventeen percent
of the patients in the beclomethasone group experienced an oropharyngeal side effect of
the trial drug, versus 15% of the patients of the placebo group.
Conclusions This study shows a clear beneficial effect of 1500 µg beclomethasone
MDI daily during two years compared with placebo on the two-year course of FEV1 in
patients with stable moderate COPD.
List of Abbreviations
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Forced Expiratory Volume in One Second
Vital Capacity
Mid Expiratory Flow at 25% of the VC
Mid Expiratory Flow at 50% of the VC
Forced Expiratory Flow, at (mean from) 25-75% of the VC
Peak Expiratory Flow
Forced Residual Capacity
Residual Volume
Total Lung Capacity
Metered Dose Inhaler
FEV1
VC 
MEF25
MEF50 
FEF25-75
PEF 
FRC 
RV 
TLC 
MDI 
Van GrunsvenDEF  13-09-1999 22:33  Pagina 114
115
Introduction
Up to now smoking has been considered as the only potentially useful intervention to
limit lung function decline, hence morbidity and mortality, in patients with chronic
obstructive pulmonary disease (COPD).1,2 Unfortunately, smoking cessation programs
and campaigns are only partly successful.3
In spite of many trials, the role of steroids in the management of COPD has not yet
been defined precisely, and evidence of their benefit remains a matter of debate.4 Over
the years, short-term trials have indeed shown functional benefits of (inhaled) steroids
in a substantial proportion of non-asthmatic COPD patients.5-7 On the basis of these
results, COPD guidelines recommend the use of inhaled steroids in patients showing
some degree of improvement after a trial period of steroid treatment.3,8 There is now a
large body of evidence demonstrating that COPD has an inflammatory component. This is
strongly suggested by the presence of inflammatory cells, including polymorphonuclear
neutrophils and activated lymphocytes in the airway mucosa of smokers and COPD
patients.9-13 Inhaled steroids are preferred to oral steroids because of the systemic 
side-effects of the latter treatment, and have recently been shown to reduce the number
of neutrophils in the bronchial mucosa of patients with COPD.14 The use of inhaled 
steroids is widespread.4 However, in spite of pathophysiologic arguments, short-term
clinical evidence and the effect of inhaled steroids in COPD patients on a long-term
basis remain ill documented.
Four long-term studies in moderate15-17 and severe COPD18 suggest that treatment
with inhaled steroids in both moderate and relatively high doses during two years could
abate the progressive lung function decline.19 A meta-analysis of randomized controlled
studies on the long-term effects of inhaled steroids in distinct COPD showed a 
preservation of the FEV1 during two years of treatment, especially in higher doses.20
Recently, Paggiaro et al showed that daily treatment with 1000 µg inhaled fluticasone
propionate during 6 months in 281 patients with moderate COPD caused a significant
decrease in the number of exacerbations and an improvement in lung function, with
few local and systemic adverse effects.21 However, the period of observation in this last
study was relatively short (six months). On the other hand, another recent six-month
study of 79 patients with severe COPD showed no beneficial effect of 1600 µg 
budesonide on lung function.22
Here, we present the results of a randomized placebo-controlled multicenter trial in
stable moderate COPD performed in France.23 The purpose of the study was to assess the
clinical effects and safety of a two-year treatment with 1500 µg inhaled beclomethasone
daily.
Methods
Background
This study was originally coordinated by one of the co-authors (J.P. Derenne) in 
cooperation with GlaxoWellcome France. So far, its results have only been presented in
abstract form23 and have not been published in full. The study was selected for a 
meta-analysis of published and unpublished studies on the long-term effects of inhaled
steroids in COPD.20 Here, we present the full analysis of the original raw data to avoid
publication bias and the restrictions imposed by the meta-analysis.24 The trial report
complies with the CONSORT statement.25
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Patient selection
Between 15 May 1989 and 9 February 1990, 28 outpatient lung clinics in France were
approached and each was asked to recruit 8 patients with COPD for the present trial.
The main eligibility criteria were tested by a pulmonologist during the pretrial visit (visit
1). Patients were eligible if their age was below 75 and if they were suffering from 
chronic bronchitis (cough and sputum on most days during at least three consecutive
months in two consecutive years, according to the criteria of the American Thoracic
Society26). The baseline (prebronchodilator) FEV1 had to be 30 to 60% of the predicted
value (according to the reference values of Quanjer27). The increase in FEV1 10 
minutes after administration of a bronchodilator (400 µg of aerosolized salbutamol)
had to be less than 15% of the predicted FEV1. Exclusion criteria were: a history of 
severe exacerbation of COPD in the past 3 months, a diagnosis of lung cancer or bullous
emphysema, a diagnosis or a clinical history strongly suggestive of asthma in the past
10 years, chronic use of (inhaled) steroids, administration of oral steroids in the past 15
days, inability to follow the protocol, participation in another trial, pregnancy or 
lactation, stomach ulcer without treatment, pulmonary tuberculosis, and inability to use
an inhaler. Patients who met the inclusion criteria entered a two-week pretrial period
during which their usual treatments (anticholinergics, beta2 agonists, theophylline,
mucolytics, almitrine) were maintained. The baseline assessment (visit 2) was made at
the end of this period. If the prebronchodilator FEV1 did not differ more than 10% from
the pretrial FEV1 at visit 1, IgE was less than 200 IU and/or blood eosinophils were less
than 500/mm3, and PaO2 was at least 55 mm Hg, the subjects were definitely included
and randomized. The study gained the approval of the Ethical Committee. All 
participants received verbal and written information, and signed an informed consent form.
Study design
The treatment regimen in this two-year randomized controlled multicenter study was
beclomethasone dipropionate (BecotideTM) MDI 1500 µg daily (three puffs of 250 µg,
twice daily) versus placebo. Furthermore, a block randomization was performed. Each
of the 28 investigators was given a set of 8 sealed envelopes containing the assignment
codes. The code could be broken in the event of a serious adverse effect. Patients were
seen at the clinic with three-monthly intervals during the two-year study (visit 2 to 10),
and were also instructed to come to the clinic in case of an exacerbation (defined as
mucopurulent sputum and fever). At each visit, a box with 8 MDI’s, sufficient for three
months, was supplied. In case of an exacerbation the investigators prescribed a course
of antibiotics for a maximum of 15 days. If the investigator judged it necessary (e.g. in
case of increased dyspnea) a course of oral prednisone was prescribed. If patients 
dropped-out, a specific registration form was filled in, describing the reason for 
drop-out (adverse events, ineffectiveness of the drug, personal reasons, etc.). 
Measurements
Patient characteristics and smoking behavior
General and clinical patient characteristics (see Table 8.1) were registered during visit 1.
Smoking history was registered at baseline, and actual smoking behavior was assessed
at each visit. 
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Pulmonary function and blood gases
At each visit, lung function measurements were performed according to the criteria of
the European Respiratory Society.27 All measurements were taken with the same 
apparatus, and if possible, with the same technician and at the same hour of day. In case
patients had acute rhinitis, sinusitis or an exacerbation, the taking of measurements was
postponed. Bronchodilators were not allowed within six hours prior to the assessment.
The measurements of FEV1, VC, MEF25, MEF50, FEF25-75, PEF were performed every
three months. The FRC, RV and TLC were assessed every half year, and reversibility in
FEV1 (as a percentage of FEV1 predicted) was assessed annually. Reversibility was tested
by measuring FEV1 10 minutes after 4 puffs of 100 µg salbutamol (VentolinTM- MDI)
had been administered. 
Arterial blood gases (PaO2, PaCO2, pH, saturation, bicarbonates and HbCO) were
measured annually. 
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Table 8.1: Baseline characteristics. Variables between the treatment groups were 
tested. Only p-values <0.05 are represented. Standard deviations are given in parentheses.
Beclomethasone 1500 mg/day Placebo 
n=100 n=94
Age (yr) 62 (7) 63 (8)
Height (cm) 168 (8) 167 (7)
Male (n) 85 86
Body Mass Index (kg/m2) 25.4 (3.9) 24.5 (4.3)
FEV1 Prebrochondilator (L) 1.36 (0.41)* 1.25 (0.35)
FEV1 Prebr. (%pred.) 48 (11)** 44 (11)
<35 %pred. (number of patients) 17 21
35-50 %pred. (number of patients) 41 47
>50 %pred. (number of patients) 42 25
FEV1/VC (%) 52 (13) 49 (12)
FEV1 Postbronchodilator (L) (pretrial visit) 1.44 (0.43) 1.35 (0.37)
FEV1 Postbr. (%pred.)(pretrial visit) 51 (12) 48 (11)
Revers.FEV1 (%pred) 3.4 (3.0) 3.8 (3.6)
Pack Years 37 (27) 41 (28)
Smokers (current/former/non-smokers) 27/62/11 28/56/10
Cigarettes/day 14 (9){n=27} 15 (9){n=28}
log10(IgE+1)(IU/ml) 1.74 (0.57) 1.68 (0.49)
Ln Eosinophil Count/mm3 4.18 (1.95) 3.89 (2.09)
Concomitant Drugs (continuous use):
Anticholinergics 19% (% of subjects) 22%
Beta2 mimetics 59% 61%
Theophylline 58% 55%
Mucolytics 40% 48%
Almitrine 10% 17%
*p=0.044, **p=0.0018
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Steroid and antibiotic courses 
Prescribed courses of antibiotics or oral steroids and the number of days treated were
registered at each follow-up visit. 
Dyspnea and ‘general well-being’
Dyspnea was assessed at baseline, and after 3, 6, 12, 18 and 24 months according 
to Fletcher (1=no dyspnea, 2=no dyspnea when walking on flat ground, 3=no 
dyspnea when walking slowly, 4=dyspnea even when walking slowly, 5=dyspnea while
undressing).28
At the same time, the patients were asked to rate their ‘general well-being’ on a 
visual analog scale (VAS) (100 mm unticked vertical line, uppermost boundary (100)
corresponding to the patient’s worst possible self-perception of his/her well-being 
(‘I have never felt that bad’) and lowermost boundary (0) corresponding to the best 
possible status (‘I have never felt so good’).29
Every three months, the physician in charge subjectively assessed and recorded the
clinical status of the patient (good, moderate or bad).
Hospitalization, consultation
Hospitalization (including the number of days) and the number of unplanned 
intermediate consultations were recorded at each visit.
Adherence to treatment and safety
At each visit, the patients were asked if they had succeeded in taking the prescribed
drugs regularly or not. If they had not succeeded in this, the investigators insisted on
explaining the importance of regular use of the trial drug. Also at each visit, the subjects
were asked if the drug of treatment was well tolerated and if not, the investigator had to
fill in a standard (serious) adverse event form.
Study end points
The main outcome parameter was the change in the prebronchodilator FEV1. Secondary
outcome parameters were the postbronchodilator FEV1 (which was only assessed 
annually), IVC, MEF25, MEF50, FEF25-75, PEF, FRC, RV, TLC, the number of courses of
antibiotics and/or oral steroids, the number of hospitalizations (in days), arterial blood
gases, the physician’s subjective assessment of clinical status and the patients’ 
self-assessment of well-being. 
Power Assessment
The estimated number of evaluable participants in each trial group was 108. This 
calculated number was based on the hypothesis that the minimal detectable difference
in decline in (prebronchodilator) FEV1 between the two trial groups had to be 0.04 L/yr
(0.02 L/yr in the beclomethasone and 0.06 L/yr in the placebo group), with the SD of
FEV1 of 0.1 L and using a unilateral t-test with alpha=0.05 and beta=0.1. 
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Analysis
At the time of data collection, all data were manually checked and then computerized.
After computerization, a 5% sample was rechecked. For the purpose of the analysis 
presented in this article, a further sample of 5% of the original patient records were
again compared with the computer draw-outs. This routine check showed full reliability
of the data. The analysis was performed with the statistical package of SAS (SAS
Institute Inc., Cary, NC, USA).30
An intention-to-treat analysis was performed. The effect of beclomethasone (versus
placebo) on prebronchodilator and postbronchodilator FEV1 was measured with a 
multiple repeated measurement technique, in which patient and time effects on FEV1
were investigated separately. A preliminary analysis had shown no interaction between
measurement and treatment. Therefore, a random coefficient model was chosen in
which all available individual time points of FEV1 measurements were incorporated and
analyzed.31 Patients were only analyzed if they attended at least one follow-up visit.
Effects on other lung function parameters (postbronchodilator FEV1, MEF25, MEF50,
FEF25-75, PEF, static volumes), and on blood gases, dyspnea, clinical status, VAS score,
‘nutritional status’, were also assessed with the same kind of model. Correction for 
baseline values was performed in all models.
Differences between the beclomethasone and placebo group concerning dichotomous
dependent variables (e.g. the number of courses of antibiotics and oral steroids, the
number of hospitalizations because of pulmonary disease) were tested using logistic
regression analysis.
For prebrochodilator and postbronchodilator FEV1, more extensive analyses were 
performed as well. In order to correct for possible confounders of the effect of inhaled
beclomethasone on the change in (prebrochodilator or postbronchodilator) FEV1, the
baseline variables of FEV1, age, height, gender, FEV1, airway reversibility, pack years, IgE
(log10(x+1) transformed), eosinophils (ln transformed), the concomitant drugs used
(anticholinergics, beta2 agonists, theophylline, mucolytics and almitrine) were introduced
in the models with the FEV1 as dependent variable. The number of steroid and antibiotic
courses during the study were introduced in the model as well. In addition, data about
the number of cigarettes smoked daily during the study (assessed at each visit) were
incorporated into the analysis at each time point of measurement. In a backwards 
procedure, variables with the highest p-value were subsequently deleted until only 
variables with p<0.05 remained in the multivariate model (‘final models’). 
In the final models of prebrochodilator and postbronchodilator interaction, terms of
possible predictors of the effect of beclomethasone with FEV1 were incorporated (FEV1
at baseline as a continuous variable or as a class variable (<35, 35-50, >50 % pred.), sex,
reversibility, pack years and (log10)IgE).
Results
Randomization 
Figure 8.1 shows the trial profile. Data from 100 patients in the beclomethasone group
and from 94 in the placebo group were obtained and analyzed (Table 8.1). In spite of 
a slightly higher baseline FEV1 in the beclomethasone group, the repartition of 
the patients in the American Thoracic Society severity classes3 was not significantly 
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Figure 8.1: Trial profile of the study. 
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different within both groups (Table 8.1). All the analyses on FEV1 were corrected for the
small difference in baseline FEV1 between the two treatment groups.
Withdrawals
The mean study duration was 1.55 (range 0-2.18) years in the beclomethasone group and
1.60 (range 0-2.16) years in the placebo group (unpaired t-test, p=0.64). In the actively
treated group, 62 patients completed the study protocol, compared to 63 in the placebo
group. Reasons for drop-out (Figure 8.1) did not differ between both groups. In 7 out 
of 19 cases in the beclomethasone group, the drop-out due to an adverse event was 
considered to be related to the trial drug, compared to 4 out of 17 in the placebo group. 
Effect on FEV1
Figure 8.2 shows the course of the prebronchodilator FEV1. Intention-to-treat analysis
showed an increase in the uncorrected prebronchodilator FEV1 of +16 mL/yr in the
beclomethasone treated group, compared to a decline of -13 mL/yr in the placebo group.
Repeated measurement analysis, which corrected for possible confounders like baseline
FEV1, showed a statistically significant increase in the prebronchodilator FEV1 of +38
mL/yr(SE 18, p=0.031) in the beclomethasone group in comparison with placebo during
two years. Postbronchodilator FEV1 tended to increase during the first year of follow-up
121
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Figure 8.2: Course of prebronchodilator FEV1 (L) of the Beclomethasone group 
versus that of the Placebo group. BEC = Beclomethasone group, PLA = Placebo group. The solid
lines represent all available data (intention to treat). Standard errors and the number of patients at each
point in time in the study have been added. The dotted lines represent the subgroup of patients having
finished the study per protocol (explanatory analysis). The difference between the two trial groups in
terms of baseline prebronchodilator FEV1 does not exist in the explanatory analysis.
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in both groups. This tendency was sustained over the second year in the beclomethasone
group, whereas it was lost in the placebo group. As a result, after correction for possible
confounders like baseline postbronchodilator FEV1, repeated measurement analysis
showed a statistically significant increase in the postbronchodilator FEV1 in the 
beclomethasone group during the two-year treatment in comparison with the placebo
group (+149 mL/yr(SE 70, p=0.035), Figure 8.3).
Effect on other lung function indices
Table 8.2 shows that the MEF25 as an index of obstruction of the small airways improved
significantly during treatment with beclomethasone compared to placebo (estimate
+0.067(L/sec)/yr, SE 0.023, p=0.003). There were no significant differences between
treatments regarding other lung function parameters. 
Effect on arterial blood gases
The arterial blood oxygen saturation, which was subnormal in both trial groups at 
the start of the study, improved significantly by +0.5(SE 0.2)%/yr (p=0.02) during 
beclomethasone therapy compared to placebo (Table 8.2). Also, (subnormal) PaO2
ASTHMA AND COPD – TREATMENT WITH INHALED CORTICOSTEROIDS 
Figure 8.3. Course of postbronchodilator FEV1 (L) of the Beclomethasone group 
versus that of the Placebo group. BEC = Beclomethasone group, PLA = Placebo group. The solid
lines represent all available data (intention to treat). SE and the number of patients at each point in time
in the study have been added. The dotted lines represent the subgroup of patients having finished the
study per protocol (explanatory analysis). 
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increased with +1.4(SE 0.7)%/yr in the beclomethasone treated group compared to
placebo, which was of borderline significance (p=0.053).
Effect on the number and duration of steroid and antibiotic courses
Table 8.3 shows the number of steroid and antibiotic courses in both groups. Logistic
regression analysis performed on these variables showed no statistical significance
when the beclomethasone was compared with the placebo group (steroid course:
RR=0,80 {95%c.i. 0.23-2.80, p=0.34}, antibiotic course: RR=0,72 {95%c.i. 0.30-1.71,
p=0.09}).
During the study, the duration of steroid courses tended to be shorter in the 
beclomethasone group, this difference reaching significance from 7 to 9 months 
(Table 8.3). The total number of days of steroid courses was 530 (of 56,949 days of 
treatment) in patients of the beclomethasone group compared to 568 (of 55,149 days of
treatment) in the placebo group (p=0.90, Z-score, Wilcoxon Rank-test).
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Table 8.2: Overall estimates of lung function indices, arterial blood gases, dyspnea,
VAS score and clinical status during the study. Univariate repeated measurement analysis 
was performed on all parameters, correcting for baseline differences. Data of time*treatment models are
represented.
Baseline values Estimate SE P-value 
Beclomethasone Placebo (Becl vs Pla)
Secondary dynamic lung 
function indices
MEF25 (L/sec) 0.511 0.448 +0.067/yr 0.023 0.003
MEF50 (L/sec) 0.871 0.759 +0.002/yr 0.026 0.93
FEF25-75 (L/sec) 0.812 0.681 +0.026/yr 0.018 0.14
PEF (L/sec) 3.60 3.50 +0.004/yr 0.058 0.94
VC (L) 2.694 2.635 +0.020/yr 0.026 0.43
Statistic lung volumes 
FRC (L) 3.900 4.020 -0.071/yr 0.072 0.32
RV (L) 3.033 3.227 -0.058/yr 0.070 0.40
TLC (L) 5.867 5.986 -0.061/yr 0.077 0.43
Arterial blood gases
PaO2 (mm Hg) 71.1 71.8 +1.4/yr 0.7 0.053
PaCO2 (mm Hg) 38.6 40.1 -0.36/yr 0.31 0.24
pH 7.4 7.4 -0.002/yr 0.004 0.65
O2 saturation (%) 93.6 93.5 +0.5/yr 0.2 0.02
Bocarbonate (mmol/L) 25.0 25.3 +0.067/yr 0.334 0.84
Semiquantitative measures
Dyspnea score 2.03 2.20 +0.045/yr 0.053 0.39
(mean from 1-5) 
Self-rated well-being 40.1 43.3 -0.61/yr 1.44 0.67
VAS score (0-100 mm) 
Physician related clinical 1.27 1.46 +0.03/yr 0.04 0.44
status (mean from 1-3) 
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Effect on 
dyspnea and ‘general well-being’
In the beclomethasone group, the
overall dyspnea improved in 24 of the
88 patients (27%) (with at least two
dyspnea score assessments), in the
placebo group in 27 of 83 patients
(32%) (X2 test, p=0.96). Repeated
measurement analysis showed that
dyspnea, the self-perceived well-
being status, VAS score and the 
physician’s subjective rating of clinical
status were not influenced by the 
treatment (Table 8.2). 
Effect on intermediate 
consultations and hospitalization
During the study, the patients of both
trial groups were given a comparable
number of intermediate consultations
(1.3) due to pulmonary problems. In
the beclomethasone group, 13 patients
were hospitalized due to pulmonary
problems, compared to 16 patients in
the placebo group. The total number
of days of hospitalization was more
than twice as much in the placebo
group (376 days) compared to the
beclomethasone group (152 days).
After correction for the total number
of days of treatment (56,949 in the
beclomethasone and 55,149 in the
placebo group), this difference was
not found to be significant (Z-score =
0.93, Wilcoxon Rank test). 
Predictors of 
the effect of beclomethasone
None of the variables of baseline
FEV1 (both as a continuous variable
and class variable), sex, reversibility
of obstruction, pack years and serum
IgE did interact with the effect of
beclomethasone on the prebrochodilator
or postbronchodilator FEV1 compared
to placebo.
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Adverse effects, safety and compliance
In the beclomethasone group, 98 adverse events were reported (of which 27 were
serious) and in the placebo group 94 (of which 33 were serious). One event (bronchitis
in one patient of the beclomethasone group) was reported as a serious adverse event. In
the beclomethasone group, 23 adverse events occurred that possibly related to the trial
drug (in 17 of 100 patients), compared to 14 events in 13 of 94 patients in the placebo
group (X2=2.06, p=0.15). Ninety-seven percent of the patients stated to tolerate the trial
drug well, and 84% of the subjects stated to be compliant at each three-monthly visit.
No differences in these parameters were found between the two trial groups. 
Discussion
In this study, 1500 µg beclomethasone MDI daily administered during two years to
patients with moderate COPD had a significantly beneficial effect on the course of 
FEV1, compared to placebo. Beclomethasone therapy did better than slowing down the
progressive decline in FEV1 predicted by the natural history of the disease1: it actually
reversed it. There were no clear positive effects of beclomethasone as compared to 
placebo in terms of symptoms and oral steroid and antibiotic courses.
Methodological issues
Studies of this type require that careful attention is paid to methodological issues before
interpreting the results, particularly when some results are more or less surprising. In
the present study, several points deserve to be mentioned.
An increase in FEV1 over two years in a COPD population can be considered a 
surprise. The effect of beclomethasone, compared to placebo, on the postbronchodilator
FEV1 (approximately +150 mL/year) was even larger than on the prebronchodilator
FEV1. This is important because postbronchodilator FEV1 is generally considered as a
more accurate estimate of lung function (decline) in COPD than prebronchodilator
FEV1. However, the corresponding results only pertain to three measurements. Also,
due to missing values in the multivariate model, which corrected for possible confounding
variables, the number of measurements which were to be included was strongly reduced.
The better result in terms of postbronchodilator FEV1 compared to prebronchodilator
FEV1 should therefore be considered with due caution.
After one year of study, a sudden increase in FEV1 was observed in both treatment
groups (Figures 8.2 and 8.3). Additional analysis showed that all the corresponding
measurements were equally distributed throughout the year, which indicated that there
were no seasonal effects. However, it appeared that, during months 9 to 12, less oral 
steroids and antibiotics had been prescribed, probably indicating a lesser number of 
exacerbations, and possibly explaining a higher average FEV1 at the end of this period.
Such types of events, probably coincidental, justify the need for longer observation
periods where therapeutic interventions in COPD are concerned.
Considering the rate of decline of FEV1 in COPD described in the literature (-60 to 
-80 mL/yr)1, the mean uncorrected decline in FEV1 in the placebo group of this study
was less (-20 mL/yr) than expected, and was in fact ‘physiological’. This can probably
partly be explained by the participants’ smoking behavior. Smoking cigarettes is the
125
CHAPTER 8: BECLOMETHASONE DIPROPIONATE IN COPD
Van GrunsvenDEF  13-09-1999 22:33  Pagina 125
126
most important contributor to a progressive lung function decline in COPD. It has been
shown that, in people who have stopped smoking, this progressive decline decreases to
near normal rates.2 A relatively low percentage of patients (approximately 30%) smoked
at the start of our study. In addition, the current smokers in both groups smoked less
cigarettes a day at the end of the study than they did at the beginning (a decrease from
14 to 8 cigarettes in the beclomethasone group {p=0.005, Wilcoxon Rank Test}, and
from 15 to 12 in the placebo group {p=0.043}), although no specific smoking cessation
intervention had taken place before or during the study. The reduction of tobacco 
consumption in both groups may be due to a positive ‘in care effect’, and probably 
contributed to the evolution of FEV1 in both cases.2
Retrospective analysis of the inclusion criteria of all 194 patients randomized, showed
that approximately 5% of the patients had a FEV1 below 30% of the predicted value, and
7% had a FEV1 of more than 60% of the predicted value. Strictly considering all the
other inclusion criteria (airway reversibility < 15% predicted, stable FEV1 {≤ 10% 
difference between pretrial and baseline visit}, IgE < 200 IU and/or eosinophil count 
< 500/mm3, PaO2 at least 55 mm Hg), it was found that another 20% of the patients did
not fulfill these. A possible explanation for this important restriction to the study is that
inclusion of patients proved more difficult than expected, so that the criteria of inclusion
were sometimes enlarged by the investigators. Nevertheless, there was the same 
number of patients not fulfilling all the inclusion criteria in both groups, and re-analysis
restricted to the patients who fulfilled all inclusion criteria (70 beclomethasone, 71
placebo) yielded comparable positive results in favor of beclomethasone versus placebo
(+47(SE 17) mL/yr improvement of prebronchodilator FEV1, p= 0.006, postbronchodilator
FEV1: +50(26) mL/yr improvement, p=0.056).  
Approximately one out of three patients dropped out of the study, with no difference
between the two trial groups. The drop-outs of the placebo group had a lower baseline
FEV1%pred than the placebo patients who completed the study {40.4(8.6)% compared
to 45.8(10.9)% (p=0.018)}. Because a lower baseline FEV1 is known to lead to the risk of
a steeper decline in FEV1, the drop-out within the placebo group may have caused an
underestimation of the effect of beclomethasone versus placebo on the course of FEV1.
However, explanatory analysis showed roughly the same effects of beclomethasone 
versus placebo on FEV1, and thereby the possibility of selective drop-out was excluded.
Discussion of outcomes 
FEV1 was taken as the main outcome in this study. This is often the case in COPD 
studies, because FEV1 is a well known index, considered simple to measure and follow
up, and because it ‘speaks clearly to the mind’ of COPD oriented physicians. However,
there are many other issues to consider. 
In COPD, inflammatory changes have been shown to be present, especially in the
small airways.32 Inhaled steroids should therefore theoretically improve lung function
indices reflecting obstruction in the small airways. In this view, the very significant
improvement of MEF25 noted in the treatment group here is an important finding. It
might attest to the reality of the anti-inflammatory effect of beclomethasone in 
the treated group, and supports the validity of the analysis in terms of FEV1.
Pathophysiologically speaking, the reduced degree of airway obstruction, and particularly
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of small airway obstruction, should be associated with a decrease in the degree of 
hyperinflation. Indeed, RV and FRC tended to decrease over time in the beclomethasone
group.
In line with the increase in MEF25 under beclomethasone, the novel finding of
improved oxygenation levels can hypothetically be viewed as the result of an improved
ventilation/perfusion equilibrium deriving from a lower degree of inflammation in the
distal airways. Nevertheless, it should be noted that PaCO2 did not decline significantly
during treatment with inhaled beclomethasone. When analyzing a number of 
clinical effect parameters, the risk of finding a significant effect by mere chance does
normally increase. The putative effect of beclomethasone on PaO2 should therefore be
considered with due caution.
No effects of beclomethasone (versus placebo) were observed on the intensity of 
dyspnea. This may be viewed as a discrepancy given the improvement in FEV1, but 
subjective clinical measures as dyspnea are known to correlate poorly with the severity
of obstruction in asthma or COPD.33 In addition, it is now well recognized that the relief
of dyspnea that is induced in COPD, for example, by bronchodilators, is much more the
result of a reduction in hyperinflation than of increased expiratory flow.34 Since 
beclomethasone had no significant effect on static lung volumes in this study, the lack
of improvement of dyspnea is a logical finding. Several explanations can be proposed,
including 1) the heterogeneity of the population in terms of the severity of obstruction,
with a minority of severely hyperinflated patients and 2) the fact that a great majority of
patients received bronchodilators on a regular basis (Table 8.1), which may have masked
hypothetical benefits of beclomethasone in terms of hyperinflation related dyspnea. 
The patients’ self-perceived well-being and the physician’s subjective assessment of
clinical status were not modified by beclomethasone as compared to placebo. This is not
surprising if one considers that dyspnea is probably one of the main determinants of the
quality of life in COPD. It should be kept in mind that the indices studied are relatively
rough: principally due to the time of its realization, this study did not include a 
sophisticated assessment of the quality of life. 
Beclomethasone did not affect the number of oral steroid or antibiotic courses 
significantly, nor did it affect the total number of days spent under oral steroids or 
antibiotics. A possible explanation may be that the criteria for the prescription of these
treatments were left to the decision of the physician in charge of the patient rather than
being defined by the protocol. In the literature, the long-term effect of inhaled steroids
on exacerbations in COPD is not clear. Renkema et al found no decrease in the number
of exacerbations during two-year treatment with 1600 µg budesonide daily18, whereas
Paggiaro et al found a decrease in the severity of exacerbations with 1000 µg 
fluticasone/day.35 The limited duration of this study (6 months) makes it difficult 
to draw any conclusions regarding exacerbations. It is noteworthy that 60 of 160
patients with stable COPD (38%) had an exacerbation of COPD within eight weeks after
they had stopped with inhaled steroids (wash-out period) because of participation in a
trial with inhaled fluticasone.36 Not finding a sparing effect of inhaled steroids 
regarding oral steroids in our study may be viewed as a disappointment in the light of
the increasingly well described side-effects of oral steroids in COPD. As opposed to 
what is observed in asthma, this points to the notion that exacerbations of COPD are 
probably not predominantly due to increased airway inflammation, but may proceed
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from many non- inflammatory mechanisms (e.g. left heart failure or bacterial infection).
It again raises the unresolved question of the appropriateness of oral steroid therapy in
acute exacerbation of COPD.37
The majority of the adverse events considered to be related to the inhaled steroid drug
in our study were local side-effects (oral candidiasis, cough after inhalation, dysphonia,
pharyngitis, dry mouth), which are the result of oropharyngeal deposition of inhaled 
steroids.38 No significant difference between the trial groups was shown. Also note that
the patients in our study used MDI’s as inhaler devices and not spacer devices as these
were not yet used on a regular basis at the time of this study. The use of spacer devices
is likely to decrease oropharyngeal deposition and systemic availability significantly, and
thus to further improve the benefit-risk balance of inhaled steroids.39
Approximately 15% of the subjects of our study perceived one or more (especially
oropharyngeal) adverse events that were considered to be related to the trial drug.
Systemic side-effects like a decrease of bone density, a decrease of serum cortisol, or
skin bruising may occur with high doses of inhaled steroids.38,40 At the time of the
study, the assessment of bone density was not as easy and accurate as now. Moreover,
because of the difficulty of obtaining urinary samples, it was agreed not to proceed with
cortisol measurements. In addition, the phenomenon of skin bruising was not well
recognized at the time of the study. As systemic side-effects were not specifically 
studied, it is not possible to fully comment on the long-term safety of beclomethasone
dipropionate 1500 µg daily in the COPD patients from this study.
Inhaled steroids and COPD 
That inhaled steroids can have a positive effect on lung function in COPD, including in
non-reversible forms of the disease, is not disputable on a short-term basis.19 As three
major studies on the topic are pending publication, there is still doubt about the 
long-term clinical effects of inhaled corticosteroids in COPD.4,19 Indeed, among these
studies, '... the Copenhagen study showed no benefit from inhaled budesonide 800 µg daily
(with 1.2 mg for the first six months) on any outcome measure. The EUROSCOP study
showed non-significant benefit in terms of FEV1 decline with budesonide 800 µg daily, whilst
the ISOLDE study showed benefit in terms of quality of life, along with non-significant 
improvement in FEV1 decline, with fluticasone propionate 1 mg daily' (quoted from 
41). In
addition, exacerbations were significantly reduced in the ISOLDE group.41
Our study, conducted among a much smaller population, which, nevertheless, was
probably large enough to draw valid conclusions, yielded results that seem to be at
variance with those of the three above-mentioned ones. It does show a statistically 
significant difference in (prebronchodilator) FEV1 of approximately +40 mL per year
during treatment with beclomethasone compared to placebo on the FEV1, which may be
of clinical relevance. In a recent meta-analysis, in which 152 of the patients from our 
present study were included, a comparable two-year effect of inhaled steroids on FEV1
was shown.20 This difference may be due to differences in the population studied, for
instance, a greater proportion of more severe cases in our study (inhaled steroids being
likely to be more efficient in the most severe forms of the disease). It could also be a
dose related effect, 1.5 mg of inhaled beclomethasone daily represents one of the higher
doses used on a long-term basis in COPD. In this view, it is interesting to note that the
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ISOLDE study used a significantly higher relative dose than the Copenhagen study and
EUROSCOP.  
Conclusion
In conclusion, we showed that a high dose of beclomethasone of 1500 µg daily 
beneficially modified the course of lung function beneficially during two years in
patients with stable moderate COPD. This can raise safety concerns and certainly 
implies that efforts should be made to define selection criteria, which might lead to a
rationalized prescription of inhaled steroids in COPD. Indeed, it will probably become
apparent from other studies that inhaled steroids ‘are unlikely to be the ideal drugs for 
this disease’41, but our study suggests that they may indeed have a place in therapeutics,
given the limited therapeutic scope that is available for COPD.
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Chapter 9 
Summary, General Discussion and Final Conclusions/
Recommendations
Summary
Chapter 1 presents an introduction containing the general background, and the contents
of the studies reported in this thesis. Asthma and chronic obstructive pulmonary disease
(COPD) have a relatively high prevalence in general practice. Because inflammation of
the bronchial wall plays more or less a key role in both disease entities, anti-inflammatory
treatment seems a logical treatment option. In the long-term, both in asthma and in
COPD, irreversible changes take place in the lower airways, as a consequence of the
chronic inflammatory process. It seems therefore essential that anti-inflammatory 
treatment is started as early as possible. Inhaled steroids have already proven their 
beneficial anti-inflammatory action, especially in asthma. Mild cases of asthma or
COPD are mostly treated in general practice. General practice is therefore the most 
suitable domain to study the efficacy and effectiveness of treatment with inhaled 
corticosteroids as early as possible (may be even before the full clinical presentation of
the disease). 
Treatment of patients with (mild signs of) asthma or COPD with inhaled corticosteroids
is the central theme of the research in this thesis. Part One of the thesis contains 
original data from the DIMCA study, a large general-practice-based study on Detection,
Intervention, and Monitoring of patients with mild signs of COPD and Asthma. Several
aspects of early intervention with the relatively new inhaled corticosteroid fluticasone
propionate {Flixotide®} in patients with mild signs of asthma or COPD without a clear
diagnosis are investigated, such as ‘fear of corticosteroids’ (Chapter 2), clinical effects
(Chapter 3) and compliance of treatment (Chapter 4). In Part Two related questions are
presented concerning the dosage and duration of treatment with inhaled corticosteroids
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in patient with diagnosed mild asthma (Chapter 5 and 6) and in patients with diagnosed
moderate to severe COPD (Chapter 7 and 8). 
Part one (data from the DIMCA programme)
The reasons of patients with early signs of asthma or COPD for refusing to participate
in early treatment with fluticasone propionate are investigated in Chapter 2. Screening,
monitoring and the three interventions with fluticasone in DIMCA showed on average
25 to 35% refusers. For those invited to one of the three drug intervention studies, 
‘dislike of medication’ was the most important reason for non-participation (33%, 45%
and 67% of the refusers). ‘Fear of corticosteroids’ was the specific reason for non-
participation in only 8% of the refusers who had a ‘dislike of medication’. We concluded
that a specific fear of corticosteroids was not a major obstacle for early intervention with
inhaled corticosteroids. 
Chapter 3 decribes the clinical effects of fluticasone propionate in subjects believed to
be at the very onset of developing obstructive airways disease, i.e. before a reliable 
diagnosis could be made. Two randomized placebo-controlled trials were conducted
after a two-year monitoring of lung function and symptoms. In the first trial ('mild signs
of COPD’), 48 subjects with a moderate increase in decline in FEV1 of more than
0.04L/yr were invited for a 2-year trial with fluticasone propionate 500 µg daily. In 
the second (1-year) trial ('mild signs of asthma’), 29 subjects with signs of bronchial
hyperresponsiveness were treated. In the COPD trial, the overall course of FEV1 during
the study did not improve for the better by fluticasone compared to placebo. In the 
asthma trial, bronchial hyperresponsiveness was also not influenced by fluticasone
compared to placebo. In both trials there were no significant differences in symptoms
between the fluticasone- and placebo-treated patients. We concluded that there is no
ground for screening subjects with mild signs of asthma or COPD without a clear 
clinical diagnosis for reason of treatment with inhaled corticosteroids.
Chapter 4 assesses the two-year compliance to inhaled fluticasone during the trials
described in Chapter 3. It was hypothesized that compliance would be low in these
patients without a clinical diagnosis of asthma or COPD and hence with few symptoms.
Fluticasone had to be inhaled twice daily with the use of a dry powder inhalator
(Rotadisks®) during one year (in the asthma group) or two years(in the COPD group).
All full and empty disks returned were counted manually. In a telephone survey, the
patients were asked about perceived effects and/or side-effects of the trial drug. The
mean overall individual compliance rates of 72% (range: 7 to 102%) in the COPD trial
and 71% (range: 8 to 99%) in the asthma trial were maintained throughout the study.
The willingness of patients to use the trial drug in daily practice if efficacy would have
been shown was positively related to compliance during the trial (p=0.017). It was 
concluded that compliance rates were high in spite of the ‘mild stage’ of the disease. 
The results also emphasize the importance of patient education in establishing early 
treatment with inhaled corticosteroids in case of proven efficacy. 
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Part two
Chapter 5 describes the literature search and subsequent meta-analysis of the effect of
inhaled corticosteroids on bronchial responsiveness in corticosteroid-naive asthma. The
study was set up in response to recent consensus reports advocating early introduction
of high doses of inhaled corticosteroids in asthma to reduce the bronchial inflammation
as quick as possible. Because of the possibility of adverse effects during long-term 
treatment with high doses of inhaled corticosteroids, it is also advised to reduce the dose
as soon as the clinical state is stable. However, these recommendations are not supported
yet by clinical evidence. Bronchial responsiveness, which is closely related to bronchial
inflammation and can be measured by a bronchial provocation test (for example with
histamine), was taken as the main effect parameter. Eleven studies were selected. In
most of the studies relatively high doses of inhaled corticosteroids were used (on average
1000 µg daily). The overall effect size of inhaled corticosteroids versus placebo treatment
was +1.16 (95%c.i. +0.76 to +1.57) doubling dose of the bronchoconstricting agent. This
effect remained when only the short-term studies (of 2 to 8 weeks) were analysed. We
demonstrated that high doses of inhaled corticosteroids were able to control inflammation
in corticosteroid naive asthma already within 2 to 8 weeks. On the basis of this meta-
analysis it remained unclear whether there is a dose-response relationship between
inhaled corticosteroids and the effect on bronchial hyperresponsiveness. For this
moment, following the recent guidelines of ‘start high, go low’ is mandatory.
In an observational study (Chapter 6), the aim was to investigate whether long-term 
therapy with inhaled corticosteroids can be discontinued in mild asthma when patients
are in a clinically stable phase of the disease. Data were derived from a two-year 
randomized controlled bronchodilator intervention study in general practice during
which no inhaled corticosteroids were allowed. The experimental group consisted of 19
mild asthmatic patients who had used inhaled corticosteroids daily during at least the
year preceding this study. The control group consisted of the 70 patients with asthma,
who had not used corticosteroids in the year preceding the study. In the experimental
group, 12 of the 19 patients (63%) dropped out during the study because of dependency on
corticosteroids. In the control group, only 8 of the 70 patients dropped out for this 
reason (11%). This difference was significant (Chi-square= 20.1, p<0.0001). In the
patients of the experimental group (ex-corticosteroid users), the annual FEV1 decline
was much larger than in the control subjects (0.165 versus 0.040 L/yr, p=0.022). From
these secondary analyses it was concluded that stopping maintenance treatment with
inhaled corticosteroids is not advisable on a routine base in patients with mild asthma
even when the disease seems stabilized. When discontinuing inhaled corticosteroids is
considered, patients should be closely observed and followed by the general physician.
Chapter 7 deals with the assessment of the long-term clinical effects of inhaled 
corticosteroids in COPD. There is much debate about this topic. We therefore performed
a meta-analysis of the original data-sets of three placebo-controlled studies on this 
subject (of at least 24-month duration). Patients with ‘asthmatic’ features such as 
reversibility of bronchial obstruction were excluded from the analyses. Patients had
moderately severe COPD (FEV1 = 45% of predicted). Ninety five selected patients were
treated with inhaled corticosteroids (87 with 1500 or 1600 µg inhaled beclomethasone
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or budesonide daily, and 8 with 800 µg beclomethasone daily) and 88 with placebo. 
The estimated two-year difference in prebronchodilator FEV1 was +0.034L/year 
(95% confidence interval +0.005 to +0.063, p=0.26) to the advantage of the inhaled 
corticosteroid group compared to placebo. Compared with the low-dose treatment, 
the high-dose treatment resulted in a more beneficial course of FEV1 (+0.039L/jaar vs.
+0.002L/yr, p=0.043). The exacerbation rate was not influenced by treatment with 
inhaled corticosteroids. No possible predictors of the response to inhaled corticosteroids
(such as smoking behaviour) were found. We concluded that, in patients with 
clearly defined moderately severe COPD, a beneficial course of FEV1 was evident after 
long-term treatment with relatively high doses of inhaled corticosteroids. 
As a result of the good cooperation with the French research group while working 
on the meta-analysis (Chapter 7), we were allowed to analyse the original data from 
the (yet unpublished) French study. Chapter 8 contains the results of this study. In a
group of 194 patients with stable moderate to severe COPD, the clinical effects and 
safety of a two-year treatment with 1500 µg inhaled beclomethasone (Becotide® MDI)
daily versus placebo were assessed. During the study a significant increase in the 
prebronchodilator FEV1 of +0.038L/yr(SE 0.018, p=0.031) in the beclomethasone group
was shown in comparison with placebo. The postbronchodilator FEV1 showed a 
comparable change. The number and duration of steroid and antibiotic courses were
comparable in both components of the study. Blood oxygen saturation improved by
+0.5(SE 0.2)%/yr (p=0.02) under beclomethasone therapy as compared to placebo.
Seventeen percent of the patients in the beclomethasone group had experienced 
an (especially oral) side effect of the trial drug, versus 15% of the patients of the 
placebo group. This study showed a beneficial and relatively safe effect of 1500 µg 
beclomethasone MDI daily during two years in comparison with placebo in patients
with stable moderate to severe COPD. 
General Discussion
Inhaled corticosteroids are often prescribed in general practice, both in asthma and in
COPD.1 However, a number of questions have not been resolved yet, such as: ‘At what
stage should these anti-inflammatory drugs be introduced?’, and ‘What should be the
dose and duration of treatment in diagnosed subjects?’.
Part One of this thesis contains data on several aspects of the experimental treatment
of patients with mild signs of ashma and COPD (without a clear diagnosis) with inhaled
corticosteroids. Questions to be answered were: ‘Are inhaled corticosteroids effective in
very early stages of asthma or COPD’?, and ‘What are barriers in prescribing inhaled
corticosteroids in this group of patients?’. In order to identify early stages in the 
development of asthma or COPD, data from a large Detection, (early) Intervention
and Monitoring programme on COPD and Asthma in general practice (DIMCA 
programme) were presented in this part.
In Part Two of the thesis we investigated clinical effects of inhaled corticosteroids in
diagnosed groups of asthma and COPD patients. 
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Part one (data from the DIMCA Programme)
Detection of an early stage of COPD
The increased FEV1 decline during the two-year monitoring period of DIMCA was the
central feature for detecting patients with an increased risk of developing COPD. There
are two reasons why one may doubt the relevance of the measurement of an increased
FEV1 decline as risk factor for COPD in patients with near normal lung function. Firstly,
an increased FEV1 decline is a well-known feature of diagnosed COPD. It remains
hypothetical to suppose that patients with a progressive lung function decline during
two years of monitoring but with (near) normal lung function develop COPD. Secondly,
the individual significance of the assessment of FEV1 decline can be doubted. Moreover,
in our study, the mean standard deviation of the individual decline was high (at least
0.065 L/yr).2 However, the frequency and duration of the FEV1 measurements (three-
monthly during two years) seemed sufficient to detect a reliable decline in patients with
an observed FEV1 decline of >0.08 L/yr.3
Detection of an early stage of asthma
During the same two-year monitoring period of DIMCA we also selected patients 
without a FEV1 decline but with signs of (asymptomatic) bronchial hyperresponsiveness
(i.e. a decreased PC20 histamine and/or a reversible bronchus obstruction on a few 
occasions). We hypothesized these items were useful precursors of asthma. Zhong et 
al showed that 10 out of a group of 50 students with asymptomatic bronchial 
hyperresponsiveness developed asthma in the following two years.4 On the other hand,
Kolnaar showed that asymptomatic bronchial hyperresponsiveness in adolescence did
not show the asthma-related characteristics (such as allergy) compared to symptomatic
bronchial hyperresponsiveness.5
‘Fear of corticosteroids’
Groups identified as having mild signs of COPD and asthma were invited to participate
in early intervention with 500 µg fluticasone propionate daily. Chapter 2 states the 
reasons for non-participation in this early intervention. Fear of side-effects of the 
drug and the absence of symptoms were frequently mentioned as reasons for non-
participation. However, a specific fear of inhaled corticosteroids seemed not to be 
the major obstacle for participation. Maybe the full explanation of possible action
and side-effects of fluticasone that was given at the start of the study reduced the 
expected ‘fear of corticosteroids’. In a self-treatment programme involving 22 adult 
asthmatic patients, Van der Palen et al hypothesized that the reluctance of patients to
double inhaled corticosteroids if necessary seemed to reflect indirectly the ‘fear of 
corticosteroids’.6 They suggested more efforts should be made to educate patients 
with asthma about both the effects and side-effects of inhaled corticosteroids.
Clinical effects of inhaled corticosteroids in subjects with mild signs of COPD or asthma
We investigated if inhaled fluticasone (500 µg daily) was capable to reverse a slightly
progressive FEV1 decline during two years in subjects with this mild sign of COPD. 
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We also assessed the effect of the same dose of inhaled fluticasone on bronchial 
responsiveness during one year in subjects with this possible sign of asthma. We 
hypothesized that each of the two signs would be the result of early inflammation of the
bronchial wall. Chapter 3 showed no clear effects of inhaled fluticasone 500 µg daily on
lung function and symptoms in both groups. Thus, in these patient groups secondary
prevention of the disease seemed not to be possible through early treatment with a
mean dose of inhaled corticosteroids. This result indicates that there is no ground for
recommending early detection of all patients with mild signs of asthma or COPD 
without a clinical diagnosis (including symptoms) followed by treatment with inhaled
corticosteroids. However, in a group of 31 patients with undiagnosed but clinical
obstructive airways disease, early treatment with 500 µg fluticasone daily compared
with placebo during one year (another DIMCA trial) did show significant improvements
in FEV1 and PC20 histamine.7 At an early date, results of the START study will provide
more evidence about the optimum time to begin treatment with inhaled corticosteroids.8
In the START study the clinical effects of inhaled budesonide (200-400 µg daily during
three years) versus placebo are assessed in nearly 7,000 patients with newly diagnosed
asthma.
As I have already mentioned, the inclusion criterion of bronchial hyperresponsiveness
in the asthma trial does not necessarily indicate (pre)asthma.5 This may be one of 
the explanations for the lack of effect of inhaled corticosteroids on bronchial 
hyperresponsiveness in the asthma trial. 
On the basis of a review of clinical predictors of the effect of inhaled corticosteroids
in COPD9, we expected the lung function to be more preserved by treatment with inhaled
corticosteroids in comparison with placebo when ‘asthmatic features’ such as allergy, a
higher reversibility, a higher bronchial hyperresponsiveness and a lower consumption
of tobacco were present. However, in our experimental study in both trials, no 
subgroups with an enhanced effect of inhaled corticosteroids were identified. A 
possible explanation might be the relative ‘healthy state’ of the patients, so that the room
for improvement was too small. The number of patients could also have been too small
to show a significant effect in subgroups. 
Non-drug treatment options in patients with mild signs of asthma or COPD?
As I have stated in the introduction, treatment should probably be multifactorial. This
thesis, however, focusses only on one particular early intervention, i.e. treatment with
inhaled corticosteroids. In patients with mild signs of asthma or COPD, other treatment
options may therefore also be more or less effective.
In COPD, giving up smoking is the most effective intervention to prevent further
deterioration of the lung function. In the Lung Health Study, a multicentre 5-year
study on the effects of ipratropium bromide on the FEV1 in patients with mild COPD
during 5 years, a smoking cessation intervention at the start of the study resulted in a
physiological decline of FEV1 in the placebo group during the study.10 Logically, the best
way to prevent the development, or further development, of COPD is not to start 
smoking, and for patients who do smoke, to stop smoking as soon as possible. Recent
guidelines are meant to assist the general practitioner to help patients with smoking
cessation, for example by prescribing nicotine replacement therapy.11
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In asthma, avoidance of exposure to allergens is a tool to minimize bronchial 
hyperresponsiveness and thus symptoms. Household mite avoidance measures in 29
patients with an isolated allergy to household mite without clinical asthma (of which 13
patients received placebo treatment) showed improved peak flow parameters and 
symptoms after six weeks.12 Health insurance companies are increasingly reimbursing
the purchase costs of matrass covers when an allergy to household mite has been
demonstrated, also in absence of the full clinical presentation of asthma or rhinitis.
Early detection of ‘high-risk’ patients?
From a general practitioner’s point of view, one important question is which patients
from the general population may be considered to run a ‘high risk’ of developing clinical
asthma or COPD and how they can be detected (and treated) as soon as possible. 
Several possible risk factors for the occurrence of aeroallergen sensitization - and
thus asthma - in children were identified, such as atopic family history, food antibodies
and early atopic dermatitis.13 However, the sensitivity of these factors for aeroallergen
sensitization was low.13 It is therefore not easy to predict whether or not a child will 
develop allergic asthma. Also in adulthood, atopy is a well-known risk factor for the
occurrence of asthma.14 Until more specific predictors of high-risk for asthma become
available, general practitioners should give extra attention to patients with prolonged
cough or wheezing from atopic families. 
The most common risk factor for COPD is cigarette smoking. However, only 15% 
of the smoking patients develop COPD.15 Furthermore, COPD may aggregate in 
families.15 Measurement of the FEV1/VC may help to identify smokers susceptible to
the development of chronic airflow limitation.16 Stanescu et al found that middle-aged
smokers are at no evident risk of functional deterioration if their FEV1/VC ratio is 
normal.16 Until more specific research on detection of high-risk patients with COPD is
available, it might be appropriate to offer all smokers of 50 years and over (especially
when COPD was diagnosed in the family) a one-time spirometry containing data about
the FEV1 and VC.
Compliance
Rates of compliance to inhaled fluticasone in the trials in patients with early signs of 
asthma or COPD were relatively high (72%), although the results show that side-effects
of the drug seemed to outweigh the clinical effects (Chapter 4). One possible explanation
of this high compliance rate may be the ongoing communication with the patient
during the study, as they were asked about their general well-being and the possible
effects and side-effects of the drug and encouraged to continue the measurement 
schedule of the study. In a trial with 50 adult patients with moderate to severe asthma,
compliance to a twice-daily dosing schedule with inhaled corticosteroids was monitored
electronically during 6 weeks.17 A good patient-clinician communication was strongly
related to compliance (mean rate 63% of prescribed).17 This stresses the importance 
of a good relationship between the patient and the doctor as a major condition for 
adherence to therapy.18
Our study also showed that compliance was higher in patients who were willing to
use the drug in daily practice when efficacy would be proven. Education plays a key role
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in improving compliance and motivating patients to be treated.19
The patients’ own responsibility regarding the treatment is considered to be a major
factor in improving compliance in asthma cases. Implementation of guided self-
treatment plans in the general practice is more and more advised.20 Van der Palen
showed a small increase of compliance from 83 to 92% in 21 asthma patients when a
self-treatment guideline was introduced during four weeks.6 Although the clinical 
benefits of guided self-treatment are not yet entirely clear, the shift towards more 
personal responsibility for the treatment of the disease may be encouraged. This may
also lead to more ‘equality’ and thus probably to a better patient-doctor relationship.21
Part two
Top-down strategy of inhaled corticosteroids in ‘corticosteroid-naive' mild asthma
Chapter 5 described a meta-analysis of the effect of inhaled corticosteroids on bronchial
responsiveness in patients with asthma who had never used inhaled corticosteroids. In
this way a ‘clean’ effect of inhaled corticosteroids on the early inflammation of the 
bronchial wall could be assessed indirectly by measuring bronchial hyperresponsiveness.
Bronchial provocation testing, known as an indirect measure of inflammation, was the
main outcome parameter of the meta-analysis. We concluded that high doses of inhaled
corticosteroids (1000 µg daily) reduced bronchial responsiveness significantly within 
2-8 weeks. We therefore found sufficient reason to support the ‘start high’ strategy in
the recent concensus reports on asthma.22
VanderMolen et al found that a four-week treatment of 91 patients with corticosteroid-
naive asthma with 800 µg versus 200 µg budesonide daily improved lung function 
and decreased peak expiratory flow variability in both groups equally.23 However, no
bronchial provocation testing for the assessment of bronchial responsiveness was done
in their study and therefore the study was not included in the meta-analysis. Although
it is also believed that peak expiratory flow variability is a reliable and simple indicator
of bronchial responsiveness, a recent study with data from the DIMCA programme
showed a poor correlation between peak expiratory flow rate and bronchial provocation
testing.24 A recent review showed a number of studies in which no correlation was
shown between bronchial provocation testing and direct measures of inflammation
(BAL, induced sputum or bronchial biopsy).25 These results reflect the difficulty of 
finding the ‘golden standard’ for noninvasive assessment of bronchial inflammation.
Recent evidence suggests that nitric oxide in exhaled air also may reflect the presence
and severity of airway inflammation, but due to large ranges of the level of nitric oxide
its use as a marker of inflammation is not yet justified.26
Stopping treatment with corticosteroids in asthma
The general opinion is that inhaled corticosteroids have to be used daily over a long
period. Adverse effects such as oropharyngeal complaints are relatively common.27
Also, the occurrence of systemic side-effects of inhaled corticosteroids, especially in 
higher doses, such as effects on bone, growth, skin thinning and bruising, cataract and
glaucoma27 may warrant reducing or stopping treatment once the disease is ‘under 
control’. 
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Chapter 6 showed that 12 of 19 subjects with mild stable asthma had a deterioration
of their asthma (increased decline of FEV1,) especially in the first six months after they
stopped inhaling corticosteroids. Haahtela et al also showed that stopping with 1200 µg
inhaled budesonide after a two-year treatment caused a relapse of the steady clinical
state of mild asthma during the following year (decrease of PD15 histamine after one
year, decrease in morning peak flow and increase in symptoms after 3 months), while a
gradual reduction to a lower dose caused no deterioration.28 Two other studies also 
indicated that discontinuation of treatment with inhaled corticosteroids in mild 
asthma does not result in a deterioration of the clinical condition.29,30 It is not yet 
clarified which patients are at risk of asthma deterioration when stopping with inhaled
corticosteroids. Therefore, if a general practitioner considers to stop treatment with
inhaled corticosteroids, a close monitoring of lung function and symptoms is advisable,
especially in the first six months. 
Inhaled corticosteroids in COPD
There exists a certain overlap between patients with a clinical diagnosis of COPD and
asthma. Because inhaled corticosteroids have proven their value in the treatment in
asthma but not in COPD, it would be mandatory to assess the clinical effect in patients
with clear COPD without ‘asthmatic features’ such as reversible airway obstruction.
This starting-point, as well as the general doubt about the clinical effect of inhaled 
corticosteroids in COPD, was the basis of Chapter 7. A meta-analysis was performed of
all published and known unpublished studies providing results of long-term treatment
with inhaled corticosteroids in patients with strictly diagnosed COPD (i.e. with a 
irreversible bronchus obstruction). Inhaled beclomethasone/budesonide (daily dose
approximately 1500 µg) caused a modest but significant preservation of lung function
during two years of treatment in comparison with placebo. One of the studies that 
attributed the majority of data to the meta-analysis was an unpublished French study.
We had the opportunity to analyse the original data from this study (Chapter 8), of
which the conclusions are comparable with those of the meta-analysis. As the data from
the two studies overlap, this was not very surprising. On the other hand, we expected the
analysis of the original data-set of the French study, also including COPD patients with
‘asthmatic features’, to result in a larger effect on the FEV1 than that which was 
actually found. As in the meta-analysis, and in contrast to other studies, no predictors
of the effect of inhaled corticosteroids such as reversibility of obstruction and allergy
could be identified.9
Although our study showed a small beneficial effect of a relatively high dose of 
inhaled corticosteroids in moderate to severe COPD, the debate about its precise role in
COPD will undoubtedly continue.31 The results of the three large unpublished but 
already finished trials (EUROSCOP32, ISOLDE, and the COPENHAGEN CITY LUNG
study), assessing the effect of inhaled corticosteroids in COPD, are not very promising.33
See Table 9.1 for a brief overview of the three studies mentioned (the data in the studies
were derived from oral presentations at the 1997 congress of the European Respiratory
Society in Berlin and the 1998 congress in Geneve33). On the basis of our meta-
analysis there were indications that a dose of 800 µg of the inhaled corticosteroid 
(beclomethasone) was insufficient to inhibit the progressive lung function decline
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during two years in our patients with moderate to severe COPD (mean FEV1 50% pred.).
This may partly explain the absence of the effect of a three-year daily treatment with 
800 µg budesonide on the long-term lung function decline in patients with (mild)
COPD (FEV1 77% pred.) in the EUROSCOP study, and with 800-1200 µg budesonide
in patients with (mild) COPD (FEV1 86% pred.) in the COPENHAGEN CITY LUNG
study. On the other hand, a three-year trial with a higher dose of inhaled corticosteroids
(1000 µg fluticasone daily) in patients with severe COPD (FEV1 50% pred.) participating
in the ISOLDE trial did not show a different long-term lung function decline between
the active and placebo group either. Only in the ISOLDE trial did the number of 
exacerbations decrease during active treatment. The same trial showed a significant
increase in the quality of life. 
On the basis of our results and all these preliminary findings, the conclusion must be
that only a small beneficial long-term effect of inhaled corticosteroids, in a high dose,
has been demonstrated in patients with moderate to severe COPD. This stresses 
the importance of future development of new treatment options in COPD. In the mean
time, the most effective intervention in COPD, i.e. giving up smoking, has to be 
encouraged more. Recent international recommendations for physicians may help to
encourage patients to ban the cigarette from their lives.11 ‘The four A’s’ seem the 
central tool in these recommendations: Ask about smoking at every opportunity, Advise
all smokers to stop, Assist the smoker to stop (for example by prescribing nicotine
replacement therapy) and Arrange follow-ups.11
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Table 9.1: Preliminary results of three long-term multicenter trials on the effects of
inhaled corticosteroids in COPD.33
EUROSCOP ISOLDE COPENHAGEN CITY LUNG
Participants 1,277 751 290
Duration 3 years 3 years 3 years
Intervention budesonide fluticasone  budesonide (1200 µg 0-6
800 µg vs. 1000 µg months) 800 µg 
placebo vs. placebo vs. placebo
Baseline FEV1 77%pred. 50%pred. 86%pred.
Long-term effect on FEV1 no no no
decline 
Effect on no data yes no
exacerbations
Effect on quality of life/  no assessment yes no
functional status
Van GrunsvenDEF  13-09-1999 22:33  Pagina 144
Future asthma and COPD drug therapy - some options
Inhaled corticosteroids are undoubtfully the most effective anti-inflammatory treatment
of asthma. However, in the light of the possible (systemic) side-effects of these anti-
inflammatory drugs, other treatment options may be considered, especially in mild 
stages of asthma. Leukotriene receptor antagonists (such as montelukast, zafirlukast)
and leukotriene synthesis inhibitors (such as zileuton) are newly developed oral drugs
directed against leukotrienes as part of the inflammatory components in the airways in
asthma.34 As a consequence, leukotriene modifiers have shown to decrease bronchospasm,
eosinophil recruitment and bronchial hyperresponsiveness in patients with asthma.34
Clinical studies in patients with mild to moderate asthma have shown that leukotriene
modifiers, compared with placebo, improve lung function, decrease the need of ß 
agonists and decrease symptoms of asthma, especially at night.35 Reported adverse
effects were relatively mild, although it must be said that long-term clinical studies have
not yet been performed. The oral administration of leukotriene receptor antagonists
may also have the advantage of a better compliance than inhaled anti-asthmatic drugs.
Huse et al showed that, during a one-year registration of anti-asthmatic prescriptions 
in 455 patients, the compliance with oral anti-asthmatic medication was 70% in 
comparison with inhaled medication (52%, p<0.0001).36
In COPD, free (oxygen) radicals from cigarette smoke or activated neutrophils are
known to cause irreversible lung tissue damage.37 Anti-oxidant drugs therefore become
increasingly important in the treatment of COPD. Some clinical studies showed that
oral acetylcysteine decreased the number of exacerbations38 and days of illness.39 One
study suggested a decrease of the FEV1 decline as a result of acetylcysteine.40 This study
was only published as an abstract, however. It was hypothesized that anti-oxidant 
treatment might be more effective among those COPD patients who respond less well
to inhaled corticosteroids (low reversibility and heavy smoking).41 Further studies will
have to evaluate the precise role of acetylcysteine in the treatment of COPD. However,
Dutch general practitioner’s guidelines for the treatment of COPD recommend a trial of
acetyl-cysteine in case of frequent exacerbations.42
Main conclusions of the general discussion
-It remains doubtful if an increased FEV1 decline in subjects with near normal 
lung function and without symptoms or with few symptoms is a precursor of the 
development of COPD, and that bronchial hyperresponsiveness in subjects without
symptoms or with few symptoms is a precursor of the development of asthma. 
-Education about the possible action and side-effects of inhaled corticosteroids may
reduce the ‘fear of corticosteroids’.
-The absence of a beneficial effect of inhaled fluticasone in subjects with mild signs of
asthma was possibly caused by the relatively ‘healthy state’ of the patients, so that the
room for improvement was too small.
-In subjects with mild signs of COPD, smoking cessation seems the best measure to
prevent a (further) development of COPD.
-In order to detect patients with a ‘high risk’ of (further) developing COPD, a one-time
spirometry could be offered to all smokers of 50 years and over. 
-A good patient-doctor relationship on the basis of ‘equality’ may be a key factor in
enhancing compliance to the treatment.
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-The bronchial provocation testing is considered as the ‘golden standard’ for measuring
bronchial inflammation until more specific non-invasive measurements become 
available. 
-Future investigations will have to indicate which patients with asthma who stop 
treatment with inhaled corticosteroids run the risk of the disease deteriorating.
-Clinical evidence shows that, in COPD, inhaled corticosteroids are moderately effective in
relatively high doses in moderate to severe stages of the disease. It remains unclear what
clinical characteristics predict the effect most.
-In the light of the possible adverse effects of inhaled corticosteroids, future research
will have to determine the value of leukotriene modifiers in the drug treatment of
patients with mild asthma.
-Future research may demonstrate if anti-oxidant drugs (such as acetylcysteine) are an
alternative treatment option for patients with COPD and frequent exacerbations. 
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Final Conclusions/Recommendations
The main findings as described in this thesis resulted in the following conclusions and
recommendations for the general practice:
-Presently, there is insufficient evidence to recommend detection of all patients with
mild signs of asthma or COPD without a clinical diagnosis, followed by treatment with
inhaled corticosteroids. It is likely that some selected cases may  benefit, but more
research is needed to identify the appropriate target group ('high risk’ group).
-General practitioners do not have to be afraid that the ‘fear of corticosteroids’ will tip
the scale in favour of non-participation in early intervention with inhaled corticosteroids
in asthma and COPD. Educational efforts such as instruction about effect and side-
effect of inhaled corticosteroids may improve participation further. 
-High long-term compliance rates to inhaled corticosteroid/ fluticasone propionate can
be achieved in asthma and COPD, also in patients with early signs of the disease and
thus with few symptoms. Repetition, instruction and education about the disease and
the (side-)effects of treatment with inhaled cortiocsteroids, as well as a good patient-
doctor relationship seem valuable tools to improve and sustain compliance. This is 
compatible with a pro-active monitoring approach. The general practitioner and 
practice nurse play an important role in fulfilling this task.
-When general practitioners consider to introduce inhaled corticosteroids in asthma
patients for the first time, it is advisable to ‘start high’, and to ‘go low’ as soon as control
has been achieved. In a stable phase of the disease, it is even possible to stop treatment
safely in a number of patients. However, accurate supervision of symptoms, use of 
bronchodilators and lung function is necessary -especially in the first six months after
the reduction or cessation of treatment- to avoid unexpected exacerbation of the disease. 
-High daily doses of inhaled corticosteroids slightly modify the progressive course of
lung function in moderate to severe COPD beneficially. The role of lower doses of inhaled
corticosteroids remains unclear. Furthermore, future investigations will have to 
reveal which COPD patients may benefit most from long-term treatment with inhaled
corticosteroids. In the meantime, a better implementation of smoking cessation 
strategies is highly recommended.
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Chapter 12 
In Dutch: Samenvatting en Slotconclusies/Aanbevelingen
Samenvatting
Hoofdstuk 1 behandelt een algehele introductie van de achtergrond, doel en inhoud van
de studies die in dit proefschrift besproken worden. Astma en chronisch obstructieve
longziekte (COPD) zijn frequent voorkomende chronische longziekten in de 
huisartspraktijk. Daar ontsteking van de luchtwegwand (bronchiale inflammatie) bij
beide ziektebeelden in min of meerdere mate optreedt, lijkt anti-inflammatoire 
behandeling een zinvolle behandelingsoptie. Op lange termijn treden bij astma en
COPD onomkeerbare veranderingen in de lagere luchtweg op, waarschijnlijk ten 
gevolge van die chronische ontsteking. Het vroegtijdig starten van anti-inflammatoire
behandeling lijkt dan ook essentieel. Inhalatiecorticosteroïden hebben hun anti-
inflammatoire werking reeds bewezen bij astma, bij COPD is de positie nog 
onduidelijk. Patiënten met een lichte vorm van astma of COPD worden voornamelijk
door de huisarts behandeld. De huisartspraktijk is dan ook meest aangewezen locatie
om onderzoek te verrichten naar het effect van een zo vroeg mogelijke behandeling met
inhalatiecorticosteroïden, zelfs nog voordat de volledige klinische diagnose is gesteld. 
Het thema van dit proefschrift is de behandeling van patiënten met (lichte tekenen van)
astma en COPD met inhalatiecorticosteroïden. Deel 1 van het proefschrift bevat data van
de DIMCA studie, een groots opgezette studie in de huisartspraktijk over vroegtijdige
opsporing (Detection), behandeling (Intervention), en Monitoring van patiënten met
vroege tekenen van COPD en Astma. Verschillende aspecten van vroegtijdige interventie
met het relatief nieuwe inhalatiecorticosteroïd fluticason propionaat {Flixotide®} in
deze patiëntengroepen zonder een duidelijke diagnose worden onderzocht, zoals
‘steroïdangst’, (Hoofdstuk 2), klinische effecten (Hoofdstuk 3) en therapietrouw
(Hoofdstuk 4). In Deel 2 van dit proefschrift worden andere openstaande vragen beantwoord,
waarbij onderzoeksgegevens worden gepresenteerd van groepen patiënten met
gediagnostiseerd (licht) astma of COPD. De onderzoeksvragen hebben betrekking op de
dosering en duur van behandeling met inhalatiecorticosteroïden bij patiënten met
(licht) astma (Hoofdstuk 5 en 6) en bij patiënten met matig ernstig COPD (Hoofdstuk
7 en 8). 
Deel 1 (resultaten van het ‘DIMCA’ programma)
In Hoofdstuk 2 worden redenen onderzocht om deelname aan vroegtijdige behandeling
met fluticason propionaat te weigeren bij patiënten met lichte tekenen van astma of
COPD zonder een duidelijke diagnose. De screening, monitoring en de (drie)
interventiestudies met fluticason in DIMCA lieten 25 tot 35% weigeraars zien. ‘Aversie
tegen medicatie’ was de belangrijkste reden van weigering tot deelname aan een van de
interventies met fluticason (33%, 45% en 67% van de weigeraars). Specifieke ‘steroïdangst’
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was slechts bij 8% van de weigeraars die een hekel aan medicatie hadden een reden om
niet deel te nemen. ‘Steroïdangst’ lijkt dus geen obstakel te zijn voor vroege interventie
met inhalatiecorticosteroïden. 
Hoofdstuk 3 beschrijft de klinische effecten van fluticason propionaat bij patiënten met
lichte tekenen van astma of COPD zonder dat de volledige klinische diagnose is gesteld.
Twee gerandomiseerde placebo-gecontroleerde trials werden uitgevoerd na een twee jaar
durende monitoring van longfunctie en klachten. In de eerste trial ('lichte kenmerken
van COPD’) werden 48 patiënten met een matig versnelde achteruitgang van de 
longfunctie (FEV1 > 0.04 L/jaar) gedurende twee jaar behandeld met fluticason propionaat
500 µg/dag. In de tweede trial ('lichte kenmerken van astma’) werden 29 patiënten met
tekenen van bronchiale hyperreactiviteit gedurende 1 jaar behandeld. In de ‘COPD’
groep werd het verloop van de FEV1 gedurende de studie niet beïnvloed door 
behandeling met fluticason vergeleken met placebo. In de ‘astma’ groep werd de 
bronchiale hyperreactiviteit niet beïnvloed door behandeling met fluticason versus
placebo. Ook trad er geen verandering in het aantal klachten op. Geconcludeerd werd
dat er onvoldoende reden is om patiënten zonder een duidelijke klinische diagnose van
astma of COPD te screenen en vervolgens gedurende langere tijd te behandelen met
inhalatiecorticosteroïden.
In Hoofdstuk 4 wordt de therapietrouw aan fluticason gemeten in de in Hoofdstuk 3
genoemde onderzoeken. De hypothese was dat de therapietrouw laag zou zijn in een
groep patiënten zonder een klinische diagnose van astma of COPD en dus met weinig
bronchiale klachten. Fluticason moest gedurende een jaar (in de ‘astma’ groep) of twee
jaar (in de ‘COPD’ groep) tweemaal daags geïnhaleerd worden met een droge 
poederinhalator (Rotadisk®). Alle teruggebrachte volle en lege schijfjes werden 
handmatig geteld. Door middel van een telefonische enquête werden vragen gesteld
over ervaren werking of bijwerking van het medicijn. De gemiddelde therapietrouw was
72% (spreiding 7 tot 102%) in de ‘COPD’ trial en 71% (8 tot 99%) in de ‘astma’ trial. De
bereidheid van patiënten om het studiemedicijn in de dagelijkse praktijk te gebruiken
als de werking bewezen zou zijn, was positief gecorreleerd aan de therapietrouw 
gedurende de trial (p=0.017). Geconcludeerd werd dat de therapietrouw hoog was
ondanks het vroege stadium van de ziekte. De grote bereidheid om inhalatie- 
corticosteroïden te gebruiken indien de werking bewezen zou worden, was volgens de
onderzoekers het gevolg van de duidelijke uitleg (educatie) aan de patiënten over het
doel, werking en bijwerking van het studiemedicijn. 
Deel 2
Hoofdstuk 5 beschrijft een meta-analyse naar het effect van inhalatiecorticosteroïden op
bronchiale hyperreactiviteit in patiënten die voor de eerste maal inhalatiecorticosteroïden
kregen voorgeschreven ('corticosteroid-naive’). Volgens consensusrapporten zou met
een hoge dosering moeten worden begonnen, en zou de dosering snel kunnen worden
verlaagd als de inflammatie onder controle zou zijn. Dit advies wordt echter niet 
ondersteund door klinisch bewijs. Bronchiale hyperreactiviteit, als maat voor de 
inflammatie en gemeten met behulp van een bronchiale provocatietest (bv. met 
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histamine), was de belangrijkste effectparameter. Elf studies werden geselecteerd. In de
meeste studies werden relatief hoge doseringen inhalatiecorticosteroïd (1000 µg/dag)
gebruikt. Het totale effect van inhalatiecorticosteroïden versus placebo was +1.16 (95%
betrouwbaarheidsinterval +0.76 to +1.57) verdubbelingsdosis van het bronchus- 
vernauwende middel. Dit effect bleef aanwezig als alleen de kortetermijnstudies werden
geanalyseerd (2-8 weken). Op basis van deze resultaten was het onduidelijk of lagere
doseringen hetzelfde resultaat zouden hebben bereikt. Vooralsnog lijkt het volgen van
het adagium ‘start hoog, en verlaag’ gerechtvaardigd.
In een observationele studie (Hoofdstuk 6) werd gemeten of langdurige behandeling
met inhalatiecorticosteroïden kon worden gestopt wanneer patiënten met een lichte
vorm van astma in een stabiele fase van hun ziekte waren. De onderzoeksgegevens 
werden ontleend aan een twee jaar durende in de huisartspraktijk gesitueerde 
gerandomiseerd gecontroleerde interventie waarbij patiënten alleen met luchtwegverwijders
werden behandeld. De experimentele groep bestond uit 19 patiënten met (lichte) astma die
gedurende het jaar voorafgaande aan genoemde studie inhalatiecorticosteroïden hadden
gebruikt. De controlegroep bestond uit 70 patiënten met astma die geen 
inhalatiecorticosteroïden hadden gebruikt in het jaar voorafgaande aan de studie. In de
experimentele groep vielen 12 van de 19 patiënten (63%) uit gedurende de interventie-
studie wegens afhankelijkheid van corticosteroïden. In de controlegroep vielen slechts
8 van de 70 patiënten uit om die reden (11%). Dit verschil was significant (Chi-kwadraat
= 20.1, p<0.0001). Ook het longfunctieverlies in de experimentele groep (ex-steroïd-
gebruikers) was groter dan in de controlegroep (FEV1 daling 0.165 versus 0.040 L/jaar,
p=0.022). Stoppen met een onderhoudsbehandeling met inhalatiecorticosteroïden kan
niet routinematig geadviseerd worden bij patiënten met licht astma, ook al lijkt de ziekte
onder controle. Als toch overwogen wordt om behandeling met inhalatie-
corticosteroïden te stoppen, dan dient dit onder zorgvuldige medische controle te
gebeuren.
Over de klinische langetermijnseffecten van inhalatiecorticosteroïden bij patiënten met
COPD bestaat nog veel discussie. In Hoofdstuk 7 werd een meta-analyse van de originele
datasets van drie placebo-gecontroleerde studies (met een studieduur van minstens 24
maanden) verricht. Patiënten met astmatische kenmerken (zoals reversibiliteit van de
luchtwegobstructie) werden niet geanalyseerd. De patiënten hadden matig tot ernstig
COPD (FEV1 = 45% van voorspeld). Vijfennegentig geselecteerde patiënten waren 
behandeld met inhalatiecorticosteroïden (87 met 1500/1600 µg beclomethason of
budesonide per dag, 8 met 800 µg beclomethason per dag), en 88 met placebo. Het verschil
in de prebronchodilatoire FEV1 over twee jaar was +0.034 L/jaar (95% betrouwbaarheids-
interval +0.005 tot +0.063, p=0.026) in het voordeel van de met inhalatiecorticosteroïden
behandelde groep vergeleken met placebo. De hoge dosering resulteerde in een beter
verloop van de FEV1 dan de lage dosering van het inhalatiecorticosteroïd (resp. +0.039
L/jaar vs. +0.002 L/jaar, p=0.043). Het aantal exacerbaties werd niet beïnvloed door de
behandeling. Er werden ook geen voorspellers van het effect gevonden (zoals 
bijvoorbeeld het rookgedrag). Patiënten met duidelijk gedefinieerd matig tot ernstig COPD
hadden een beter verloop van de FEV1 bij behandeling met relatief hoge doseringen 
inhalatiecorticosteroïden.
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Door de goede samenwerking met de Franse onderzoeksgroep naar aanleiding van de
meta-analyse in Hoofdstuk 7 kwam er een aanbod om de volledige data van de (nog niet
gepubliceerde) originele Franse studie te analyseren. Hoofdstuk 8 beschrijft de resultaten
van deze studie. In een groep van 194 patiënten met matig tot ernstig COPD werden de
behandelingseffecten en eventuele bijwerkingen van een twee jaar durende dagelijkse
behandeling met beclomethason 1500 µg (versus placebo) onderzocht. Gedurende de
studie nam de prebronchodilatoire FEV1 in de beclometasongroep vergeleken met de
placebogroep significant toe met +0.038 L/jaar(SE 0.018, p=0.031). De postbroncho-
dilatoire FEV1 liet een vergelijkbare verandering zien. Het aantal prednison- en
antibioticakuren was vergelijkbaar gedurende de studie in beide behandelgroepen. De
zuurstofsaturatie verbeterde met +0.5(SE 0.2)%/jaar (p=0.02) gedurende
beclometasonbehandeling vergeleken met placebo. Zeventien procent van de patiënten
in de beclometasongroep hadden (niet ernstige, veelal oropharyngeale) bijwerkingen
van het onderzoeksmedicijn, versus 15% van de patiënten van de placebogroep. Deze
studie toonde aan dat behandeling van patiënten met stabiel matig tot ernstig COPD
met beclomethason in een dosering van 1500 µg per dag gedurende twee jaar relatief
veilig was en resulteerde in een voordelig verloop van de longfunctie. 
Slotconclusies/Aanbevelingen:
-Vooralsnog is er onvoldoende bewijs om vroege detectie en vervolgens behandeling
met inhalatiecorticosteroïden aan patiënten met lichte tekenen van astma en COPD aan
te bevelen. Het is mogelijk dat er in selecte gevallen sprake is van een voordelig effect,
maar er is meer onderzoek nodig om de doelgroep (‘high risk’ groep) te identificeren.
-(Huis)artsen hoeven niet te vrezen dat ‘steroïdangst’ bepalend is voor het weigeren om
deel te nemen aan vroege behandeling met inhalatiecorticosteroïden bij patiënten met
astma en COPD, zeker niet indien een duidelijke uitleg van de (bij)werking heeft 
plaatsgevonden. Dit laatstgenoemde educatieve element kan deelname aan behandeling
nog verder bevorderen.
-Een hoge graad van therapietrouw aan geïnhaleerd fluticason propionaat kan bereikt
worden bij patiënten met astma en COPD, ook bij patiënten met vroege tekenen van de
ziekte en dus weinig symptomen. Herhaling, instructie en educatie over de (prognose
van de) ziekte en de (bij)werkingen van behandeling met inhalatiecorticosteroïden lijken
waardevolle instrumenten om therapietrouw te verbeteren en te waarborgen. Deze
benadering sluit aan bij het principe van pro-actief monitoren. De (huis)arts of de 
praktijkverpleegkundige kan een belangrijke rol spelen in het vervullen van deze taak.
-Als (huis)artsen overwegen om patiënten met (licht) astma voor het eerst met inhalatie-
corticosteroïden te gaan behandelen, dan is het aanbevelenswaardig om met een hoge
dosering te starten, en de dosering af te bouwen als controle van de inflammatie is
bereikt. In een stabiele fase van de ziekte is het bij een aantal patiënten zelfs mogelijk
om de behandeling veilig te stoppen. Echter, dit dient te gebeuren onder adequate 
periodieke controle van de arts op symptomen, gebruik van luchtwegverwijders en 
longfunctie, vooral in de eerste zes maanden na stoppen of afbouwen. Hiermee wordt
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voorkomen dat de ziekte onverwacht verergert. 
-Hoge dagelijks doseringen van inhalatiecorticosteroïden lijken het progressief 
longfunctieverlies bij patiënten met matig ernstig COPD enigszins te kunnen 
verminderen. De rol van lagere doseringen inhalatiecorticosteroïden blijft onduidelijk.
Verder onderzoek zal ook moeten uitwijzen welke COPD patiënten het meeste baat 
hebben bij langdurige behandeling met inhalatiecorticosteroïden. Intussen is een 
betere implementatie van ‘stoppen met roken strategieën’ noodzakelijk.
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Chapter 13
In Dutch: Dankwoord
De afgelopen vijf jaar heb ik met veel inzet gewerkt aan dit proefschrift. Ik wil graag een
aantal mensen bedanken die het mogelijk hebben gemaakt dat ik dit proefschrift in deze
periode kon vervaardigen, ondanks mijn werkzaamheden als praktizerend huisarts.
Allereerst wil ik graag mijn promotoren bedanken. Onno van Schayck, jij bedankt voor
alle bijstand in de meest ruime zin des woords, en altijd weer de positieve spirit om 
probleempjes te helpen oplossen. Chris van Weel, bedankt voor je goede en snelle
adviezen bij ieder manuscript, en de bereidheid om samen ‘even’ naar Parijs te gaan om
het contact met mede-onderzoekers te versterken. Cees van Herwaarden, dank voor
onze vaak aan filosofie grenzende discussies in de wandelgangen van buitenlandse 
congressen over longziekten. Statistiek is een boeiend maar soms moeilijk onderdeel
van de verwerking van de resultaten van dit proefschrift. Zonder de uitstekende en niet
aflatende hulp van Reinier Akkermans was ik dan ook ongetwijfeld blijven steken in een
X2-toets. Bedankt voor je hulp. Lea Peters was mijn steun en toeverlaat bij de 
dataverzameling en correctie. Zij was tevens een zeer nauwgezette intermediair tussen
mij en de patiënt, vooral in de periode dat mijn ‘schrijfwerk’ moest beginnen. Twanny
Rouwhorst verzorgde vaak mailings, de produktie van Figuren of tabellen, en tot slot ook
de lay-out van dit proefschrift. Allebei veel dank hiervoor. Lilian Bierman was als 
longfunctie-assistente een onmisbare en zeer betrouwbare schakel in de data- 
verzameling, evenals Victoria Verwaaijen-Larsson. Veel dank voor jullie hulp. Guido van
den Boom, jou wil ik graag dankzeggen voor je waardevolle en kritische opmerkingen met
betrekking tot het gehele DIMCA project en je humor als kamergenoot. Mede dankzij jou
is DIMCA geworden wat we beoogden. Ook de andere naaste collegae van DIMCA, José
Donkers, Ans Janssen, Marjolein van der Star en Prasanna Tirimanna, allemaal bedankt
voor de kritische en gelukkig ook regelmatig luchtige noten waar nodig om het project
tot een goed einde te brengen. Met jou, Sonja Cloosterman, ook promovendus op dit
vakgebied, heb ik in de afgelopen jaren menig, soms zeer serieus, gesprek gevoerd over
onderzoek doen en alles wat dat met zich meebrengt. Ook de rest van de ‘CARA-groep’
(excusez le mot!), Bart Thoonen, Ingrid Bijl-Hofland en Tjard Schermer, jullie dank ik
voor je ondersteuning en collegialiteit. Daarnaast wil ik graag Johan Molema bedanken
voor zijn zorgvuldige en goed bruikbare commentaren op diverse manuscripten. Hans
Folgering wil ik dankzeggen voor de theoretische en praktische ondersteuning vanuit de
longfysiologie, wat nog altijd een moeilijk maar interessant onderdeel is van longziekten.
Richard Dekhuizen en Pieternel Pasker-de Jong dank ik voor hun kritische noten met
betrekking tot de meta-analyse in COPD. Verder ben ik Dirkje Postma, Huib Kerstjens
en Tineke Renkema van het Academisch ziekenhuis Groningen zeer erkentelijk voor
het verstrekken van de data van hun onderzoek voor dezelfde meta-analyse bij COPD,
en de prima suggesties ter verbetering van het uiteindelijke manuscript. Professor
Derenne en Thomas Similowski dank ik voor het vertrouwen dat zij mij gaven dat ik
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hun Parijse data op de juiste manier zou bewerken ter publikatie. Deze dank is ook van
toepassing op de medewerkers van Glaxo Wellcome France, die mij ondersteunden bij de
volledige analyse van de Parijse dataset. Uiteraard bedank ik ook de nog niet genoemde
leden van de begeleidingscommissie voor hun goede methodologische adviezen met
betrekking tot dit onderzoek, Henk van den Hoogen, Wil van de Bosch en Maureen
Rutten-van Mölken. Ook Peter Jagt en Hans Tamminga van de firma Glaxo Wellcome
Nederland wil ik in dit kader graag bedanken voor hun positief kritische houding ten
aanzien van het DIMCA onderzoek. Ook hiervan heb ik veel geleerd. Zonder mijn 
stagiaires Karin van Bosheide, René van Kollenburg en Mirjam van Deuveren zou de
klus veel moeilijker geklaard zijn. Ook wil ik de collega-huisartsen en centrum-
assistentes uit mijn praktijk dankzeggen voor de morele steun die ik vooral in de laatste
fase van dit onderzoek mocht ontvangen. Dit onderzoek had natuurlijk nooit kunnen
slagen zonder de hulp van de deelnemende huisartsen, doktersassistentes en hun
patiënten. Ontzettend bedankt voor jullie medewerking. Pa en ma, bedankt voor jullie
niet aflatende belangstelling en stimulerende ondersteuning sinds ik begon met deze
studie. Tot slot dank ik jou, Marion, voor je medeleven en steun, vooral op die momenten
dat mijn onderzoek wat moeizamer verliep. Kai en Riko, met jullie heb ik ter 
ontspanning menig balletje getrapt. Helaas moesten jullie regelmatig zonder je papa
spelen omdat ik aan mijn proefschrift moest werken. Maar nu is het dan eindelijk af! 
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Chapter 14 
In Dutch: Curriculum Vitae
Pierre van Grunsven werd geboren in Nijmegen op 30 september 1962. Na het behalen
van het eindexamen Gymnasium B in 1980 studeerde hij in verband met uitloting voor
Geneeskunde gedurende twee jaar Biologie aan de Katholieke Universiteit van
Nijmegen. In 1981 behaalde hij de propaedeuse Biologie. In 1982 startte hij uiteindelijk
met de felbegeerde studie Geneeskunde aan de Katholieke Universiteit van Nijmegen.
In 1989 behaalde hij het artsexamen. In zijn vervangende dienstperiode (1990-1991)
was hij onderzoeksmedewerker op de Vakgroep Huisartsgeneeskunde te Nijmegen bij
de onderzoeksgroep astma/COPD (waarvan Prof.dr. C. van Weel hoofd was en Prof.dr.
C.P. van Schayck uitvoerend onderzoeksleider). Hier werd de basis gelegd voor het latere
wetenschappelijke werk. In 1991 werd hij ingeloot voor de huisartsopleiding op de
Vakgroep Huisartsgeneeskunde, Katholieke Universiteit te Nijmegen. Ook de 
opleidingsplaats voor huisarts was in Nijmegen (Gezondheidscentrum ‘Het Weeshuis’,
bij Mw. B.T.I.M. van der Bom en P.H.J. Giesen, huisartsen). Begin 1994 begon hij als
huisarts aan het promotieonderzoek waarvan dit proefschrift het resultaat is. In diezelfde
periode verrichtte hij waarnemingen in en rond Nijmegen. In 1997 vestigde hij zich als
huisarts in Gezondheidscentrum Lindenholt te Nijmegen. In de toekomst wil hij zich
richten op de combinatie praktizerend huisarts-universitair docent. In dit laatste kader
is hij reeds werkzaam bij het Kenniscentrum Pijnbestrijding van het Academisch
Ziekenhuis Nijmegen. Daarnaast is hij redacteur van CARAvisie en Het Chronisch Pijn
Spreekuur, en lid van de landelijke werkgroep CAHAG (CARA-huisartsenadviesgroep).
Hij is gehuwd met Marion Coster en heeft twee zonen, Kai en Riko. Muziek speelt een
belangrijke rol in zijn leven en zijn werk als dokter, zoals moge blijken uit de omslag
van het proefschrift en bijgaande CompactDisc (in plaats van stellingen).
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